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ABSTRACT
Single-point mutation in genome, for example, single-nucleotide polymorphism (SNP)
or rare genetic mutation, is the change of a single nucleotide for another in the genome
sequence. Some of them will result in an amino acid substitution in the corresponding
protein sequence (missense mutations); others will not. This investigation focuses on
genetic mutations resulting in a change in the amino acid sequence of the corresponding
protein. This choice is motivated by the fact that missense mutations are frequently found
to affect the native function of proteins by altering their structure, interaction and other
properties and cause diseases. A particular disease is the Snyder-Robinson syndrome
(SRS), which is an X-linked mental retardation found to be caused by missense mutations
in human spermine synthase (SMS). In this thesis, a rational approach to predict the
effects of missense mutations on SMS wild-type characteristics was carried. Following
this work, a structure-based virtual screening of small molecules was applied to rescue
the disease-causing effect by searching the small molecules to stabilize the
malfunctioning SMS mutant dimer.
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CHAPTER ONE
INTRODUCTION
Human DNA is not identical among the individuals, which results in natural
differences between people from different ethnic groups as well as healthy and sick
people. On the DNA level, the differences could be large or small. The smallest
difference can be a single-nucleotide occurring at both the coding and non-coding regions
[1]. If such a difference occurs in some fraction of the population (> 1%), the difference
is termed single nucleotide polymorphism (SNP) [2,3]. The SNPs occurring at the noncoding region does not affect the gene product, i.e. the protein sequence is not changed,
such types of SNPs are termed silent mutations [4]. However, silent mutation could also
be found in the coding region because each amino acid is coded by more than one codon.
Thus, even the mutation changes the codon, though it is still possible that the protein
sequence is not affected. However, a silent mutation still could affect the function of the
cell by altering the gene’s expression and regulation.
On the other side of the spectrum are non-synonymous SNPs (nsSNPs) which cause
changes in protein sequence. The most dramatic change is induced by the nonsense
mutations which result in a premature stop codon and produce truncated, usually nonfunctional proteins [4]. Missense mutation, on the other hand, is a change of a single
amino acid into another. Such a mutation could be polymorphism if it is observed in
significant fraction of the population, or it could be a rare missense mutation if found in
an individual or small group of people, as, for example, in a family. In both cases, on
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protein level, these mutations are termed single point missense mutations and they are the
primary focus of this thesis. It is known that missense mutations can be responsible for
many human diseases by affecting protein stability [5-10], protein-protein interactions
[11,12], the characteristics of the active site [5,6], and many others [13-22]. The ability of
predicting whether a given missense mutation is disease-causing or harmless would be of
great importance for the early detection of patients with a high risk of developing a
particular disease. More important is the ability to offer a specific treatment that will
reduce or completely eliminate the effects caused by disease-causing missense mutations.
In the past few years, significant progress has been made in building databases of
disease-causing missense mutations [23-26] and sequentially using these classified
mutations for early detection of patients at risk [27-30]. However, there has been very
little work done in developing possible treatments. Perhaps the reason for this limitation
stems from the lack of a complete understanding of the pathogenesis of the effects caused
by the mutations [31,32]. Another possible reason is that the common approach in drug
discovery is to design competitive inhibitors that alter the effect of the disease [33-37].
However, such an approach may not be successful in designing drugs capable of
reversing the effects of disease-causing mutations because most of these effects cannot be
reversed by simply inhibiting a particular reaction or an interaction. Instead, the drug
design should be preceded by a detailed investigation of the effects caused by the
mutation, followed by an analysis that determines which effects cause the disease and
lastly, by a search for small molecules that can restore the wild type function of the
corresponding protein by binding to it.
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Mono-genetic diseases are particularly promising targets for exploring the
possibility of reversing the effects of disease-causing missense mutations. First, the fact
that a particular disease is typically caused by a single mutation makes the analysis of the
effects much easier as compared to a complex disease and thus reduces the ambiguity of
in silico modeling. Second, the observation that different mutations within the same gene
result in the same phenotype indicates that these mutations should induce similar effects
on both the target protein’s function and interactions and this provides the unique
opportunity to facilitate in silico modeling in identifying the dominant molecular effects
causing the disease. Third, the fact that a disease is caused by a malfunction of a
particular protein makes it more feasible to find a treatment that will reverse the effect.
Because the target protein is known, the effects caused by missense mutations will be
pinpointed by in silico modeling and small molecules bound to the target protein could be
able to reverse the effect. Fourth, the fact that the disease is caused by a single mutation
in a particular protein allows experiments be designed and carried out to directly test in
silico generated hypotheses and to follow the effects induced by small molecule binding.
Identification of genetic disorders is crucial step for both providing an early
diagnosis of disease predisposed patients (personalized diagnostics) [38-42] and
prescribing the optimal drug (personalized medicine) [43,44]. However, identifying
disease-causing genetic differences and distinguishing them from harmless variations is
not a trivial task [45-48]. Typically, predicting a disease-causing disorder is done by
matching it to databases of known disease-causing genetic defects or by machine learning
algorithms. However, the success of both of these approaches depends on the database of
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known disease-causing mutations and neither method can classify any new mutations.
Thus, in terms of early diagnostics, it is quite possible that a new disease-causing DNA
variant or a rare mutation will not be predicted by these methods and thus would result in
non-treatment for the patient. At the other end of the spectrum are methods utilizing first
principle approaches. While in principle these methods should be capable of detecting
new disease-causing mutations, typically they are not used for screening since they are
too time consuming. To bridge this gap, approaches based on the first principle
calculations, but much faster and adjusted to match experimental data were developed
[49]. Such combined approaches have several advantages over the existing methods and
offer several additional outcomes, which can be extremely useful in personalizing the
treatment for the patient: (a) Since the proposed approach is not based on a comparison,
but on first principle approaches, it can detect defects that could potentially cause disease
even in cases of mutations never seen before in other patients; (b) it avoids ambiguities
associated with predicting the effects of multiple mutations in terms of their additivity or
compensation (neutralization); and (c) in addition to the prediction, it provides details of
the molecular mechanism of the effects and thus in the long run can be used for more
effective personalized treatment (Chapter 2).
Nowadays, the vast majority of the efforts are directed to study and develop
treatments for diseases affecting large fraction of the human population, a prominent
example of this being cancer research, which is a complex disease; while mono-genetic
diseases frequently referred to as “neglected diseases”, do not receive much attention of
the scientific and pharmaceutical communities. Although these diseases are often rare and
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do not affect a large fraction of the human population, they can have devastating effects
on patients. They are sometimes severe and affected patients almost always cannot fully
participate in society. For patients and their families, any progress made in understanding
the origin of disease carries the hope for the development of treatment or medication that
would reduce the burden of the disease.
Snyder-Robinson syndrome (SRS) [50], an X-linked mental retardation disorder, is a
typical monogenetic disease. In this thesis, we carried a computational analysis on three
missense mutations associated with SRS [5,51,52] (Chapter 3). Following Chapter 3,
recently a new missense mutation Y328C was also identified to cause SRS and the results
of both in silico and in vitro investigations are reported in Chapter 4. In our previous
studies [6], we predicted that the disease-causing mutation sites on SMS can harbor
harmless mutations (Chapter 5). However, so far there are no nsSNPs found in human
SMS (Chapter 6). Maybe the human SMS is so well optimized by the evolution, thus any
deviation away from the wild type (WT) structure will affect phenotype. In order to
answer this question, we engineered four mutations by transferring the protein sequence
from spermidine synthase (SRM) of Thermotoga maritime, which is the only bacterial
SRM known to grow up at a high temperature (80°C) (Chapter 6). Finally, an approach of
structure-based virtual screening of small molecules was utilized to find small molecules
which can rescue the wild type activity by binding to the malfunctioning mutant protein
(Chapter 7).
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CHAPTER TWO
IN SILICO METHODS FOR MODELING EFFECTS OF MISSENSE MUTATIONS
Several methods were applied through all of the projects in the thesis. I will introduce
these methods prior going to the specific projects, which will be presented in the
following chapters: a) the in silico modeling requires 3D structure of the protein.
However the protein structure file in the Protein Data Bank (PDB) may have missing
atoms or residues, i.e. the position of some residues or atoms may not be determined by
X-Ray crystal experiments. Thus, at the beginning of this chapter, a method of how to fix
the structural defects is introduced. A protocol to make the mutants is also described; b)
secondly a method, Molecular Mechanics Generalized Born method scaled with
optimized parameters (sMMGB) [1], is introduced; c) an algorithm used to evaluate the
effect on protein-protein interaction (binding free energy change) upon the single point
mutations is described; d) the effect of a mutation on protonation states of titratable
groups is also a plausible mechanism causing the disease, thus the pKa calculations were
also carried out in my research, and the method of pKa calculations is discussed; e)
finally the effect of amino-acid substitution on protein flexibility is another important
factor which may cause an important change on protein conformation and in turn affect
protein function, thus molecular dynamics (MD) simulations were applied, and the
procedures and parameters of MD simulations are included in this chapter.
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Fixing Structural Defects and in Silico Mutants Generation
The PDB files were downloaded from the Protein Data Bank [2,3]. However, it was
found that frequently the corresponding structures had either missing atoms or residues.
Thus the first task was to generate them in silico according to the protein sequence card
located at the top of each PDB file. It was done by “Profix”, a program in Jackal package
(http://wiki.c2b2.columbia.edu/honiglab_public/index.php/Software:Jackal) which can be
downloaded from Barry Honig’s Lab, Columbia University. The parameters which were
used in our approach are: Amber force field in conjunction with the option of fixing the
structural defects using heavy atoms representation (no hydrogens). The hydrogen will be
added later with “pdbxyz” module in the TINKER package [4].
All of the mutants were made by the program SCAP [5] in Jackal package as well.
The SCAP generated mutations were done with both Amber and Charmm force fields
using the option “heavy atom modeling”. No significant differences were found for the
predictions made with Amber and Charmm force fields, but this dual option was used in
cases where SCAP failed to generate mutant side chain with Amber/Charmm force field
and vice versa.

Calculating the Changes of Folding Free Energy
Background
Protein folding free energy is an important characteristic directly related to protein
stability. Some proteins are very stable, while others unfold under very small perturbation
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of the native conditions. In both cases not all amino acid contribute equally to the protein
stability and interactions, some of the being crucial and frequently termed ‘hot spots” [6,7]
while others contributing very little to the folding free energy. However, the contribution
of a given amino acid to protein stability cannot be easily predicted, even if the 3D
structure of the corresponding protein is available. Therefore, developing methods to
improve predictions of hot spots and even more to assess the contribution of a given
amino acid to the folding or binding free energy is of great importance [8,9]. Accurate
predictions (see [10] for comparison of different methods) will be beneficial for
understanding the role of individual amino acids on protein stability and to rationalize the
effects of non-synonymous single nucleoside polymorphism (nsSNP) [11,12] and
missense mutations on the protein fold [13-15].
Of particular interest is predicting the effects caused by disease-causing missense
mutations since the function of protein can be affected in a variety of ways [12,16,17].
Among them, the most common effect is changing protein stability, i.e. destabilizing or
stabilizing the wild type protein fold [14,18-24], in addition to altering the
macromolecular interactions [25], hydrogen bond network [13,26,27], and many other
effects [28,29]. However, the predictions about the changes of the folding energy should
not only indicate if they favor the stability or not, but the predicted absolute magnitude
should be accurate as well to allow to distinguish between disease-causing and harmless
mutations. Because of this significant efforts were devoted to develop methods and
approaches to evaluate the stability changes upon amino acid substitutions, but despite of
the efforts, accurate calculations of folding free energy are still a challenge [30].
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Currently there are several distinctive approaches which were developed to predict
the protein stability changes due to mutations. They can be classified into four categories:
1) First principle methods, which calculate the folding free energy changes based on
detailed atomic models [31-41] and may be quite computationally expensive and may not
be applicable in cases of large set of mutations [42]. 2) Methods using statistical
potentials [43,44], which were successfully used to estimate the change of protein
stability upon the mutations [45-52]. 3) Methods utilizing empirical potential combining
both physical force fields and free parameters fitted with experimental data [53-58]. 4)
Machine learning methods, generating predictions based on learned relations delivered
from the training set [59-63].
The approaches utilizing physics-based energies to calculate the folding free energy
or its change upon mutation(s), have to address the issue of how to model the unfolded
state as well. This is non-trivial task, since the unfolded state, perhaps, has different
characteristics for each particular protein and may differ depending on experimental
conditions (for example, thermal unfolding versus urea unfolding). Over the years,
various approaches were reported in the literature: some of them starting from the
original X-ray structure and modeling unfolding by either increasing van der Waal radii
of the atom [64] or increasing the temperature above the normal [65,66]; others, starting
from extended amino acid chain and modeling unfolded as a Gaussian chain [24,67,68]
or quasi-random distribution of amino acids [69,70]. In terms of assessing the difference
between unfolded state energy of wild type and mutant protein, alternative approaches
assumed either no interactions in unfolded state [13,14] or interactions limited within a
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short segment of residues centered at the site of mutation [71,72]. All above mentioned
methods have advantages and disadvantages with respect to the computational time and
the applicability to full scale energy calculations.
Typically a modeling utilizing all-atoms energy calculations is accomplished using a
particular force field and plausible concern could be to what extent it can be applied in
conjunction with another force field. In the past we were attempting to address such a
question in terms of electrostatic component protein-protein binding energy [73] and
effect of single point mutations on protein stability and interactions [13,14]. In our hands,
the trend of the results was generally similar among different force field, but individual
cases were frequently strongly force field dependent. Such an observation motivated us to
suggest averaging over the results obtained with different force fields [13,14], an
approach that we apply in this study as well.
In the past years, several prominent methods and web servers for predicting free
folding energy changes upon mutations have immerged. One of them is Eris [74-76],
developed by Dokholyan and coworkers, which utilizes Medusa force field [77]. It was
tested against 595 mutants with experimentally available data and the resulting RMSD
was reported as 2.4 kcal/mol. Recently, Zhou and Zhou constructed a residues specific
all-atom potential of mean force from 1011 protein structures and used it calculate the
folding free energy change for 895 mutants [49]. The benchmarking resulted in RMSD
1.52 kcal/mol. The FoldX is perhaps the most popular web server [78] for predicting
folding free energy changes. It was developed by Serrano and coworkers. FoldX is based
on empirical potential function and was tested against 667 mutants [79]. From machine
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learning algorithms, the most prominent is I-Mutant (version 2.0), developed by Casadio
and coworkers. It was benchmarked against 2087 data points [80].
In this thesis, we apply molecular mechanics Generalized Born (MMGB) approach to
estimate the folding free energy of the wild type and the mutants in conjunction with a
specific model of the unfolded state. Since it is established in the literature [81] that
MMGB/PB approaches tend to overestimate the free energy changes, we scale down the
originally predicted changes by a linear function and optimize the weights against
experimental data points of 662 mutants. To reduce the sensitivity of the results with
respect to the particular choice of force field, the calculations are done with three force
field parameters (Charmm, Amber and OPLS) and then results averaged. Then the
optimized weight were used to carry a blind test against 447 experimentally determined
folding free energy changes resulting in RMSD of 1.78 kcal/mol. The slope of the
corresponding fitting line was 1.0382 with the correlation coefficient 0.3 and the standard
deviation was 0.54 kcal/mol.

Materials and Methods
(a) Experimental dataset
The experimental dataset was derived from the ProTherm website (Thermodynamic
Database for Proteins and Mutants:
http://gibk26.bio.kyutech.ac.jp/jouhou/Protherm/protherm_search.html) [82-84]. The
ProTherm database provides information of various experimental conditions including
pH of the experiment. For the purpose of this thesis, we choose the experimental pH to be
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between 6 and 8, assuming that at such pH the ionizable residues will have default
charged states. No pKa calculations were performed to either explore experiments done
at low/high pH or to adjust charges of amino acids with pKa shifted away from standard
values. This was done to avoid the effect of plausible errors in assigning charges of
titratable groups. In addition, only cases of single mutations were collected resulting in
2395 experimentally determined changes of the folding free energy (ΔΔG).
During the initial screening of the data, it was noticed that for some mutations the
change of the folding free energy was reported by either different sources or different
experimental methods (for example the change of the folding free energy for the mutant
C112S in azurin from Pseudomonas aeruginosa (the pdb ID: 5AZU) [85] has reported 15
times and the ΔΔG values range from -4.4 kcal/mol to -0.24 kcal/mol at PH 7.5). In all
such cases, including cases with available data for different pH (6<pH<8) and
temperature, we took the average value, since there is no indication which data point is
most reliable.
The ProTherm database provides the Protein Data Base (PDB) identifiers for the
corresponding 3D structures of the proteins which experimental ΔΔG were collected in
the database. These structures are the core of our approach. However, frequently the 3D
structures in PDB have missing atoms, residues or entire structural segment. In order to
carry our analysis, we need polypeptide chain not to have missing atoms, residues and
gaps. Thus we fixed such structural defects by the method explained above. During this
procedure some structures with unusual numbering or long missing segments failed to be
fixed properly. They were deleted from the initial dataset. In addition, our protocol
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requires the wild type structure and the structure of the corresponding in silico built
mutant to be energy minimized with TINKER [4] (see next section for details). It was
noticed that several proteins failed to be minimized because TINKER generated identical
hydrogens coordinates (for example maltodextrin/maltose-binding protein, pdb ID:
3MBP [86] and Barnase, pdb ID: 1BNI [87]). The proteins corresponding to either of the
above cases were filtered out from our dataset resulting in a final dataset containing 1109
mutants from 60 wild type proteins.

(b) Folding free energy calculation
The folding free energy changes upon single point mutations were calculated as
described in our papers [13-15] and will be outlined in the next paragraphs (Figure 2.1).
The folded state is considered to be represented by the energy minimized structure, either
the wild type (WT) or in silico generated mutant. The unfolded state is considered to be
represented by two structural elements: (a) a structural segment of length “x” (x=3, 5, 7, 9,
13,…) centered at the mutation site and (b) rest of the protein. Assuming that the residue
at the site of mutation does not interact with the rest of protein, this approach will result
in identical energies of unfolded state “b” of WT and mutant protein, i.e. the unfolded
state which excludes the structural segment of length “x”.
Technically, it was done by energy minimizing all wild type and mutants proteins
using the program “minimize” in TINKER package [4] using the Limited Memory BFGS
Quasi-Newton Optimization algorithm and we set the final Root-mean-square gradient
(G-RMS) 0.01 per atom. The solvent was modeled using the Still Generalized Born
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model and the protein internal dielectric constant was set as 1.0. In this work, all of the
protein structures were minimized with three force field parameters, Amber98 [88],
Charmm27 [89] and OPLS [90]. After a successful minimization, a length of “x” residues
segments (x=odd numbers like 3, 5, 7, 9, 13…, for example x=3 means three residue
segments) at the center of the mutation site is extracted from the minimized structures
(both wild type protein and the mutants). After this step, all minimized structures (the
entire protein and “x” residue segment) were subjected to “analyze” module in TINKER
package for calculating the potential energy, and then the results were averaged among
the three force field parameters to test the sensitivity of the results.
The folding free energy of both the WT protein and the mutants is calculated as:

ΔG(folding) = G(folded)-G(unfolded)
= G(folded) – G0(unfolded) – Gx(unfolded);

(2.1)

where G(folded) is the total potential energy of the folded state and the G(unfolded) is the
total potential energy of the unfolded state. The free energy, G(unfolded), of unfolded
state, is split into two terms, G0(unfolded) and Gx(unfolded), as discussed in our previous
works [13-15]. Gx(unfolded) is the free energy of unfolded state of “x” residue segments
at the center of mutation site, while G0(unfolded) is the free energy of unfolded state of
the rest of protein (Figure 2.1). Under our assumption, the G0(unfolded) is identical for
WT and mutants and cancels out in Equ (2.2) and therefore does not need to be calculated.
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Figure 2.1 Ribbon presentation of the approach of modeling folded and unfolded states
representative structures. The magenta part represents the “x” residue segments, and the
cyan part represents the “the rest of protein”. The unfolded state is split into two parts
which are “x residue segments” and “unfolded state of the rest of protein”.
The folding free energy change due to a mutation is calculated with the following
equation:

ΔΔG(folding_mutation) = ΔG(folding_WT) – ΔG(folding_Mutant)
= G(folded_WT) – Gx(unfolded_WT) – G(folded_Mutant)
+ Gx(unfolded_Mutant);

(2.2)

where ΔΔG(folding_mutation) represents the folding free energy change due to a
mutation; ΔG(folding_WT) and ΔG(folding_Mutant) are folding free energy of the WT
protein and the mutant respectively.
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The ΔΔG(folding_mutation) are calculated with the three force field parameters
mentioned above and then results averaged:

ΔΔGcal=[ΔΔG(folding_mutation_Amber)+ΔΔG(folding_mutation_Charmm) +
ΔΔG(folding_mutation_OPLS) ]/3

Where

(2.3)

ΔΔG(folding_mutation_Amber),

ΔΔG(folding_mutation_Charmm),

and

ΔΔG(folding_mutation_OPLS) are the folding free energy change due to a single
mutation calculated with the force field parameter Amber98, Charmm27 and OPLS
respectively.
Here four assumptions were made: i) we assume that missense mutation affects only a
small region surrounding the mutation sites which is described by “x” residue segments
part, and cause negligible effect to the rest of the protein, hence G0(unfolded) will be the
same for WT protein and the mutants and will cancel in Equ. (2.2); ii) the entropy in the
WT and mutant proteins are considered to be very similar, therefore it will cancel out in
Equ. (2.2) as well. The applicability of this assumption will be discussed later in this
article; iii) the non-polar term of the solvation energy is not taken into account due to its
relatively small contribution to the energy and the fact that the accessible surface area
(ASA) of the WT and the mutant protein are very similar (single point mutation); iv) the
approach is based on single-point calculations where the folded and unfolded states are
represented by a structure instead of ensemble of structures. This assumes that the
potential wells do not change upon the mutation.
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(c) Obtaining the fitting weights
The above described approach is essentially simplified version of the molecular
mechanics Generalized Born (MMGB) method [42,91,92] with a specific model of
unfolded state [13-15]. It is recognized that MMGB method tends to overestimate the
magnitude of the predicted free energy changes (compared with the experimental data)
and because of that the predicted ΔΔG may have to be scaled to match the experimentally
determined changes of the folding free energy. Here we carry the following optimization
procedure to minimize the RMSD between the scaled calculated results and experimental
data. The calculated ΔΔGcal are scaled by a linear function with two adjustable
parameters “a” and “b” and the resulting scaled ΔΔG (sΔΔG) is:

sΔΔGcal=a*ΔΔGcal+b

(2.4a)

The RMSD is calculated by Equ. (2.3b) below using the scaled ΔΔG (sΔΔG) :

√∑

(2.4b)

where “n” is the number of data points; sΔΔGcal and ΔΔGexp are calculated and
experimental ΔΔG, respectively. The optimal values of the adjustable parameters “a” and
“b” are obtained by the regular conditions of finding optimum:
(2.5)
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(2.6)

Solving equation (2.5) and (2.6) with respect to the adjustable parameters “a” and “b”
results in the following expressions:
(∑

) (∑

∑

)

∑

(2.7)

∑

∑

∑
∑

∑
∑

(∑

)

(2.8)

For the purpose of this thesis, the database of experimentally determined ΔΔG is split
into two parts: training (60%) and test (40%) sets. The training set was used to find the
optimal values of the parameters “a” and “b”, while the test set was used for
benchmarking. The selection of the sets was done by ranking the wild type protein PDB
ID based on alphabet and chose the first 37 wild type protein with 405 mutants as the part
of the training database. The next protein in the dada set with respect to the alphabetical
order is the staphylococcal nuclease (PDB ID: 1STN) [93] which has 537 mutants, almost
half of the whole database. In our analysis we refer to the mutations as mutation
involving charged residue ( for example AE), mutations do not involving charged
residue (for example AL), mutations preserving the charge (for example ED) and
mutations reversing the charge (for example EK). Since mutations in the 1STN
represent such a significant fraction of the entire data set, the cases for the training set
were selected to have proportional presentation for the above mentioned classes. Thus,
there are 171 1STN mutations involving charged residue (for example 1STN_E57G) and
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half of them, 85, were selected for the training set. There are 342 1STN mutations not
involving charged group and half of them, 172, were included in the training data set. The
total number of mutations from 1STN protein which was included in the training set is
172+85= 257, resulting in 662 cases in the final training set. Note that rare mutations in
the 1STN protein, as two charges shift like 1STN_K28E and zero charge shifts like
1STN_E43D were not included in the training set, but included in the benchmarking set.
In addition, the training and benchmarking sets were shuffled to test the sensitivity of the
method (see Table 2.1S).

Results
(a) Obtaining the optimal values of the parameters “a” and “b” using the training set
The changes of the folding free energy, ΔΔG, were calculated as described in the
method section (Equ. (2.2)) for the mutants in the training set. The length of the segment
“x” was fixed to be equal to three (x=3). The effect of different lengths is discussed latter
in the manuscript.
Using Equ. (2.7) and (2.8) with 662 training data points to minimize the RMSD, one
obtains the following values for the adjustable parameters: “a” = 0.093 and “b” = -1.088.
Using these values, sΔΔG is calculated with Equ. (2.4a) and plotted against the
experimental data of the training set (Figure 2.2(A)). The slope of the fitting line is
1.0026, and the correlation coefficient R = 0.28. The corresponding standard deviation is
0.51 kcal/mol and RMSD between ΔΔGexp and sΔΔGcal is 1.79 kcal/mol. While the
correlation coefficient is not impressive, mostly due to several outliers at the top of the
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figure, the corresponding RMSD is very good. Another indication of the success of the
approach is that the slope of the fitting line is practically one and the free coefficient is
practically zero and this was achieved without enforcing such conditions in the
optimization procedure.

(b) Blind test using the obtained optimal values for “a” and “b” parameters
The blind test was done on the rest 40% of the data points (447 mutants) using the
optimal parameters obtained above. Figure 2.2(B) shows the correlation of experimental
ΔΔG (ΔΔGexp) and scaled calculated ΔΔG (sΔΔGcal) for the blind test. The slope of the
fitting line is 1.0868 and the free coefficient is practically zero. The corresponding
correlation coefficient R is 0.34, the resulting standard deviation is 0.58 kcal/mol and the
RMSD between ΔΔGexp and sΔΔGcal is 1.76 kcal/mol. These results are very similar to
the results obtained with the training set indicating the training was successful. The low
correlation coefficient is due to the outliers on the right-hand side of the graph, wrongly
predicted due to structural defects or deficiencies of our protocol.

(c) Testing the method against the entire data set
To further test the protocol and to demonstrate that the results are independent of the
specific choice of the training and testing data sets, we benchmark the scaled ΔΔG, sΔΔG,
against all experimental values collected for our work (Figure 2.2(C)). The results are
fitted with a straight line with slope practically one and zero free coefficient, again
demonstrating the validity of the proposed method. The corresponding standard deviation
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is 0.54 kcal/mol and the RMSD between ΔΔGexp and sΔΔGcal for the entire 1109 mutants
is 1.78 kcal/mol.

Figure 2.2 Comparison between experimental ΔΔG (ΔΔGexp) and scaled calculated ΔΔG
(sΔΔGcal). The parameters of the fitting line are provided in the graph. (A) for the training
database and the correlation coefficient R is 0.28; (B) for the blind test and the
corresponding correlation coefficient R is 0.34; (C) for the entire dataset and the
correlation coefficient R is 0.3.

To address the sensitivity of the results with respect to the choice of the training and
benchmarking sets, the entire dataset was reshuffled and randomly split into two equal
parts and then the above procedure was repeated. The results (Table 2.1S a,b) show that
the protocol is not sensitive to the selection of the training set.
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(d) Finding the optimal length of the segment “x”
The results above were obtained using a fixed length of three for the segment “x”.
However, different lengths may generate better results. To test the effect of the segment
“x” length on the performance of our method, the calculations, including finding the
optimal parameters “a” and “b” were repeated with x = 3, 5, 7, 9, 11, and 13. The results
are shown in our supplementary materials Figure 2.1S.
The results shown in Figure 2.1S and Table 2.1 indicate that sΔΔG calculated with
different length of segment “x” are practically the same. The calculations were repeated
against the test data set and entire data set and the corresponding parameters are provided
in Table 2.1 as well. One can see that the slopes of the fitting lines, the RMSDs and R
values are practically unchanged as “x” takes different lengths.

Table 2.1 Comparison of linear regression of ΔΔGexp vs. sΔΔGcal with the sΔΔGcal
performed with different length of residue segments for Training Database/Blind
Test/Entire Dataset.

segments
3 seg.
5 seg.
7 seg.
9 seg.
11 seg.
13 seg.

Slope
1.003/1.087/1.038
1.017/1.128/1.066
0.999/1.168/1.073
0.995/1.114/1.043
0.999/1.084/1.033
1.001/0.965/0.980

R value
RMSD
0.28/0.34/0.3 1.79/1.76/1.78
0.25/0.32/0.28 1.80/1.77/1.79
0.23/0.3/0.26 1.82/1.78/1.8
0.23/0.28/0.25 1.82/1.79/1.8
0.22/0.26/0.24 1.82/1.8/1.81
0.23/0.25/0.24 1.82/1.8/1.81

The parameters shown in Table 2.1 indicate the similarity of sΔΔGcal calculated with
different length of segment “x”. However, a slight tendency is observed such that with
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the increase of the segment length, the RMSD tend to increase and the correlation
coefficient to decrease. The optimal value is x=3.

(e) Comparison with other existing methods
To the best of our knowledge, currently three methods dominate the field of
predicting folding free energy change upon single point mutations: Eris [74-76], FoldX
[79] and I-Mutant 2.0 [80]. It is desirable to compare our method against these leading
solutions in order to assess the performance. Below we outline the results obtained with
each of the above mentioned solutions on our data set.
Before presenting the results, it should be pointed out that the predictions with Eris
were done with fixed backbone without pre-relaxation. Eris failed to generate results
involving Cys, therefore these cases were omitted from our analysis. With respect to
FoldX and I-Mutant 2.0 generated predictions, we used the default parameters for the
temperature and pH, namely T = 298K and pH = 7.0. The linear regressions of ΔΔG exp vs.
ΔΔGcal were performed and the comparison of these three methods is shown in Table 2.2
alone with our method. The ROC curve was also calculated following the methodology
described by Khan and Vihinen [10] and results are shown in Supplementary Material
(Figure 2.2S and Table 2.2S). Comparing with results reported in [10], one can see that
sMMGB slightly underperforms at very low false positives (FPR<0.1), but outperforms
servers listed in the same reference at FPR>0.1.
Table 2.2 provides interesting trends of the performance of the methods. With respect
to the mean value, all methods predict mean ΔΔG of similar magnitude. The mean value
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is negative indicating that all methods, including ours, tend to over predict the
destabilizing effect of mutations. In terms of the correlation coefficient, the best
performer is the I-Mutant, however all four methods result in poor correlation coefficient.
The RMSD is an important characteristic of the predictions and our method together with
I-Mutant outperforms the others. Similarly the standard deviation of our protocol is much
smaller than other methods, including I-Mutant, indicating that our predictions are less
scattered. Lastly, the slope of the fitting line is the best for our method, almost equal to
one, while all other methods give much worst coefficients. Similar observations were
made by excluding the data points used to train I-Mutant (Table 2.3S).

Table 2.2 Comparison of linear regression of ΔΔGexp vs. ΔΔGcal with the ΔΔGcal
performed with different methods; T: for the Training Database (662 mutants); B: for the
Blind Test (447 mutants); E: for the Entire Dataset (1109 mutants);

T
B
E
T
Eris
B
E
T
FoldX
B
E
T
I - Mutant B
E
sMMGB

Slope

R value

RMSD

1.003
1.087
1.038
0.554
1.082
0.754
0.458
0.683
0.544
0.518
0.783
0.624

0.28
0.34
0.3
0.29
0.48
0.36
0.17
0.34
0.22
0.32
0.52
0.4

1.79
1.76
1.78
3.92
3.83
3.89
5.29
3.57
4.67
1.86
1.65
1.78
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Mean of
ΔΔGcal
-1.2
-1.17
-1.19
-1.26
-1.38
-1.3
-1.2
-1.6
-1.23
-1.24
-1.00
-1.14

Standard
Deviation
0.51
0.58
0.54
1.87
1.93
1.89
1.87
3.73
1.86
1.17
1.24
1.2

Discussion
(a) Analysis of scaled calculated sΔΔGcal
Summarizing the results of sMMGB predictions benchmarked against various data
sets (Table 2.3), one can see that there is no much difference of the corresponding
RMSDs, mean and standard deviation of the corresponding distributions. The correlation
coefficient in all cases is not impressive, but has a slight tendency to get better in the
blind test, compared with the training data set. However, the effect is small. The low
correlation coefficient is due to relatively small fraction of outliers which we choose not
to remove from our analysis. In summary, the results indicate that the choice of the
optimal value for the adjustable parameters “a” and “b” is not data set specific and results
in performance almost identical across different data sets. In addition, the optimal value
for the “b” parameter is small, about a unity, indicating that there is no significant
constant shift in our predictions. The fact that the optimal adjustable parameter “a” is
close to 1/10 reflects the trend that standard MMGB approach over predicts the energy
changes by factor of 10.
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Table 2.3 The results of linear regression for training database, blind test and the entire
dataset
Database

Slope

R value

Mean of

Standard

ΔΔGcal

Deviation

RMSD

Training database

1.0026

0.28

1.79

-1.2

0.51

Blind test

1.0868

0.34

1.76

-1.17

0.58

Entire dataset

1.0382

0.3

1.78

-1.19

0.54

(b) Analysis of the performance of the sMMGB approach with respect to assumptions
taken
The model of unfolded state in our approach assumes that the “x” residue segments
have the same conformation in folded and in unfolded states. Obviously this is a
simplification which does not necessary should hold for all cases. In addition, the
probability of having different conformations in folded and in unfolded states should
increase with the length of the segment “x”. In another words, large “x” should make this
assumption less valid. Indeed, Table 2.1 shows that the results correspond to such an
expectation. With increase of the residue segment “x” length, the correlation coefficient
decreases from 0.34 (x=3) to 0.25 (x=13). Therefore, the optimal length is recommended
to be x=3.
Another hypothesis which the sMMGB implies is to assume the entropy of the WT
protein is very similar to that of the mutant. Thus, the entropy terms would cancel out in
Equ. (2.2). While it is beyond the scope of the present work to investigate the role of
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conformational ensembles of folded and unfolded states on the output of the predicted
sΔΔGcal on such large set of mutations, here will present an analysis based on the side
chain entropy estimation using side chain length as measure of the side chain entropy.
Ala and Gly are two amino acids having much shorter/smaller side chains comparing to
the rest amino acids. Assuming that the entropy of an amino acid can be estimated from
the degree of freedom of its side chain, the Ala and Gly residues should have much less
entropy than the other types amino acids and substitution to another type of residues
should involve change of the entropy. To probe the effect, we select mutations involving
Ala/Gly from the entire data set (termed “Entropy test data set”), and then use Equ. (2.2)
and the empirical parameters “a = 0.093” and “b = -1.088” to obtain sΔΔGcal. The data is
shown in Figure 2.3 together with the parameters of the linear fit. The slope is 1.0531 and
the correlation R is 0.35. The standard deviation is 0.56 kcal/mol and RMSD is obtained
as 1.6 kcal/mol. Comparing these values with previously obtained (Figure 2.2), we see
that they are very similar, i.e. the slope is quite close to unity, and RMSD is quite small.
The absence of significant difference between cases involving short and long side chains
indicates that side chain entropy is not a dominant factor for the sMMGB analysis.
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Figure 2.3 Linear regression of ΔΔGexp vs. sΔΔGcal ------ for the Entropy test dataset.

(c) Effect of different force field parameters
The sMMGB predictions were made with three force field parameters: Amber98 [88],
Charmm27 [89] and Oplsaa [90], to minimize the 3D structures of both WT proteins and
the mutants and to obtain the corresponding molecular mechanics and solvation energies.
The resulting energy changes per mutation were found to differ among the force fields,
which confirm our previous observation made for protein-protein interactions [73] and
protein stability [13,14]. In some exceptional cases the predicted sΔΔGcal was found to
vary more than 30 kcal/mol across different force fields. For global comparison, Figure
2.3S shows sΔΔGcal calculated with different force field parameters and the trend of
prediction is quite similar, but there are some outliers which are not associated with the
same mutation for each force field parameters. The fact that the calculations with
different force field parameters started with identical 3D structures (of the WT and the
mutant), but generated different predictions indicate how sensitive the results are with
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respect to the choice of the force field. Overall the best results in terms of RMSD
(between ΔΔGexp vs. calculated ΔΔGcal) were obtained with AMBER force field
parameters (RMSD= 7.97 kcal/mol), while the worst performance was obtained with
OPLS force field parameters resulting in RMSD= 8.18 kcal/mol. Such a sensitivity of the
results with the respect to the force field parameters was our motivation for average the
results across different force fields. Indeed, the averaged ΔΔGcal perform much better,
resulting in RMSD= 5.53 kcal/mol. These RMSDs are taken without scaling of ΔΔG, i.e.
prior preforming the optimization. After scaling the corresponding RMSD were
RMSDAMBER=1.80 kcal/mol, RMSDOPLS= 1.81 kcal/mol and RMSDAVE=1.78 kcal/mol.
During the time the article was under review, new experimental data was added to
ProTherm database and we used these new entries to perform an additional test which
results are presented in supplementary result (Table 2.4S).
Additional test was done using an optimized linear combination of the results
obtained with each force field parameters, but the performance was found to be worse.

Calculating the Changes of the Binding Free Energy
Binding affinity is another important characteristic of native proteins, since almost
every protein interacts with another partner(s) or forms a dimer of higher level
assemblage. In our previous works [13,14,25], the binding free energy (ΔΔG(binding))
was calculated as the difference between the total potential energy of the complex minus
the total potential energy of the separated monomers (Figure 2.4):
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ΔΔG(binding) = ΔG(complex) – ΔG(monomer_A) – ΔG(monomer_B)

(2.9)

where ΔG(complex) is the potential energy of the complex, ΔG(monomer_A) and
ΔG(monomer_B) are the potential energies of monomer “A” and “B”, respectively. The
energies were calculated using TINKER software [94] utilizing MMGB method. Entropy
was considered to be the same for the monomer and the complex and thus cancels out in
Equ. (2.9), because of that the change of the potential energy from unbound to bound
states was considered to be the free energy of binding. These calculations are done for
WT structures and for each mutant and the difference, which evaluates the effect of the
mutation of the affinity (binding free energy), is calculated as [25]:

ΔΔΔG(mut)= ΔΔG(binding_WT) – ΔΔG(binding_mutant)

(2.10)

where ΔΔG(binding_WT) is the binding energy of the WT monomers and
ΔΔG(binding_mutant) is the binding energy of the corresponding mutant.
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Figure 2.4 Illustration of binding energy calculations

In the procedure of calculation, the corresponding protein-protein complex and the
separated monomer structures (“A” and “B”) were energy minimized with the TINKER
package [95] using the “minimize” module which performs energy minimization using
the Limited Memory BFGS Quasi-Newton Optimization algorithm [95]. The solvent was
modeled using the Still Generalized Born model [96] and the internal dielectric constant
was set to 1.0. The minimization was done using four different force field parameters
Charmm19, Charmm27 [89], Amber 98 [88] and OPLS [97] to test the sensitivity of the
results. The convergence criteria applied was RMS gradient per atom = 0.01. After
successful energy minimization, the energies of the minimized structures were obtained
with “analyze” module of TINKER.
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pKa Calculations
The motivation for performing pKa calculations to reveal the effect of mutations on
the ionization states of titratable groups comes from the observation that even mutations
that do not involve titratable groups may affect ionization states by perturbing the
original dielectric boundary of the protein or by altering the hydrogen bond network
[25,98]. Thus, while clinically observed missense mutations involve no titratable group,
still they can affect the pKa’s of their neighbors.
The pKa values of the ionizable groups were calculated using the Multi Conformation
Continuum Electrostatics (MCCE) method as previously described [99-101]. Default
parameters were used as protein dielectric constant of 8.0 and ionic strength of 0.15M.
The MCCE topology files were obtained following Refs. [102-105] and are provided in
the supporting materials. The charges of the ligands were kept fixed during MCCE
calculations.
If the protein forms a dimer, then calculations were performed on the WT dimer and
separated monomers as well as on all mutants. The calculated pKa of the ith amino acid
using WT structure (either dimer or separate monomers) and the corresponding mutant
structures was compared as:

pK i (mut)  pKai (WT )  pKai (mutation )

(2.11)

where pKai(WT) is the pKa of amino acid “i” calculated with the WT structure and
pKai(mutation) is the pKa of the same amino acid but calculated using mutant structure.
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MD simulations
To assess the effect on protein flexibility upon single missense mutations, MD
simulations were performed by CHARMM (Chemistry at HARvard Macromolecular
Mechanics, version c35b1) [89]. Both of the WT structure and the mutant structure were
minimized by CHARMM. Minimization was carried with harmonic constrains
periodically updated by CHARMM loop to prevent the bad contacts or unlikely
conformations, when a SHAKE method gives an error in the case of large displacement.
Dynamics procedure was divided into three steps: heating, equilibration and dynamics
itself. The heating procedure was divided into 50000 steps (each timestep is 0.002ps) and
finally the system was heated to 300 K; then the second step which was the equilibration
process lasted for 0.2 ns at a constant temperature 300K; the last step was dynamics itself
and we set 2 ns at T=300K for this procedure. During the MD simulation, the parameter
“FACTS (Fast Analytical Continuum Treatment of Solvation, which is an efficient
generalized Born implicit solvent model)” was set to model the solvent, and the default
value for nonpolar surface tension coefficient (gamm= 0.015 kcal/mol*Å2) was used.
The resulting snapshot structures were compared to the original starting structures
using the Multiple Alignment with Translations and Twists (MATT) program [106]. The
superimposed structures were used to calculate the root mean square deviation (RMSD)
for each snapshot. Then time average of RMSD is obtained as:
n

RMSD 

 RMSD
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i

i 1

n

(2.12)

where RMSDi stands for the RMSD of the ith snapshot and “n” is the snapshot number.
Such a quantity has important property to tend asymptotically to a particular value and
thus to be used to assess the convergence.
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CHAPTER THREE
COMPUTATIONAL ANALYSIS OF MISSENSE MUTATIONS CAUSING SNYDERROBINSON SYNDROME
Abstract
The Snyder-Robinson syndrome is caused by missense mutations in the spermine
sythase gene (OMIM 300105) that encodes a protein (SMS) of 529 amino acids. Here we
investigate, in silico, the molecular effect of three missense mutations, c.267G>A
(p.G56S), c.496T>G (p.V132G), and c.550T>C (p.I150T) in SMS which were clinically
identified to cause the disease. Single-point energy calculations, molecular dynamics
simulations and pKa calculations revealed the effects of these mutations on SMS’s
stability, flexibility and interactions. It was predicted that the catalytic residue, Asp276,
should be protonated prior binding the substrates. The pKa calculations indicated the
p.I150T mutation causes pKa changes with respect to the wild type SMS which involve
titratable residues interacting with the S-methyl-5'-thioadenosine (MTA) substrate. The
p.I150T missense mutation was also found to decrease the stability of the C-terminal
domain and to induce structural changes in the vicinity of the MTA binding site. The
other two missense mutations, p.G56S and p.V132G, are away from active site and do
not perturb its wild type properties, but affect the stability of both the monomers and the
dimer. Specifically, the p.G56S mutation greatly reduces the affinity of monomers to
form a dimer and therefore has dramatic effect on SMS function since dimerization is
essential for SMS activity.
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Background
Snyder-Robinson syndrome (SRS, OMIM 309583) [1] is an X-linked recessive
disease which causes mild-to-moderate mental retardation, osteoporosis, facial
asymmetry, thin habitus, hypotonia, and a nonspecific movement disorder [2]. Genetic
studies showed that the SRS is caused by defects in the spermine synthase (SMS, OMIM
300105) gene [2-5]. Particularly, a splice variant of the SMS gene in males from the
original Snyder-Robinson family was found that leads to the loss of exon 4, inserts a
premature stop codon and results in a truncated protein containing only the first 110
amino acids [4]. A missense mutation at position 56 substituting Gly with Ser c.267G>A
(p.G56S) was reported in the SMS gene from a second family with Snyder-Robinson
syndrome [3]. It was shown that the p.G56S mutation greatly reduces SMS activity and
leads to severe epilepsy and cognitive impairment [3]. The mutation c.496T>G
(p.V132G), in the exon 5 of the SMS gene in two Mexican brothers with Snyder–
Robinson syndrome was also found [5]. Another missense mutation, c.550T>C (p.I150T)
[6], was identified by Schwartz and co-workers (personal communication). Thus,
currently three missense mutations in SMS protein and a splice variant in SMS gene are
clinically shown to be associated with SRS. However, the molecular mechanism of how
these genetic defects cause SRS is still unknown. While the truncated protein resulting
from the splice variant of the SMS gene is not expected to retain the wild type function of
the SMS protein, the molecular effects of the above missense mutations on the SMS
function cannot be revealed without performing a detailed analysis. Such an analysis is
reported in this chapter.
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The SMS protein is an aminopropyltransferase which converts spermidine into
spermine and thus is very important for regulating polyamines’ concentration in the cell.
It has been shown that polyamines play an important role in cell proliferation,
differentiation, programmed death and tissue repair [7]. Polyamine biosynthesis was
found to be negatively regulated by some tumor-suppressor genes, such as the
adenomatous polyposis coli gene [8]. The suppression of polyamine levels can increase
apoptosis, decrease cell growth, and prevent tumor formation. Thus, understanding the
polyamine biosynthetic pathway could reveal important targets for the design of
therapeutic agents [9]. The predominant polyamines found in prokaryotes and eukaryotes
are spermidine (SPD) and spermine (SPM). They can act as ligands at multiple sites on
DNA, RNA, proteins, phospholipids, and nucleotide triphosphates. In addition, in higher
organisms, SPM is required for modulating ion channel activities of certain cells. The
loss of SPM has profound effects in mice since deletion of the SMS gene results in
reduced size, sterile, deaf and has neurological abnormalities, and very short life span
[10,11]. Polyamines synthesis is catalyzed by aminopropyltransferases which include
spermidine synthase and SMS. In this process, S-adenosylmethionine decarboxylase
(AdoMetDC) provides the aminopropyl donor decarboxylated S-adenosylmethionine
(dcAdoMet) for the synthesis of both spermidine and spermine. Particularly, spermine
synthase adds aminopropyl group to the N-10 position of SPD to form SPM.
Recently, the 3D structures of human SMS with either spermidine or spermine were
experimentally determined [11]. Structural analysis combined with site-directed
mutagenesis indicated that two residues, Asp201 and Asp276, play a key role in the
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catalytic reaction. The human SMS forms a dimer of two identical subunits. Each subunit
is made of two functional domains: the N-terminal domain which is important for
dimerization, and the C-terminal domain which includes an active site for spermine
synthesis [11]. Interestingly, the N-terminal of SMS is very similar to AdometDC and the
C terminal of SMS has structural homology with spermidine synthase [11]. It was shown
that both domains are enzymatically inactive when expressed separately, but have well
defined 3D structures [11]. The importance of dimerization for the function of SMS
protein was studied using a series of deletion mutants. It was demonstrated that the Ndomain causes dimerization and without dimerization the SMS losses its activity [11].
Genetic variations or defects can affect the function of the cell and the function of the
corresponding protein in many different ways (see for example) [12-18]. In this study, we
investigate three missense mutations (Figure 3.1) clinically shown to cause SnyderRobinson syndrome by the means of computational modeling of their effect on stability,
dynamics and function of the SMS dimeric protein. The goal is to reveal the molecular
mechanism of the effects, which will provide guidance for further studies toward
developing treatment of the disease.
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Figure 3.1 The 3D structure of SMS dimer in cartoon representation. The MTA is shown
in yellow stick and SPD in blue stick. The mutation sites are shown in sphere: p.G56
(red), p.V312 (magenta), and p.I150 (cyan).

Materials and Methods
Proteins
The wild type (WT) structures of human SMS protein crystallized with either
spermidine (PDB ID 3C6M) or spemine (PDB ID 3C6K) [19] were downloaded from the
Protein Data Bank (PDB) website [20]. In both cases the asymmetrical unit was found to
have four molecules, while the biological unit is a dimer. The dimer made of chains “A”
and “B” was found to have many van der Waals (vdW) clashes and was removed from
the calculations. Instead, the biological unit was taken as the dimer made of chains “C’
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and “D”. There are minor differences between 3C6M and 3C6K structures due to
different ligands (spermidine and spermine) and different crystallographic groups (P1 and
P32). However these differences are negligibly small at the dimer interface. Most of the
calculations reported in this paper were done using the 3C6K structure because a
significant part of the N-terminal domain is not solved in the 3C6M structure. However,
the pKa calculations involving mutations at site 150 were done using both 3C6M and
3C6K structures because these two sites are located in close proximity to the active site
residues and to the spermidine/spermine binding pocket and even very small structural
difference could have significant impact on the calculations.
The mutant structures were built in silico by side chain replacement done with the
program SCAP [21]. Three mutant structures per wild type protein were generated. Each
of them corresponded to a mutation introduced at the site 56, 132, and 150 (Figure 3.1)
and the clinically observed mutations (p.G56S, p.V132G, and p.I150T).

Energy Calculations
To reduce the computational time, the structures were split into N-terminal domain
(a.a. 1-125) and C-terminal domain (a.a. 126-381), the last one including the central
domain as well. The energy calculations including both folding free energy and binding
free energy are following the protocol described in Chapter 2.
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pKa Calculations
The pKa calculations involving mutations at site 150 were done using both 3C6M and
3C6K structures. Because the pKa values of titratable groups are known to be affected by
mutations at distant sites, the ligands (S-methyl-5'-thioadenosine: MTA, spermidine: SPD
and spermine: SPM) were included in the MCCE calculations in case of wild type (WT)
and p.I150T mutant. The MCCE topology files were obtained following Refs. [22-25]
and are provided in the supporting materials. This resulted in the following net charges:
spermine = +4e, spermidine = +3e and MTA = +1e. The charges of the ligands were kept
fixed during MCCE calculations.
Calculations were performed on the WT dimer and separated monomers (using both
3C6K and 3C6M structures) as well on all mutants.

Web Servers
Several of web-based tools were used to predict the effect of the missense mutations
on SMS stability and dimer affinity. They are described in the following Refs. [26-32].

Results
A previous study based on the X-ray structures of spermine synthase with either
spermidine or spermine has found the catalytic residues, residues being in contact with
the substrates/products and amino acids conserved in the multiple sequence alignment
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(see Figure.3 in Ref. [19]) and we will take advantage of their analysis. The study [19]
revealed several crucial structural and biochemical characteristics governing the wild
type function of SMS. These findings are grouped in four categories for the purposes of
the present investigation: (a) The reaction follows the standard mechanism of
aminopropyltransferases and involves cleavage of a peptide bond and deprotonation of
the N-10 atom of spermidine [33,34]. Thus, protonation/deprotonation events are crucial
for spermine synthase function and motivated us to perform a detailed analysis of the
pKa’s of titratable residues at different conditions. (b) The reaction requires precise
positioning of both the reactants and products in the active site of the SMS. The positions
of the substrates are coordinated by the set of amino acids reported in the original paper
[19]. Any structural perturbation that alter the geometry of the active site or side chain
positions of coordinating residues would affect the reaction. (c) The reaction takes place
inside the SMS, where both reactants are buried and shielded from the water phase. Any
change of the stability or conformational dynamics involving structural segments
surrounding the active sites would affect the reaction. (d) The dimerization of SMS was
shown to be crucial for the function and any mutation that alters the SMS dimer stability
is expected to alter the function as well. Below we investigate the effect of three
clinically observed missense mutations on each of the above mentioned properties (see
Figure 3.1 showing mutation sites locations).
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Effect of the Missense Mutations on Ionization States of Titratable Groups
The first question to address is which titratable groups are affected by the binding of
reactants. Since no 3D structure is available of the apo form of SMS, we performed pKa
calculations using 3C6K and 3C6M structures without substrates as a model of the apo
form. This is an obvious simplification, since both structures are “closed” structures, i.e.
the reactants binding pockets are shielded from the water phase, while the apo
conformation is expected to have channel(s) leading the reactants to their binding
positions. However, in the pKa calculations, the binding pockets were empty and treated
as medium of high dielectric constant of water and thus the amino acids within the
binding pockets are exposed to the water phase as they are supposed to be in the apo form.
Of course, titratable groups located away from the binding pockets and within structural
regions that undergo conformation changes from apo to holo states will experience pKa
shifts, but these groups are not the subject of the present study, neither the amino acids in
the N-terminus domain of the SMS.
The results of pKa calculations are summarized in Table 3.1 With respect to the wild
type SMS, it was found that the catalytic residues Asp201(203) and Asp276 (278) behave
differently (in parenthesis are given the amino acid numbers in the 3C6K structure). The
Asp201 is calculated to be fully ionized with and without substrates, while the Asp276 is
predicted to be protonated without substrates but to be fully ionized when they are
present. This is a confirmation of the catalytic mechanism outlined in references [19,33].
The Asp276 serves as proton acceptor that removes a proton from the N-10 atom of
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spermidine and in order to do so, must have an elevated pKa prior the attack. The Glu353
(355) was also found to have an elevated pKa prior SPD/SPM binding, but becomes fully
ionized in the presence of substrates. However, the ionization state of neither of these
residues is affected by the p.I150T mutation, because they are far away from residue 150.
Two amino acids within the MTA binding pocket were calculated to experience pKa
shifts due to MTA binding and the p.I150T mutation (Table 3.1). The Glu220 (222) is
calculated to be partially protonated in absence of MTA, mostly because its side chain is
partially buried in the protein matrix and the ionized form has to pay a desolvation
penalty for that. The binding of MTA, however, provides favorable interactions, supports
the ionized form and makes Glu220 fully ionized. The carboxyl oxygens of Glu220 serve
as proton acceptors for the OH group of MTA and thus lock the MTA in desired position.
The Asp222 (224) is not in direct contact with MTA, but interacts electrostatically with
Glu220. In the wild type SMS, Asp 222 makes a strong hydrogen bond with Ser145 (147)
and is predicted to be fully ionized and have a low pKa value. The missense mutation at
site 150 replaces Ile with Thr, a polar residue which is a strong hydrogen donor. We
predict that in the mutant, the OD1 atom of the side chain of Asp222 establishes a new
hydrogen bond with Thr150 (Figure 3.2C) and this additionally lowers its pKa value. As
a “domino effect”, the pKa value of Glu220, which coordinates MTA, gets slightly higher
which could affect its interactions with MTA. As result of the p.I150T missense mutation,
the hydrogen bond network in the vicinity of the MTA binding site is altered with respect
to the wild type, which in turn could affect the reaction.
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The other two missense mutations, p.G56S and p.V132G were found not to affect any
ionization state, simply because the mutation sites are located in regions that do not have
titratable residues around.

Table 3.1 The Calculated pKas of Ionizable Groups with Either SPD/SPM or MTA at the
Binding Pocket
Conditions

SPD/SPM pocket
D 276/278
E 353/355
9.6 / 9.7
8.5 / 10.0

MTA pocket
E 220/222
D 222/224
6.0 / 6.5
3.0 / 1.4

no substrates

D 201/203
0.0 / 5.0

with substrates

0.0 / 0.0

1.3 / 0.0

0.0 / 0.0

0.2 / 0.0

0.7 / 1.6

I150T no
substrates

0.0 / 5.0

9.6 / 9.7

8.5 / 10. 0

6.3/7.0

0.2/0.0

I150T with
substrates

0.0 / 0.0

1.3 / 0.0

0.0 / 0.0

0.3/0.0

0.4/1.4

The calculations were performed with 3C6M and 3C6K structures and results
averaged over the “C” and “D” polypeptide chains. The residue numbers are reported for
both structures, starting with 3C6M numbers. Four conditions were modeled: pKa
calculations without substrates, with substrates and the same was repeated with
introduced missense mutation I150T. The pKa’s of residues at SPD/SPM binding site
were found not to be affected by I150T mutation, while the pKa’s of residues at the
vicinity of the MTA pocket were found to be sensitive to the I150T mutation.
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Effect of Mutations on the Stability of the Monomers
Structure-based energy calculations were performed as explained in the method
section and MTA and SPM were not included in the analysis, the reason being three fold:
(a) the missense mutations p.G56S and p.V132G are far away from the binding pockets
and thus should not be sensitive to the presence of substrates; (b) the holo (substrate
loaded) structure is expected to be much more rigid and stable than the apo structure and
thus less sensitive to missense mutations studied in this work and (c) most of the webbased tools do not include substrates in their analysis and to compare their predictions
with ours we prefer not to include substrates in our analysis either.

Structure-based Energy Calculations
The results are summarized in Table 3.2. The first observation is that the absolute
value of the energy change varies depending on the force field parameters and
polypeptide chains used, an observation that confirms our previous investigations [35].
However, averaging over all calculated energy changes results in a prediction that all
mutations will destabilize monomers. The most prominent is the effect calculated for
p.I150T mutation, and the smallest effect is predicted for p.V132G mutation.
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Table 3.2 The Results of Structure-Based (3C6K) Energy Calculations
Missense
mutation/
chain
G56S – C
G56S – D
V132G-C
V132G-D
I150T-C
I150T-D

Charmm-19

Charmm-27

Amber-98

OPLS

Average

Average (CD chains)

2.1
-1.3
-12.7
-10.6
-3.3
7.5

-1.1
-14.8
-1.0
2.8
-2.3
-4.7

0.8
-1.8
3.2
-0.1
-9.0
-15.5

-4.2
-2.0
5.3
4.2
1.3
-2.3

-0.6±1.4
-5.0 ±3.3
-1.3 ±4.0
-0.9±3.3
-3.3±2.1
-3.7 ±4.7

-2.8 ± 1.8
-1.1 ±2.4
-3.5 ±2.4

Four different force field parameters (Charmm-19, Charmm-27, Amber-98, and
OPLS) were used. All energies are in kcal/mol. Negative energy change indicates that the
mutation decreases the stability, while positive increases it. The modeling was done using
‘‘C’’ and ‘‘D’’ chains of 3C6K structure independently and then results were averaged.
Standard error is reported as well.

Predictions Made with Web-based Tools
The predictions of web-based tools are shown in Table 3.3 for each missense
mutation studied in this work. The most controversial predictions are made with
CUPSAT, where the effect on denaturant stability is predicted to be just opposite to the
effect on thermal stability. The only other discrepancy among the predictions is the
p.G56S missense mutation effect predicted with Eris, which is calculated to slightly
increase the monomer stability. However, the consensus among the methods, including
sequence based predictions, is that all mutations will decrease monomer’s stability.
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Table 3.3 Predictions of Effects on Monomer Stability (ΔΔG) Made with Web-Based
Tools
Web-server
CUPSAT
(thermal)
CUPSAT (denat.)
Eris
I-Mutant 2.0
FoldX
MUpro
MuStab
Consensus

G56S
+11.53

V132G
-4.12

I150T
-2.57

-1.45
+0.20
-2.1
-3.48
Destabilizing
Destabilizing
Destabilizing

+7.66
-5.27
-3.04
-0.57
Destabilizing
Destabilizing
Destabilizing

+4.14
-4.27
-2.97
-3.32
Destabilizing
Destabilizing
Destabilizing

The results of the structure-based tools are in kcal/mol and negative energy change
indicates that the mutation is predicted to destabilize the SMS structure, while positive
number suggests the opposite. The results were averaged for ‘‘C’’ and ‘‘D’’ chains. The
sequence based servers do not predict the magnitude of the change, but its direction only
in terms of stabilizing/destabilizing. The last row provides consensus prediction.

Structural Origin of Predicted Effects
Comparing results of the structure-based energy calculations with TINKER and webbased tools, we see that they are in very good agreement for all mutations. Almost all
methods predict that the mutations will destabilize SMS monomers as our TINKER
analysis suggests as well. The predictions obtained with CUPSAT are the most
ambiguous, since the effect of thermal and denaturant stabilities are calculated to be just
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opposite. Without focusing on this discrepancy, which is associated with CUPSAT
algorithm, below we discuss plausible structural factors causing the stability changes.
The p.G56S mutation is evaluated by our calculations, all sequence-based and most of
the structure-based servers to destabilize the monomers. The wild type residue, the Gly, is
frequently found to be located at structural positions requiring either flexibility or sharp
turn. Substitution of Gly to Ser residue causes structural reorganization (Figure 3.2A) of a
neighboring loop consisting of residues Tyr89-Gln94, which in turn affects the beginning
of the corresponding helix. Such a structural change induces extra strain and destabilizes
SMS monomer.
The p.V132G mutation is predicted by all methods (excluding CUPSAT(denat)) to
destabilize 3D structures of the monomers. The structural origin for such predictions is
shown in Figure 3.2B. The WT residue, Val, is partially buried in the monomers and fully
buried in the dimer (shown in green in Figure 3.2B). Being hydrophobic amino acid, the
WT Val stabilizes the 3D structure due to the hydrophobic effect. The missense mutation
introduces Gly, an amino acid that does not have the same hydrophobicity as Val and is
smaller as well. As results, the stability of the monomer decreases upon p.V132G
mutation. The mutation also induces small structural changes mostly associated with
neighboring side chains, while the backbone is practically unaffected.
The p.I150T mutation is predicted by our calculations to destabilize the monomers in
agreement with the web-based tools. The I150 mutation site is quite different as
compared with the other two. The side chain of the wild type and the mutant residue
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points toward the hydrophobic core of the protein. The mutation introduces a polar
residue (Thr) which has to pay a significant desolvation penalty to be buried. However, in
our protocol it relaxes structurally and establishes a hydrogen bond with Asp222 (Figure
3.2C). It should be mentioned as well that the p.I150T mutation causes structural
reorganization of a loop made of residues Leu221-Lys260. This is the largest structural
change found to be induced by any of the three missense mutations. Since it involves
structural segment that is within vicinity of MTA binding site, these structural changes
can be expected to affect the wild type function of SMS.

Figure 3.2 Zoomed 3D structure of SMS focused on the corresponding mutation site. The
“C” chain of the corresponding minimized mutant structure (white) is superimposed
structurally onto wild type minimized “C” chain (red) for comparison. The mutant “D”
chain is also shown when applicable to indicate where the interface is. (A) Zoomed Nterminal domain. Amino acids 1-19 and above 118 are removed to reduce the complexity
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of the figure. The WT and mutant backbones are shown with ribbons. The side chains of
amino acids around 56 mutation site are shown as “wires” and the missense mutation
Ser56 is shown in green. (B) The 3D structure of the SMS dimer (amino acids 120-150),
with “C” chain of the wild type (red) and the mutant p.V132G (white) superimposed. The
“D” chain of the mutant is shown as blue ribbon. The side chains of the residues within
the vicinity of the site of mutation are shown as well and the WT Val is green. (C)
Zoomed C-terminal domain of the p.I150T mutant (white) superimposed onto the wild
type structure (red). The mutant residue, Thr150 is shown in magenta, the titratable
residue affected by the mutation, Asp222, is shown in orange, the coordinating residues
Gln1648 in green and Glu220 in yellow. The MTA in blue. The hydrogen of Thr150
making H-bond with Asp222 and the hydrogens of Gln148 are also shown in the figure.

Effects on Dimer Affinity
The p.G56S mutation is predicted to significantly reduce affinity of monomers to
form a dimer, in agreement with FoldX (Table 3.4). The reason for that is the structural
reorganization shown in Figure 3.2A, which in turn affects the interactions across dimer
interface. The p.V132G mutation is predicted by our protocol to have little effect on
affinity, while FoldX calculates almost 3kcal/mol reduction. The reason for such a
difference is that we allow for extensive structural relaxation which significantly eases
any sterical clashes and minimizes unfilled cavities. In addition, the analysis of the
structure (Figure 3.2B) shows that the side chain of the wild type residue (Val) does not
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point toward the dimer interface but it is parallel to it. Because of that ValGly mutation
is predicted to have little effect of dimerization. The p.I150T mutation is predicted by us
and FoldX not to affect dimerization. This is to be expected, since mutation site is far
away from the dimer interface. Structural changes induced by p.I150T mutation
propagate to the dimer interface; however, they are small and cause almost no effect.

Table 3.4 The Results of Structure-Based (3C6K) Energy Calculations on the Dimer
Affinity Changes
Missense
mutation
p.G56S
p.V132G
p.I150T

Charmm19
-12.4
-5.6
-0.8

Charmm27
-17.0
4.3
0.3

Amber98
-18.9
-0.5
-0.2

OPLS

Average

FoldX

-7.1
-0.0
1.4

-13.9 ±2.6
-0.4 ±2.0
0.2 ±0.5

-4.82
-2.76
0.0

Four different force field parameters (Charmm-19, Charmm-27, Amber-98, and OPLS)
were used and then results averaged. All energies are in kcal/mol. Standard error is
reported as well. Negative energy change indicates that the mutation decreases the
affinity of the dimer, while positive increases it. The last column show the results
obtained with FoldX server (see Method section for details).
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Discussion
Three missense mutations, clinically shown to cause Snyder-Robinson syndrome
were investigated to reveal the details of the molecular mechanism causing the disease.
This was possible due to recently solved 3D structure of the SMS dimer in presence of
either SPD or SPM [19]. The 3D structures were subjected to pKa calculations, energy
calculations and MD simulations. The analysis was complemented with simultaneous
predictions made with web-based resources and the results were compared. Two
distinctive mechanisms were found, which the missense mutations studied in this work
utilize in order to perturb the wild type properties of the SMS. Here we use the word
“perturbation” to refer to any change of the wild type characteristics of SMS, since the
disease could be caused not only by destabilization of the 3D structure. There are many
examples of single nucleotide polymorphism that were shown to increase the stability of
either RNA [36] or the corresponding protein [37,38] and to enhance protein-protein
interactions [39]. The same argument can be made for any other SMS property, which if
altered from its wild type characteristics, could result in a pathogenic effect [40,41] or
natural difference [42].
Two of the missense mutations, p.G56S and p.V132G, occur either at the dimer
interface (p.V132G) or at its periphery (p.G56S), both far away from the active site
residues. They both are predicted to destabilize SMS monomers and p.G56S is also
predicted to strongly reduce the affinity of monomers to form a dimer. Since dimerization
is crucial for the SMS function, as shown experimentally [19], the change would be
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affecting SMS function as well. Such missense mutations, that do not affect either the
catalytic residues or the geometry of the active site, illustrate the case of missense
mutations causing disease through indirect effects that alter the function of the
corresponding protein.
The third mutation, the p.I150T, is located within the C-terminal domain which
carries the active site and is responsible for SPD synthesis. However, neither the wild
type Ile150 nor the mutant residue Thr150 is in direct contact with either catalytic amino
acids or substrates. However, our analysis revealed that a plausible scenario may involve
a “domino effect”, such that the mutant residue, Thr150, makes a hydrogen bond with a
neighboring titratable residue, Asp222, which in turn interacts with Asp220, the amino
acid that coordinates MTA (and presumably coordinates the natural substrate as shown in
Ref. [19]). It could be envisioned that altering the wild type interactions, which involve
amino acids within the active site, would affect SMS function and could be the cause of
the disease. In addition, comparing snapshot of WT and mutant, we found that a
structural region involving Asp220 changes its conformational dynamics due to the
mutation. The last, but not the least observation, is that the mutation site, I150, is within
the same beta strand as another active site residue, Gln148. Altering Gln148 position
would affect MTA binding and definitely would affect the SMS reaction. Thus, the
p.I150T mutation utilizes several different mechanisms to alter SMS function, but they all
affect active site residues, which illustrate the case of a missense mutation causing a
direct effect.
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I should be pointed out that our computational analysis is not aimed at predicting the
absolute value of the expected energy changes, but rather to predict their direction
(stabilizing or destabilizing) and more importantly to reveal the details of the suggested
changes. This is the major advantage of structure-based approaches, because they show
the details of the changes causing the malfunction of the corresponding protein and in
principle these findings could be used to develop therapeutics to neutralize the effect. In
addition, our investigation provides testable predictions about the effects of the mutations
on stability of the monomers and SMS dimer. The predicted tendencies could be tested
by the means of thermal or denaturant unfolding experiments and the calculated increase
of flexibility of the structural segment comprised of residues 221-260 due to p.I150T
mutation could be studied by NMR or other methods. The pKa changes and hydrogen
bond rearrangement predicted to occur due to p.I150T substitution could also be assessed
by NMR as well as by titration experiments.
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CHAPTER FOUR
A NEW Y328C MISSENSE MUTATION IN SPERMINE SYNTHASE CAUSING A
MILD FORM OF SNYDER-ROBINSON SYNDROME
Abstract
In this chapter we report a new missense mutation, p.Y328C, (c.1084A>G), in SMS
in a family with X-linked intellectual disability. The affected males available for
evaluation had mild ID, speech and global delay, an asthenic build, short stature with
long fingers and mild kyphosis. The spermine/spermidine ratio in lymphoblasts was 0.53,
significantly reduced compared to normal (1.87 average). Activity analysis of SMS in the
index patient failed to detect any activity above background. In silico modeling
demonstrated that the Y328C mutation has a significant effect on SMS stability, resulting
in decreased folding free energy and larger structural fluctuations compared with those of
wild type SMS. The loss of activity was attributed to the increase of conformational
dynamics in the mutant which affects the active site geometry, rather than preventing
dimer formation. Taken together, the biochemical and in silico studies confirm the
Y328C mutation in SMS is responsible for the patients having a mild form of SRS and
reveal yet another molecular mechanism causing SRS.
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Background
In the previous chapter, the molecular mechanism of three missense mutations (G56S,
V132G, I150T) on SMS causing SRS was reported. Recently, an additional mutation in
SMS has been identified in families whose phenotypes are consistent with SRS [1,2] as
well. These additional families expanded the SRS phenotype to include profound ID,
seizures, short stature, pectus carinatum and myopia. Here we describe a novel missense
mutation in SMS, C.1084A>G (p.Y328C), in a small X-linked family in which the
affected males present with a mild phenotype, and we employ the same analysis on this
newly discovered Y328C mutation in SMS.

Materials and Methods
Clinical Work and in Vitro Experiment
The following in vivo and in vitro work was performed by Dr. Charles Schwartz’s
group, at Greenwood Genetic Center and Dr. Hilde Van Esch, at the Center for Human
Genetics, University Hospitals Leuven, Herestraat 49, B3000, Leuven, Belgium.

(a) Mutation analysis
Family L091 is part of a large cohort of families and patients with X-linked
intellectual disability that were collected at the Center for Human Genetics of the
University Hospitals Leuven in order to identify causes of intellectual disability. The
protocol was approved by the Institutional Review Board of the University Hospitals of
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Leuven (Belgium), and informed consent was obtained. Genomic DNA from patients as
well as from family members and healthy controls was isolated from peripheral blood
according to standard procedures and stored at 4°C.
In a study to elucidate the genetic defects in families with apparent XLID, we
performed enrichment of the coding and flanking intronic sequences of 86 known XLID
genes followed by next-generation sequencing using the Illumina/Solexa system. Details
of this method were described in [3]. Confirmation of the mutation in SMS and
segregation analysis was done by Sanger sequencing (primer sequences available on
request).

(b) Spermine/spermidine ratio determination
Patient lymphoblast cells were pelleted by centrifugation at 450g for 3minutes. The
cells were resuspended in PBS and again pelleted by centrifugation. PBS was removed
from the cell pellet and the pellet was frozen at -80C. The cell pellet was thawed on ice,
resuspended in 50mM phosphate buffer pH 7.5 , sonicated 3x for 10 seconds each, and
centrifuged at 10,000 g for 3 minutes. The supernatant was removed to a fresh tube and
quantified using the Lowry method. A 100 ul suspension was prepared containing 35 ug
of cell lysate and 2.5uM of spermidine d8 as a loading control in a 50mM phosphate
buffer. 100 ul of an acetronitrile mixture containing 0.1% formic acid was added to the
sample and assayed on Waters Quattro Micro tandem mass spectrometer using Waters C8
column. A standard curve for spermidine and spermine was generated and the results
were analyzed using Quanlynx program as described by Sowell et al. [4].
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(c) Spermine activity assay
Patient lymphoblast cells were pelleted by centrifugation at 450xg for 3 minutes. The
cells were washed twice in ice cold PBS and pelleted by centrifugation. PBS was
removed from the cell pellet. The pellet was resuspended in ice cold Buffer A ( 50mM
sodium phosphate buffer pH 7.2, 0.3M EDTA) plus 1x protease inhibitor cocktail (Sigma
catalogue # P2714) and frozen at -80°C. The cell pellet was thawed on ice and refrozen at
-80°C again. The pellets was thawed on ice again and centrifuged at 10,000xg for 5
minutes at 4°C. The supernatant was removed to a chilled tube and quantified using the
Bradford method. 70 ug of cell lysate was used in an assay containing 100uM sodium
phosphate pH 7.5, 100uM spermidine d8 (Sigma catalogue #709891), 1x protease
inhibitor cocktail, 100uM dcSAM (provided by Dr. Ikeguci), and 50uM 4-MCHA (Sigma
catalogue #177466). After 24 hours, the reaction was stopped. Spermidine D8 and
spermine D8 were measured using tandem mass spectrometry as described by Sowell et
al. [4].

(d) Plasmid Construction.
cDNA was prepared with Superscipt First Strand Synthesis Kit for RT-PCR
(Invitrogen catalogue nubmer11904-018) from 2 micrograms of RNA prepared from
lymphoblast cell lines. The gene specific oligo SMS-RT (5’ GAA GGC TAT TTG CAG
CAC ATG TGA 3’), was used to generate the first strand cDNA for the control and
patient 1. SMSmut-RT (5’CAC TTC ATC TAT GTC ATA TTC AAC 3’) was used to
generate the first strand of cDNA for the original patient carrying a truncating mutation
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[5]. A PCR reaction with the oligos SMS-F (5’ CAC CAT GGC AGC AGC ACG GCA
CAG CAG G 3’) and SMS-R (5’ GGG TTT AGC TTT CTT CCA AAC AGT3’) and
PFU Turbo (Stratagene catalogue number 600250) were employed to generate the insert
for the control and patient 1. For the original patient, SMS-F and the oligo SMSmut-R (5’
ACC AGG CGC CCG TCG GCG GTG GGC 3’) were employed to generate the insert.
The fragments were run on a 1% TAE agarose gel and purified with a Gel Extraction Kit
(Qiagen catalogue number 287040). The purified product was cloned in pcDNA3.1D/V5His-Topo vector using the pcDNA3.1 Directional Topo Expression Kit (Invitrogen
catalogue number K4900-01). All plasmids generated from this have a V5 tag on the cterminus. The LacZ V5 plasmid was included as a positive control with the kit. Plasmids
were sequenced to confirm the insert with the vector specific primers PC (5’ GGG AGA
CCC AAG CTG GCT AGT 3’) and BGH (5’ TAG AAG GCA CAG TCG AGG 3’) and
insert specific primers SMS285For (5’ GAG AAT TTA CCC ACA TGG ATT 3’),
SMS330Rev (5’ GTC GGC CAG TAT CTG TCG AT 3’), SMS660Rev (5’ GTC TCC
ACC TCC CAG AAT GA 3’), and SMS960Rev (5’ GGA GAC GTG GAG ATT GGA
ACA 3’).

(e) Transfection
PC-12 cells were cultured on poly-l-lysine (Sigma catalogue number P4707) coated 24
well tissue culture dishes in growth media 18-24 hours priors to transfection. A
transfection complex containing DMEM (Sigma catalogue number D5796), 1 microgram
of plasmid, and 3.5 ul of NeuroMag (Bocca Scientific catalogue number NM50500) was
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prepared and added to each well. The 24 well plate was placed on the Super Magnetic
Plate (Bocca Scientific catalogue number MF10000). After 20 minutes on the Super
Magnetic Plate, the 24 well plate was removed and placed in a 5% CO2 humidified 37C
incubator. After 5 hours, the transfection complexes were removed, the cells washed one
time with PBS, and growth media added back to the cells. Twenty-four hours post
tansfection, the cells were moved to a poly-l-lysine coated glass slip and cultured in
growth media with 100ng of NGF for 36-40 hours.

(f) Immunofluorescense
Forty-eight hours after nerve growth factor treatment, the cells were washed twice
with PBS, fixed with 4% paraformaldehyde/PBS, permeabilized with 0.1% Trtiton X100/PBS, and blocked with block (2% horse sera, 0.4% BSA in PBS). The cells were
incubated with anti-V5 mouse monoclonal antibody (Invitrogen catalogue number
R960.25), washed with block, and incubated with Alexa Fluor 594 anti-Mouse IgG and
Alexa Fluor 488 Phalloidin (Invitrogen catalogue numbers A21200 and A12379 ),
washed with block, incubated with Dapi, and mounted with Gold Prolong anti-fade
medium (Invitrogen catalogue number P36930 ).

(g) Neurite assay
PC-12 cells were transfected with V5 tagged vectors containing either wild type SMS
or mutations from the original SRS family [6] or the present family and
immunofluorescence was done as described. Cells expressing the different constructs
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were imaged on a Zeiss Observer.A1 AX10 inverted microscope using AxioViosion
software 4.8. Cells with at least one neurite process, the length of which was at least the
width of the cell body, were counted as positive. Three sets of one hundred cells were
counted for each sample.

(h) Western blot
The membrane was blocked with 2% BSA/TBST, probed with anti-spermine
synthase antibody (Abnova catalogue number H00006611-M01), rinsed in TBST,
incubated with anti-Mouse IgG HRP (Pierce catalogue number 31432), rinsed in TBST,
and detected on x-ray film after development with West Dura ECL Kit (Pierce). The
membrane was stripped with Restore Western Blot Stripper (Pierce catalogue number
21059), blocked with 2% BSA/TBST, probed with anti-GAPDH antibody (Santa Cruz
Biotechnology catalogue number 32232), rinsed in TBST, incubated with anti-Mouse
IgG HRP (Pierce catalogue number 21059), rinsed in TBST, and detected on x-ray film
after development with West Dura ECL Kit (Pierce catalogue number 34075).The films
were analyzed using NIH Image J software.

(i) Native gel electrophoresis
Patient lymphocytes were centrifuged at 450g for 3min, resuspended in PBS, and
centrifuged at 450g for 3min. The PBS wash was repeated.

The cell pellet was

resuspended in ice cold native gel sample buffer(0.62mM Tris HCL pH 6.8, 0.01%
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bromophenol blue, 105 glycerol), and sonicated. Equal sample volumes were separated
on a 7.5% native gel and transferred to nitrocellulose. The membrane was blocked with 2%
BSA/TBST, probed with anti-spermine synthase antibody (Abnova catalogue number
H00006611-M01), rinsed in TBST, incubated with anti-Mouse IgG HRP (Pierce
catalogue number 31432), rinsed in TBST, and detected on x-ray film after development
with West Dura ECL Kit (Pierce catalogue number 34075). An equivalent amount of
protein was denatured in Lamelli buffer and separated on a 4-20 SDS PAGE gel (Fisher),
transferred to nitrocellulose and western blotted for GAPDH as indicated above.
In Silico Modeling
The pdb file of SMS was downloaded from the pdb bank and fixed following the
same protocol introduced in Chapter2. Figure 4.1 shows 3D structure of the human native
SMS with the ligands of SPD and MTA. And the corresponding mutation site Y328 is
represented by the colored balls. The energy calculations and MD simulations were
carried for the analysis of the effect of Y328C on SMS function.
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Figure 4.1 The 3D structure of the SMS dimer. The green one is C chain while the cyan
one is D chain. The disease-causing mutation site is shown with colored balls (orange:
carbon atom; red: oxygen atom; and blue: nitrogen atom); SPD and MTA are represented
with magenta stick and yellow stick respectively.

Results
Results from Clinical and in Vitro Experiments
All of the experimental data was provided by Dr. Charles Schwartz’s group at
Greenwood Genetic Center and Dr. Hilde Van Esch, at the Center for Human Genetics,
University Hospitals Leuven, Herestraat 49, B3000, Leuven, Belgium.
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(a) Clinical
The index patient, IV:3 (Figure 4.2), was born as the third child of healthy and
unrelated parents. His older brother and sister are healthy. Before birth intra-uterine
growth retardation was noted, as well as a single umbilical artery. He was born at 36
weeks of gestation with weight of 2000 g (10th centile) and length of 42 cm (below 3rd
centile). He was transferred to the neonatal unit because of recurrent hypoglycemia,
which resolved spontaneously. At that time a sacral dimple was noted. At the age of 2
years and a half, the boy was seen by a clinical geneticist because of global
developmental delay, with especially delayed language development. He learned to walk
at age 18 months. Despite speech therapy, his active and passive language development
remained delayed with echolalia and poor understanding. An IQ test (WPPSI-R) at the
age of 6 years showed a borderline to mild intellectual disability (total IQ 74) with a
discrepancy between verbal (VIQ 72) and performal IQ (PIQ 86). He went to a special
school for children with mild ID. In the following years he was seen at several occasions
at the pediatric consultation because of growth delay and especially low weight gain. A
metabolic and gastro-enterologic work-up was, however, normal. At recent re-evaluation
at the age of 13 years we saw a friendly slender boy with weight (24.7 kg) and length
(138.7 cm) both below the third centile. Head circumference is 52 cm which is at the 10th
centile (Table 4.1). He has a frontal upsweep and mild frontal bossing, pronounced nasal
bridge, small mouth and low-set ears. His build is slender with mild kyphoscoliosis and
long fingers. We did not observe facial asymmetry, nor abnormal gait or other
neurological symptoms. He shows a good social interaction with peers and has good eye
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contact. Because of rather rigid and perfectionistic behavior a neuropsychological
examination was performed, but no diagnosis of autism spectrum disorder could be
retained.

Figure 4.2 Pedigree of family L091. Males with proved mutation in SMS are indicated
with an *. Males II-5 and II-6 are presumed to have Snyder-Robinson syndrome because
they had intellectual disability. Individuals available for molecular analysis are indicated
by “DNA.”

Table 4.1 Clinical presentation of affected males in family L091
Clinical Features

Age
Intellectual Disability

Proband

Uncle

(IV-3)

(II-3)

13
+ (mild)

Published†

+ (mild-moderate)

10/10 (5 profound/
severe, 5 mild/moderate)
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Asthenic body build

+

+*

10/10

Diminished muscle mass

+

-

10/10

Prominent lower lip

-

+

10/10

Speech abnormalities

echolalia

Slow

10/10

Osteoporosis

nd

nd

7/7

Long hands

+

-

8/10

Kyphscoliosis

+

-

8/10

High narrow or cleft

+

+

6/8

Facial asymmetry

-

-

6/10

Unsteady gait

-

-

6/10

Long great toes

+

-

8/10

palate

†Taken from Table 4.1, Becerra-Solano et al. 2009 (5).
* present at a young age, less pronounced in adulthood
nd = not determined

The younger brother of the mother, individual III:3, also followed special school and
works now in a sheltered environment. As a child and at young adult age, this man was
also extremely slender. Apparently the maternal grandmother was never able to read or to
write. She also had two brothers with intellectual disability. These individuals were not
available for clinical examination or testing.
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Analysis of the data obtained by RainDance-amplification and sequencing by the
Illumina/Solexa system identified a mutation, c.1084A>G (p.Y328C), in the SMS gene in
the index patient. This mutation was subsequently confirmed by Sanger sequencing and
was also present in the carrier mother and her brother. The mutation was absent in the
healthy brother of the patient.

(b) Spermine/spermidine ratio
In order to confirm the pathogenecity of the p.Y328C mutation in the SMS gene, the
spermine/spermidine ratio was determined utilizing lymphoblastoid cells prepared from
the proband. The patient’s ratio of 0.529 was significantly different from the average
ratio of two controls, 1.87 (Table 4.2). This low ratio is similar to that reported for the
three previously published patients with Snyder-Robinson syndrome [1,2,5]. Next, the
spermine synthase activity was measured to insure the reduced spermine/spermidine ratio
was due to a deficiency in activity of SMS. The activity of the proband’s SMS was 381
units, significantly below the average of 6,257 units found in three control samples
(Table 4.1). Again, this was consistent with results published previously for other SMS
mutations [1,2,5].
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Table 4.2 Spermine synthase activity and spermine/spermidine ratio
Sample

SMS activity*

Spermine/spermidine

Normal control 1

7221

2.25

Normal control 2

7365

1.50

Patient IV-3

364

0.53

*activity is measured in counts of spermine d8 generated per mg lysate per hour from
spermidine d8.

Although the low spermine/spermidine ratio and low spermine synthase activity are
consistent with the males having Snyder-Robinson syndrome, their presentation is mild
relative to that observed in other patients reported with SRS (Table 4.1) [1,2,5,7]. In an
attempt to better understand this variability, we examined the neurite length of PC-12
cells transfected with constructs of SMS. A form of this assay has been utilized to study
effect of polyamines on NGF stimulated PC12 cells ([8] and the effect of SSRI inhibitors
on neurite outgrowth in NGF induced PC12 cells ([9] As shown in Figure 4.3, the Y328C
mutation in SMS did not result in a significant reduction in the percentage of cells which
had a neurite length at least the same as its cell body width. However, the pathogenic
SMS mutation identified in the original SRS family caused a significant decrease in this
number as compared to cells transfected with WT SMS. This finding might correlate with
the milder SRS presentation in family L091.
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Figure 4.3 Neurite analysis of PC12 cells transfected with plasmids containing different
contructs of SMS. The plasmids had a V-5 tag which allowed immunofluorescent
identification of transfected cells. LacZ = negative control; WT = wild type SMS;
original patient = c. 329 +5G>A (truncating); patient IV-3 = proband, family L091. s=
statistically significant; ns= not statistically significant.

(c) Western blot analysis
As shown above, the p.Y328C missense mutation in SMS results in SRS due to the
almost complete reduction of enzymatic activity. This could be a result of many things,
one of which would be the absence of protein. This possibility was investigated by
Western blot analysis. As shown in Figure 4.4, the protein level is indeed reduced to
about 20% of normal. However, this level would likely result in 80% reduction of activity
but not in complete reduction (Norris et al. submitted). One possibility is that the protein
does exist as a dimer which is required for activity.
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Figure 4.4 Western blot of SMS in lymphoblast cell lines. A. 10 ug of lymphoblast lysate
was prepared in Lamelli sample buffer, separated on a 4-20 % SDS PAGE gel, and
western blotted for SMS and GAPDH (n=3). GAPDH was used as a loading control. B.
The blots were analyzed by NIH Image J and the ratio of SMS to GAPDH reported.
Patient A = proband from original SRS family (2); Patient B = proband in present family.

(d) Monomer/Dimer analysis
Native gel analysis of patient lymphoblastoid cells was conducted in order to
determine the level of the dimer form of the Y328C spermine synthase protein since SMS
functions only when it exists as a dimer. As shown in Figure 4.5, SMS protein in the
patient exists almost completely as a dimer. The level is about 20% that of controls
consistent with the total protein analysis. Since the SMS protein exists as a dimer in the
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patient and is present at 20% of control levels, the lack of enzymatic activity is difficult
to understand. Therefore, an in depth in silico modeling study was undertaken.

Figure 4.5 Native gel analysis of SMS in lymphoblast cell lines. A. 10 ug of lymphoblast
lysate was prepared in native sample buffer, separated on a 7.5 % native gel, and blotted
for SMS. An equivalent amount of lysate was prepared in lamelli sample buffer,
separated on a 4-20% SDS PAGE gel and blotted for GAPDH (n=3). GAPDH was used
as a loading control. B. The blots were analyzed by NIH Image J and the ratio of SMS to
GAPDH reported. Patient A = proband from original SRS family (2); Patient B =
proband in present family.
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Results from in Silico Modeling
The computational results indicate that Y328C mutation has little effect on dimer
affinity. The predicted ΔΔΔG(binding_Mut) is 1.25 kcal/mol, which is small effect from
computational stand point (Table 4.1S). Our previous work indicates that the results from
MMGB calculations overestimate the experimental folding free energy changes by a
factor of approximately ten [10]. Similar effect is expected for binding free energy. Thus,
the expected dimer affinity change can be estimated to be about 0.125 kcal/mol. Such
minor effect on dimer affinity upon Y328C is not surprising since the mutation site Y328
is far away from the dimer interface (Figure 4.1). At the same time, it should be
mentioned that this small energy change favors the dimer formation. This confirms the
experimental observation that although the amount of protein is reduced to 20%, all
remaining proteins form dimers.
The calculated folding free energy change, averaged over three force field parameters,
is about three times larger (ΔΔG(mut)= -3.40 kcal/mol; Table 4.2S). The negative sign
indicates that the mutation makes the monomers less stable than the wild type protein.
Having in mind the close proximity of the mutation site to the active pocket of SMS, such
a destabilization may have significant effect of the catalysis. However, the observations
made by in vitro and in silico investigations indicate that the monomer destabilization
does not affect the dimer formation. Thus the effect on the catalysis should stem from
perturbations of the active site wild type properties.
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Both the wild type and the mutant C-terminal domains were subjected to MD
simulations as described in the method section. Figure 4.6 shows the RMSD as a function
of simulation time. It can be seen that RMSD fluctuations in wild type structure quickly
reach saturation and remain within 1.4Å, while the mutant fluctuations do not completely
saturate and are much larger (>2Å) than those of the wild type. This is consistent with the
results of the energy calculations indicating that the mutant is less stable than the wild
type. The increase of the conformational dynamics of the Y328C mutant is so significant
that perhaps it is the major factor contributing to the loss of activity.

Figure 4.6 RMSD of the wild type (WT) and the mutant (Y328C) as a function of the
simulation time.
Structural analysis of the effect of Y328C mutant was carried out to reveal the
changes in the hydrogen bond network in the vicinity of the mutations site (Figure 4.7). It

92

can be seen that in the wild type Tyr328 is involved in two hydrogen bonds. In both cases
Tyr328 oxygen serves as hydrogen acceptor accepting hydrogen bond from Tyr312 and
Thr314. In contrast, the mutant, Cys328, plays the role of hydrogen donor providing a
hydrogen bond to the neighboring Tyr 258. Such a dramatic change of the hydrogen
bond pattern around the active site of SMS definitely should have a large impact on the
catalysis.

Figure 4.7 The effects on H-bond network due to the missense mutation Y328C. The
yellow balls represented carbon atoms; the red balls represented oxygen atoms and the
white balls represented the hydrogen atoms. (A) The energy minimized WT structure
with OPLS; (B) The energy minimized mutant structure with OPLS.
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Discussion
The clinical findings observed in patients III-3 and IV-3 are very similar to those
reported for other patients with Snyder-Robinson syndrome (Table 4.1) [1,2,5,7].
Originally, this rare X-linked intellectual disability syndrome was mainly characterized
by tall stature, a thin marfanoid habitus, some facial asymmetry, osteoporosis and
kyphoscoliosis [6]. Reevaluation identified additional features such as an unsteady gait,
nasal speech, pectus excarinatum, long toes and seizures [5,7]. The identification of a
mutation in the spermine synthase gene as the cause of SRS allowed additional families
to be reported [1,2]. These additional two families, one from Brazil (de Alencastro, 2008)
and another from Mexico [2], led to the expansion of the phenotype. Although the
asthenic build was always present, not all males had a tall stature. The severity of ID now
included severe to profound along with mild to moderate. A short philtrum, mandibula
prognatheism and pectus carinatum were also noted, and seizures are not always present.
The Belgium patients reported here present with a milder phenotype, the oldest
affected man being able to live and work in a sheltered environment. Both show similar
physical characteristics and have speech problems. They do not, however, have any gait
problems. It is unclear why they are more mildly affected although their
spermine/spermidine ratio is not lower than that reported for other affected males (Table
4.1) [1,2,5] and the spermine synthase activity is as low as more severely affected males
(Table 4.1). We noted however a difference in a neurite assays involving transfected
PC12 cells. The percent of cells with neurites longer than the width of the cell body was
not statistically different from cells transfected with wild type SMS (Figure 4.3). This is
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in contrast to the significantly reduced number of neurite outgrowth in cells transfected
with truncated SMS caused by the splice mutation in the original SRS family. This would
seem to indicate that the p.Y328C mutation does not interfere with neurite outgrowth and
differentiation.
In vitro experiments showed that the newly discovered SRS causing mutation Y328C
abolishes SMS activity, while retaining about 20% of the protein and having no effect on
dimer formation. This is in contrast with previous in vitro and in silico investigations
showing that another missense mutation, the G56S mutation, causing SRS [11] abolish
the function of SMS by disrupting dimer formation. Instead, the Y328C mutation has
little effect of the dimerization but huge effect on conformational dynamics and hydrogen
bond network around the active site (Figure 4.7) and thus greatly reducing the activity.
The molecular effect of this mutation (Y328C) is quite similar to the suggested
molecular mechanism of another SRS causing mutation I150T. They are both situated in
the vicinity of the active site and are far away from the dimer interface. However, in
contrast to I150T, the Y328C mutant affects the hydrogen bond network of residues
involved in the geometry of SPD/SPM binding pocket, rather than the MTA pocket. At
the same time, these two sites, 150 and 328, were predicted to have similar mutability
(see supplementary result and Ref. [12]). Almost any substitution is expected to have
dramatic effect on the mutant SMS stability, dynamics and hydrogen bond network
around the site of mutation. Other known to date SRS causing mutations are G56S and
I132V, which are located at the dimer interface. Previous work [11] showed that they do
not affect the active site, but disrupt the SMS function by affecting dimer formation or
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stability of the SMS. Thus, comparison of the current work with previous investigations
[11] demonstrates that SRS is caused by various molecular mechanisms. However,
despite of the different molecular mechanisms, the result at cellular level is a deviation
away from the wild type spermine/spermidine ratio resulting in SRS.
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CHAPTER FIVE
IN SILICO AND IN VITRO INVESTIGATIONS OF THE MUTABILITY OF
DISEASE-CAUSING MISSENSE MUTATION SITES IN SPERMINE SYNTHASE
Abstract
Spermine synthase (SMS) is a key enzyme controlling the concentration of spermidine
and spermine in the cell. The importance of SMS is manifested by the fact that single
missense mutations were found to cause Snyder-Robinson Syndrome (SRS). At the same
time, currently there are no non-synonymous single nucleoside polymorphisms, nsSNPs,
(harmless mutations) found in SMS, which may imply that the SMS does not tolerate
amino acid substitutions, i.e. is not mutable. To investigate the mutability of the SMS, we
carried out in silico analysis and in vitro experiments of the effects of amino acid
substitutions at the missense mutation sites (G56, V132 and I150) that have been shown
to cause SRS. Our investigation showed that the mutation sites have different degree of
mutability depending on their structural micro-environment and involvement in the
function and structural integrity of the SMS. It was found that the I150 site does not
tolerate any mutation, while V132, despite its key position at the interface of SMS dimer,
is quite mutable. The G56 site is in the middle of the spectra, but still quite sensitive to
charge residue replacement. The performed analysis showed that mutability depends on
the detail of the structural and functional factors and cannot be predicted based on
conservation of wild type properties alone. Also, harmless nsSNPs can be expected to
occur even at sites at which missense mutations were found to cause diseases.
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Background
Spermine Synthase (SMS) is an enzyme which converts spermidine (SPD) into
spermine (SPM), both of which are polyamines and play an essential role in normal
mammalian cell growth and development [1-4]. The importance of SMS for normal cell
functioning is illustrated by the fact that the malfunctioning of SMS is associated with the
Snyder-Robinson Syndrome (SRS, OMIM 309583). Currently, there are no reported non
synonymous single nucleoside polymorphisms (nsSNPs) in SMS. These are presumably
harmless mutations found in the general population. Could this be a consequence of a
potential resistivity of SMS to amino acid substitutions? This is a question that the
present chapter will address.
In the previous chapters, we took advantage of the available 3D structure and
experimental data and carried out an in silico analysis of the effects of the missense
mutations, p.G56S (c.267G>A) [5], p.V132G (c.496T>G) [6] and p.I150T (c.550T>C),
which are known to cause SRS [7]. Our work showed that the mutations affect dimer and
monomer stability and perturb the hydrogen bond network of the functionally important
amino acids. However, no attempt has been made to assess the mutability of these sites
and to address the possibility that other amino acid substitutions, which are different from
those known to cause SRS, could potentially cause SRS or, more generally, be harmless.
nsSNPs and missense mutations can affect wild type protein function by a variety of
mechanisms [8-10], however, the most common effect is destabilization of the native
structure [11-16], altering macromolecular interactions [17] or affecting wild type
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hydrogen bond patterns [7,18,19]. This study focuses on predicting the effects of amino
acid substitutions on these three important native characteristics of SMS. To make the
task computationally tractable, the mutational analysis is restricted to the sites (G56,
V132, and I150) which are clinically known to harbor missense mutations causing SRS
(Figure 5.1). We mutate in silico the wild type residue at these positions to each other
amino acid and predict the effect on stability of the SMS monomer, affinity of SMS
dimer, the ionization states, and the hydrogen bond network within SMS.

Figure 5.1 3D structure of SMS with the three mutation sites shown as colored balls.
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Materials and Methods
The protein structures, energy calculation, and pKa calculation was following the
same protocol we used in previous protocols and the details were shown in Chapter 2. In
addition, to study the mutability of each mutation sites, another important definition, ZScore, is introduced.

Z-Score
In statistics, a standard score (Z-Score) indicates how many standard deviations an
observation or datum is above or below the mean. The quantity Z represents the distance
between the raw score and the population mean in units of the standard deviation. Z-score
is negative when the raw score is below the mean and positive when above (see
Wikipedia: http://en.wikipedia.org/wiki/Standard_score). In our case, the distribution is
constructed from either ΔΔG(folding_mutation) (the change of the folding free energy,
Equ. 2.2) or the ΔΔΔG(mut) (the change of the binding free energy, Equ. 2.10).
Z-score = (x-μ)/σ
where:
x is a raw score to be standardized;
μ is the mean of the population;
σ is the standard deviation of the population
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(5.1)

In this work, we use Z-Score to reflect the mutability of the mutation sites on stability
of the monomers and affinity of the dimer. A large Z-score indicates a mutation that
causes an effect significantly different from the average effect at the site.

Classification Nomenclature
The main goal of this work is to probe (in silico) the mutability of sites in the SMS
harboring missense mutations causing SRS. It is accomplished by performing energy and
pKa calculations. However, currently there is no metric which suggests how big the
energy or pKa change should be in order to consider a given mutation to be disease
causing or not. Perhaps such a threshold will be case dependent. However, in order to
provide a better quantitative description of our results we introduce two terms:

(a) “tolerance”
If the mean of the distribution of the energy change (either binding or folding free
energy change) upon amino acid substitutions at a given site is larger than the half of the
standard deviation (HSTD) for the site (Supporting information, Tables 5.1S and 5.2S),
then the site is classified as a “non-tolerable” site. Otherwise it is termed “tolerable”. In
the case of pKa calculations, the cut-off is taken to be 2pK units cumulated over all
titratable groups. This threshold is selected empirically.
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(b) “specificity”
A site is termed “specific” if more than 20% of amino acid substitutions are predicted to
cause different effects from favorable to unfavorable energy change with a magnitude
larger than the half of the standard deviation (HSTD) associated with the site (Tables
5.1S and 5.2S in supplementary material). If the effects follow the same trend, then the
site is termed “non-specific”. In terms of pKa calculations, a site is termed “specific” if
the pKa shifts among different types of substitutions differ by more than 2 pK units
(empirically selected threshold).

Experiments in vitro
All of the following experimental data is provided by Dr. Charles Schwartz’s group at
Greenwood Genetic Center.
(a) RNA
RNA was prepared from a control cell line and from patient lymphoblast cell lines
[20] using GenElute Mammalian Total RNA Miniprep kit (Sigma catalogue number
RTN-70).

103

(b) Plasmids Construction
cDNA was prepared with Superscript First strand Synthesis Kit

for RT-PCR

(Invitrogen catalogue number 11904-018) from 2ug of RNA prepared from lymphoblast
cell lines. The gene specific oligo SMS-RT (5’ GAA GGC TAT TTG CAG CAC ATG
TGA 3’), was used to generate the first strand cDNA for the control and G56S, V132G,
and I150T mutations. A PCR reaction with the oligos SMS-F (5’ CAC CAT GGC AGC
AGC ACG GCA CAG CAC G 3’) and SMS-R (5’ GGG TTT AGC TTT CTT CCA AAC
AGT 3’) and PFU Turbo (Stratagene catalogue number 600250) was employed to
generate the insert. The fragment was run on a 1% TAE agarose gel and purified with a
Gel Extraction Kit (Qiagen catalogue number 28704). The purified product was cloned
into pcDNA3.1D/V5-His-Topo vector using the pcDNA3.1 Directional Topo Expression
Kit (Invitrogen catalogue number K4900-01). All plasmids generated from this kit have a
V5 tag on the C-terminus. Plasmids were sequenced to confirm the insert with the vector
specific primers PC (5’ GGG AGA CCC AAG CTG GCT AGT 3’) and BGH (5’ TAG
AAG GCA CAG TCG AGG 3’) and insert specific primers SMS285For (5’GAG AAT
TTA CCC ACA TGG ATT 3’), SMS330Rev (5’GTG GGC CAG TAT CTG TCG AT
3’), SMS660Rev (5’ GTC TCC ACC TCC CAG AAT GA 3’)and SMS960Rev (5’GGA
GAC GTG GAG ATT GGA ACA 3’).
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(c) Site-directed mutagenesis (Table 5.3S)
Primers were designed to generate the various amino acid changes (sequences
available upon request) in the control SMS construct using the QuikChange Primer
Design Program online program provided by the Stratagene
(http://www.stratagene.com/qcprimerdesig). Mutations were generated using the
QuikChange II Site-directed Mutagenesis kit (Stratagene catalogue number 200523) and
the specifically designed primers. All plasmids were sequenced to confirm the specific
mutation mutations generated without additional changes.

(d) Cell culture
HEK cells were obtained from American Tissue Culture Collection. The cells were
cultured in DMEM (Sigma catalogue number D5796) supplemented in 10%FBS (Atlanta
Biologicals catalogue number S12450H), 1x Penicillin/Streptomycin (Sigma catalogue
number P0781), 2mM glutamine (Sigma catalogue number G7513) in a 5% CO2
humidified 37C incubator.

(e) Transfection
HEK cells were cultured on poly-l-lysine (Sigma catalogue number P4707) coated 24
well tissue culture dishes in growth media 18-24 hrs prior to transfection. A transfection
complex containing one microgram of plasmid DNA and 2 ul of Lipofectamine 2000
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(Invitrogen catalogue number 11668-027)/100ul of DMEM was added to each well. After
4 hours, the transfection complexes were removed, the cells washed one time with PBS,
and growth media was added to the cells.
(f) Native gel electrophoresis
Forty-eight hours after the transfection, the cells were washed twice with ice cold
PBS (Sigma catalogue number D8537) and scrapped into 100 ul of ice cold native gel
buffer(0.62 mM Tris HCL pH 6.8, 0.01% bromophenol blue, 10% glycerol). The samples
were vortexed and sonicated briefly and kept on ice.

Ten ul of each sample was

separated on a 7.5% native polyacrylamide gel and transferred to nylon-supported
nitrocellulose (Fisher catalogue number WP4HY330F5) using a Biorad Semi-dry
Transfer apparatus at 24 volts for 1 hour. After western transfer, the nitrocellulose
membrane was rinsed twice with TBST (25mM Tris, 150mM NaCl, 0.2% Tween 20, pH
8.0) for 5 minutes each.

(g) Western blot
Blocking buffer (5% nonfat dry milk in TBST) was added to the membrane and
incubated at room temperature for 1 hour with shaking. The membrane was then
incubated with Anti-V5 monoclonal antibody (Invitrogen catalogue number R960-25)
diluted 1:5000 in fresh blocking buffer at 4˚C with shaking, overnight. The antibody
solution was removed and the membrane was rinse three times for 20 minutes with TBST
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at room temperature with shaking. The membrane was incubated in anti-mouse IgG
Horse Radish peroxidase conjugate (Pierce catalogue number 31432) diluted 1:10,000 in
2% BSA (Sigma catalogue number A4503)/TBST for one hour with shaking at room
temperature. The antibody solution was discarded and the membrane was rinsed three
times with TBST for 20 minutes at room temperature with shaking. SuperSignal West
Dura Extended Duration Substrate (Pierce catalogue number 34075) was added to the
membrane for five minutes and the membrane exposed to autoradiography film
(Midlands X-ray catalogue number agfaB). The film was processed on a Konica SRX
101A film developer.

Results
Effect of Mutations on the Stability of the Monomers
Figure 5.2 summarizes the results of structure-based energy calculations on the
monomer stability with three different force field parameters (Charmm27, Amber98 and
Oplsaa). The results of each force field were then averaged. The results were averaged
over the C and D chains as well. All energies are in kcal/mol. A negative energy change
value indicates that the mutation decreases the stability of the monomer, while a positive
value increases the stability. Below we analyze the outcome for each mutation site
separately:
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Figure 5.2 The results of structure-based energy calculations on the monomer stability
with three different force field parameters (Charmm27, Amber98 and Oplsaa) and then
results averaged for the clinically observed missense mutations G56S, V132G, and I150T,
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we used four force fields, which are Charmm27, Charmm19, Amber98 and Oplsaa, then
results averaged). The left panels are the predicted energy changes of the folding free
energy and the right panels are the Z-Scores of folding energy change. The in the graph
is the mean of folding energy change over the 19 mutations. The results are shown for
G56 (a-b), V312 (c-d) and I150 (e-f) sites.

(a) G56 site
The G56 site is situated on a sharp loop connecting two beta strands and is almost
totally exposed to the water phase in monomers. The fact that position 56 in the WT
structure is occupied by a Gly residue is typically attributed to a necessity of the
polypeptide chain to make a tight turn, while avoiding sterical constrains. However, the
energy calculations (Figure 5.2(A)) indicate that many amino acid replacements have
almost no effect on the stability or make the folding energy slightly bigger, including
residues with large side chains, such as Trp and Ile. The structural reason for this is that
there is enough room for these side chains to find relative favorable positions and to
compensate for the stress induced by the sharp backbone turn. At the same time, there are
several amino acids which are predicted to significantly increase the monomer’s stability.
The most prominent examples are Lys, Arg, and Tyr, which are expected to increase
monomers stability by almost 10 Kcal/mol. This is due to the negative potential created
by several acidic groups (Asp 77 (Asp 79 in 3C6K) and Asp 79 (Asp 81 in 3C6K)) and
backbone oxygens of the residues in the loop where is the mutation site, which makes
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insertion of positively charged Lys and Arg energetically favorable. The Tyr mutation is
favorable due to the relatively long side chain of Tyr that allows formation of H-bond
with Gln 72 (Gln 74 in 3C6K). The most puzzling is the prediction that Met substitution
should increase the monomers’ stability, however, during the minimization process, its
side chain manages to bend and point toward the protein’s interior and thus to become
energetically favorable.
Figure 5.2(B) shows the Z-scores, arranged in increasing order, of all amino acid
substitutions at site 56. The mean of the distribution is a positive number, indicating that
most of the substitutions are expected to increase the monomers’ stability. The mean is
2.2 Kcal/mol, while the HSTD calculated for this site 1.9 Kcal/mol. Formally speaking
the site should be classified as “non-tolerable”, but since the mean and the threshold are
so close and because of many substitutions that cause almost no effect on stability (Figure
5.2(A)), it is classified as “tolerable”. The tolerability can be attributed to the mutations
for which the amplitude of the folding energy change is relatively small (all cases with Zscore between 0.0 and -1.0). Because of this, many mutations will have no effect to the
SMS folding energy, and perhaps, will not affect its function. There are only a few
mutations that are predicted to destabilize the monomers, but the amplitude of the folding
energy change is small, so the site is classified as “non-specific”. Altogether, site 56 is
termed a “tolerable non-specific” site and is quite likely to be able to hold harmless
variations, based on the folding energy alone.
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(b) V132 site
In a monomeric state, the V132 site is exposed to the water and the side chain of the
WT residue is parallel to the molecular surface, pointing toward a large cavity of the
SMS protein. There are no hydrogen bond acceptors/donors in the close proximity of this
site, but the site itself is situated within a strong negative electrostatic potential generated
by several acidic groups. This negative potential, perhaps, is part of a large electrostatic
funnel that guides the positively charged SPD inside the SMS to carry the reaction
forward.
The results of the folding free energy calculations show mixed trends, some of the
mutation destabilizing while other stabilizing monomeric structures (Figure 5.2(C)). Most
of the mutations are predicted to cause very small perturbations of the folding energy,
with several prominent exceptions. Negatively charged amino acids, Glu and Asp, are
found to destabilize the monomers. This is due to the fact that the site is already within
strong negative potential and introducing extra negative charge decreases the stability.
Relatively short, positively charged amino acids, like His and Lys, take advantage of this
and increase the monomers’ stability.
The Z-score distribution (Figure 5.2(D)) reflects the above observations and has a
mean of almost zero. Such a distribution will, according to our protocol, classify the
V132 site as a “tolerable” site with respect to the folding free energy. At the same time,
there are mutations predicted to cause opposite effects on the stability with a magnitude
larger than the HSTD of 3.1 Kcal/mol. According to our nomenclature, such a site is a
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“tolerable specific” site. The negatively charged amino acids (Glu and Asp) were found
at the left wing of the Z-score distribution, while the positively charged acids reside on
the right side. This indicates that site V132 is quite sensitive to the polarity of the charge
that is positioned there.

(c) I150 site
The side chain of Ile at position 150 is totally buried in the protein’s interior and any
mutation will result in a side chain buried as well. This site is well packed and does not
allow for large structural reorganization upon amino acid substitution. It also experiences
a strong negative potential coming from a large number of acidic residues in the
neighborhood.
The results of the folding free energy calculations are shown in Figure 5.2(E). It can
be seen that almost any mutation is expected to greatly reduce the monomers’ stability.
As it should be expected, position 150 does not tolerate negatively charge amino acids –
both Glu and Asp mutations are predicted to decrease the monomers’ stability by more
than 14 Kcal/mol. Polar and hydrophobic residue insertions have smaller effects (as
compared with charge residues) on the stability. This is due to a combination of factors,
as position 150 is buried, allowing for new hydrogen bond formations, but the space is
very confined. Thus, some residues may manage to establish hydrogen bonds, as the
clinically observed I150T, but they have to pay the desolvation cost, and thus the energy
change is reduced. Only two substitutions are predicted to increase the monomers
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stability, His and Arg substitutions. This is due to their specific side chain geometry,
which permits the formation of strong favorable interactions and in turn over
compensates the desolvation cost.
The Z-score is shown in Figure 5.2(F) and the mean of the change of folding free
energy distribution is a large negative number (HSTD is 2.6 Kcal/mol). Practically any
mutation will significantly destabilize the monomeric structure. Such a site is referred to
as a “non-tolerable non-specific” site with respect to the folding free energy. Similarly to
the V132 site, the Asp and Glu residues are at the left wing of the Z-score distribution,
indicating that site 150 does not support negative charge.

Effect of Mutations on the Affinity of the Dimer
Dimerization is absolutely required for the normal function of SMS as it was shown
experimentally [21]. Therefore, any change of the dimer affinity caused by a mutation is
expected to affect SMS function. Below we present the results of in silico modeling of
the effects of mutations on the SMS dimer binding free energy.

(a) G56 site
Position G56 is at the periphery of the dimer binding interface but the side chain of any
residue at this position will point toward the opposite partner. It should be clarified that
while SMS is a homo-dimer, the interface is not symmetrical, i.e. site G56 is not
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symmetrical across the interface. Across the interface there are neither specific hydrogen
donors or acceptors nor charged residues that could be involved in specific interactions
with an amino acid at position 56.
Figure 5.3(A) shows the binding free energy changes per amino acid substitution. It
can be seen that the vast majority of the mutations destabilize the dimer; however, at the
same significant fraction of the rest of the substitutions has little effect. There is no clear
trend with charge polarity, hydrophobicity, or the size of the side chain, which can be
attributed to these two groups. In one case, a large hydrophobic group (Trp) causes
almost no change in the binding affinity, while the Ala mutation is predicted to
destabilize the dimer. A similar example is provided by the effects on substitution with
Glu and Asp, both negatively charged, but predicted to cause a very different affect on
the affinity. The analysis of the cases showed that the effect on the binding free energy
strongly depends on the ability of the side chain to adopt a favorable geometry at the
interface and equally important on the predicted effect on monomers stability (the effect
of a mutation on the binding free energy is the difference between the effect on dimer and
monomers stabilities).

114

Figure 5.3 The results of structure-based energy calculations on the dimer affinity
(binding free energy) with three different force field parameters (Charmm27, Amber98
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and Oplsaa) and then results averaged for the clinically observed missense mutations
G56S, V132G, and I150T, we used four force fields, which are Charmm27, Charmm19,
Amber98 and Oplsaa, then results averaged). The left panels are the predicted energy
changes of the binding free energy and the right panels are the Z-Scores of binding
energy change. The in the graph is the mean of binding free energy change over the 19
mutations. The results are shown for G56 (a-b), V312 (c-d) and I150 (e-f) sites.

The mean of the corresponding distribution (Figure 5.3(B)) is a large negative
number (HSTD=3.6 Kcal/mol) indicating that almost any substitution at G56 is predicted
to decrease dimer affinity. Thus in terms of mutability, the site 56 is classified as a “nontolerable” site. While there is no clear pattern to be able to determine which effect
dominates (charge, hydrophobicity etc), the vast majority of the substitutions make the
binding weaker. Therefore the site is classified as a “non-specific” site in terms of
binding affinity, despite the prediction of the His substitution to increase affinity, since it
is an isolated case. Although no clear pattern is observed, it is interesting to note that Asp
is again the amino acid substitution with largest negative Z-score.

(b) V132 site
The V132 site is exactly at the dimer interface, but the side chain of the WT residue is
parallel to it. In addition, the V132 side chain points toward a large cavity situated at the
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interface. As it was mentioned, the V132 position experiences a strong negative potential
generated by neighboring acidic groups, which in the case of a dimer is stronger than the
monomers, due to the contribution of the charges of the other monomer within the dimer.
In terms of the binding affinity, the site V132 is a classic example demonstrating the
role of electrostatics on binding free energy. It can be seen (Figure 5.3(C)) that amino
acid side chains carrying charge strongly affect the binding affinity, while no other
mutation (except Trp) causes a change in the binding free energy. As indicated above, the
position of V132 is at the bottom of the cleft formed between SMS monomers being in
the dimer, where the pathway of the positively charged SPD coming into SMS is located.
The strong negative potential at the V132 site is the reason why acidic group substitutions,
Glu and Asp (Figure 5.3(C)), are predicted to greatly reduce dimer affinity. In contrast,
positively charged groups are found to increase binding affinity. The effect of the Trp
mutation is simply due to the hydrophobic effect, filling the cavity at the dimer interface
with the bulky hydrophobic side chain of Trp.
The mean of the corresponding distribution (Figure 5.3(D)) is a positive number;
however, it is mostly caused by several prominent contributions (positively charged side
chains), while most of the remaining substitutions cause little effect on the binding
affinity (HSTD = 2.5 Kcal/mol). Because of that, the site V132 is classified as a “nontolerable” but “specific” site. The effect strongly depends on the polarity of the charge of
the side chain at position 132. Again, the largest negative Z-score is associated with Asp
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and Glu, while positively charged side chains are at the right side of the Z-score
distribution.

(c) I150 site
The I150 site is far away from the interface and it is difficult to imagine any direct
effect of the binding, including long range electrostatic interactions.
The predicted binding free energy changes are shown in Figure 5.3(E). As anticipated,
all substitutions have almost no effect on the binding affinity, with exception of the Gly
mutant, which is obviously an artifact of our calculations. There is a slight tendency that
negatively charged groups may destabilize the binding, while positively charged groups
could make it tighter, but the effects are small, despite the long range of electrostatic
interactions.
The mean of the corresponding distribution is almost zero indicating that this is a
“tolerable” site (HSTD = 0.8 Kcal/mol). However, due to the magnitude of the calculated
changes, this site is classified as “specific” in terms of the binding affinity.
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Effects on pKa’s and Hydrogen Bond Network
Figure 5.4 shows the pKa changes induced by each amino acid substitution at each
site. The vertical axis of the graph is the sum of the pKa change. This pKa change was
calculated by the following formula:

∑ |

|

∑ |

|

(5.2)

where Sum(pKa) is the sum of the absolute value of the ith amino acid’s pKa change
due to the  th mutation (   Ala , Cys, Asp,....... ) through all titratable residues (from 1
to N). In our case, N is equal to 139, which means that in each monomer there are 139
titratable amino acids. The results were averaged over C and D chains.
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Figure 5.4 The pKa change due to each mutation for each monomer. The pKa shifts
caused by each mutation for both C chain and D chain have been calculated using MCCE
then results averaged.

The calculated pKa shifts, which reflect reorganization of the hydrogen bond network
upon each mutation, are shown in Figure 5.4. It can be seen that the hydrogen networks
around sites 56 and 132 are predicted to be less sensitive to mutations, while substitutions
at site 150 cause significant pKa shifts. This reflects the nature of the sites: the least
sensitive is site 132 because it is less populated by titratable groups than other sites
considered in this work. The site 56 has several titratable groups in the neighborhood, but
they are relatively distant from the site. In addition, neither of these residues is involved
either in catalysis or the binding, and thus does not directly contribute to the funding. In
contrast, the site 150 is close to the active site region and a side chain at position 150 can
establish new hydrogen bonds with residues participating in the hydrogen bond network
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involved in the catalytic reaction [7]. The largest is the effect of introducing titratable
groups, because of the long range of electrostatics. The site 150 is situated in a negative
potential environment and thus positively charged substitutions (Arg, Lys) are predicted
to cause the largest pKa shifts. Specifically, the Arg, having a long side chain, can
propagate toward the active site and affect the pKa and hydrogen bonding of active site
residues and thus directly affecting the kinetics of the reaction.
With regard to the pKa calculations and following the classification scheme in the
“Methods” section, site 56 is termed “non-sensitive specific”, site 132 is also “nonsensitive specific”, while site 150 is a “sensitive specific” site.

In vitro Experiments
Carrying experiments on all mutants investigated in silico would be too timeconsuming. Instead we select 6 mutants from the in silico analysis including the clinically
observed one. The selection of the mutants to be experimentally investigated is based on
the following considerations: we pick up three groups mutations which are predicted to
have strongest destabilizing/stabilizing effects on dimer affinity or monomer stability and
a mutant that is predicted to have almost no effect (but to introduce an amino acid with
drastically different physico-chemical characteristics from the wild type one). Such an
approach let us explore the most extreme cases.
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(a) G56 site
Mutations selected for in vitro experiments are: G56S (clinically observed mutation,
predicted to have little effect of monomer stability, but to strongly destabilize the dimer);
G56D (predicted to have no effect on monomer stability, but to lower drastically dimer
affinity); G56H (predicted to stabilize bot the monomer and dimer interactions); G56L
(expected to lower dimer affinity and have no effect on monomer stability); G56W
(predicted to have no effect) and G56Y (expected to increase monomer stability but to
lower dimer affinity). The in vitro experiments are shown in Figure 5.5(A). Two
distinctive patterns can be seen in Figure 5.5(A): (1) cases indicating the presence of both
monomers and dimers (WT and to certain extend, G56H) and (2) only monomer present
(G56D, G56L, G56W and G56Y). In case of WT SMS, the dimer band is darker/larger
than the monomer band (Figure 5.5(A)) indicating that the concentration of dimers is
greater than of monomers. This confirms the previous experimental observation that
dimer formation is crucial for the function of SMS (15). The clinically observed mutation,
G56S, is predicted to lower dimer affinity and the effect is confirmed by in vitro
experiments. Our in silico predictions for G56D, G56L and G56Y are also confirmed
experimentally since no dimer band is present for these cases (Figure 5.5(A)). The G56D
mutant deserves special attention since Asp56 is predicted by our pKa calculations to be
protonated in the dimer, but to be ionized in the monomer, but our energy calculations
were done assuming charged states for all titratable groups. The most closely related side
chain to a protonated Asp in our analysis is Asn, which is predicted (but not so much as
Asp) to lower dimmer affinity as well. Combined with the prediction that dimer
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formation will cause protonation of Asp56, which will require extra work, our
calculations that Asp56 will destabilize the dimer are correct. The mutant G56H is
interesting since it is the only one predicted to increase dimmer affinity and to increase
monomer stability. The in vitro experiments (Figure 5.5(A)) show a broad band spanning
from the monomer up to almost the dimer, but the “exact” dimer band is not populated.
However, the analysis of the calculated pKa’s reveals that His56 is not ionized in the
dimer, while it is ionized in the monomer (pKa(monomer)=7.1). This extra work to
deprotonate His56 will reduce the predicted stabilizing effect on the dimer affinity. The
experiments with the G56W mutant show no dimer formation, while our calculations
predict no effect on both dimer affinity and monomer stability. This mutant was
purposely selected for in vitro experiments because we were puzzled by the
computational predictions that such a bulky side chain as Trp will cause no effect
replacing Gly. Obviously, our computational protocol was incapable to account for all
details for the experiment and made wrong prediction.
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Figure 5.5 The experiments of gel electrophoresis for mutants at (A) G56 site; (B)
V132site; (C) I150 site. The upper region represents the dimer and the lower region
represents the monomer.

(b) V132 site
The mutants selected for in vitro experiments are: V132G (clinically observed
mutation, predicted to destabilize the monomer by little and have no effect on dimer
affinity); V132D, V132E (calculated to destabilize both the monomer and dimer
stabilities); V132R and V132W (predicted to have little effect on monomer stability but
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to increase dimer affinity) and V132Q (predicted to have no effect). The clinically
observed mutation, V132G, has similar pattern (Figure 5.5(B)) as the WT does. Both the
monomer and dimer band are clearly seen in the gel experiments, which confirms our in
silico predictions. All other mutants, except V132W, show no significant difference from
the WT, i.e. both dimer and monomer bands are present, but the dimer band is more
prominent. At first instance this can be viewed as failure of our in silico predictions, but
analysis of the calculated pKa’s reveals that Asp132, Glu 132 and Arg132 are neutral in
the dimer (Table 5.4S), while being fully ionized in the monomer. Since our predictions
were made assuming fully ionized side chains of all titratable residues, but these residues
are not ionized in the dimer. Therefore their effects should be similar to the effect caused
by Gln132 mutant, which does not carry charge. This mutant is predicted by in silico
analysis and confirmed by in vitro experiments not to affect dimer affinity (Figure 5.5(B))
as the neutral Asp132, Glu132 and Arg132 should be. The last mutant in our list is non
titratable residue, V132W, and the experiments indicate that monomer population is
larger than the dimer (in contrast to the WT). This is another case confirming our
computational predictions, since V132W is predicted not to affect monomer stability, but
not to decrease dimer affinity.

(c) I150 site
The list of selected mutants is: the clinically observed mutation I150T (which is
predicted not to affect dimer affinity, but to decrease monomer stability), I150D, I150E,
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I150H, I150Q and I150R (all predicted not to have effect on dimer affinity, but to affect
monomer stability). Figure 5.5(C) shows the results of in vitro experiments. It can be
seen that none of the mutants, including clinically observed one, affects dimmer
population. This confirms our predictions. However, the predicted effects on monomer
stability cannot be directly evaluated from the experimental data. The presence of
monomer band in other cases does not necessary indicate that the mutations do not have
effect on monomer stability since the only thing that can be said is the dimer-monomer
ratio. If the monomers are destabilized/stabilized, but the dimer affinity is unchanged, the
ratio dimers/monomers will not change.

Discussion
The investigation of the effect of missense mutations in SMS on the wild type
properties of SMS was carried out with combined efforts of in silico modeling and in
vitro experiments. Very good agreement between them was obtained for the cases being
studied and the applicability of the selected experimental technique. At the same time, it
was demonstrated also that correct predictions require taking into account the “correct”
charge state of the ionizable groups. Especially in case of mutations that either are still
not found in the general population or are very rare, the charged states of the mutated
residues may be drastically different from their solutions values. This indicates the
importance of pKa calculations and analysis of the charged states in the monomer and in
the dimer.
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The analysis showed that the mutability of three sites in SMS harboring missense
mutations causing Snyder-Robinson Syndrome is quite different. The most “non-tolerable”
is site I150, mutations at which are predicted by the folding free and pKa calculations to
greatly disrupt WT properties of the SMS. Because of this, we predict that it is very
unlikely that a nsSNP will be found at the I150 site. Instead, almost any mutation at site
I150 is expected to cause SRS. On the other part of the spectrum is site V132. It is
predicted by all means of our analysis to be “tolerable”. However, the calculated effects
depend on the type of substitution. Thus, site V132 is capable of having either diseasecausing or harmless mutations. The site G56 is in the middle with respect to its mutability.
In terms of monomers stability and hydrogen bond effect, it is quite “tolerable”, but many
mutations are predicted to affect dimer affinity. Since the dimer formation is essential for
the function of the SMS, such mutations are expected to be disease-causing.
This investigation provides testable hypotheses which can be further tested against
ever-growing databases of human nsSNPs, new clinical cases, or further in vitro
experiments not reported in this work of stability/affinity of the SMS and NMR
experiments on hydrogen bond networks in the SMS and mutants. It also indicates that
missense mutations causing diseases do not mark the mutation site as disease-causing.
Instead, the same mutation site may harbor harmless, nsSNPs, mutations.
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CHAPTER SIX
ENHANCING HUMAN SPERMINE SYNTHASE ACTIVITY BY ENGINEERED
MUTATIONS
Abstract
In previous chapters, the disease-causing missense mutations (G56S, V132G, I150T
and Y328C) were investigated, both in silico and in vitro, to affect the wild type function
of SMS by either destabilizing the SMS dimer/monomer or directly affecting the
hydrogen bond network of the active site of SMS. In contrast to these studies, here we
report an artificial engineering of more efficient SMS variant by transferring sequence
information from another organism. It is confirmed experimentally that the variant,
bearing four amino acid substitutions, is catalytically more active than the wild type. The
increased functionality is attributed to enhanced monomer stability, lowering the pKa of
proton donor catalytic residue, optimized spatial distribution of the electrostatic potential
around the SMS with respect to substrates and increase of the frequency of mechanical
vibration of the clefts presumed to be the gates toward the active sites. The study
demonstrates that wild type SMS is not particularly evolutionarily optimized with respect
to the reaction spermidine → spermine. Having in mind that currently there are no
variations (non-synonymous single nucleotide polymorphism, nsSNP) detected in healthy
individuals, it can be speculated that the human SMS function is precisely tuned toward
its wild type and any deviation is unwanted and disease-causing.

130

Background
Polyamines are widely present in many organisms including mammals, plants as well
as some bacteria, and play important roles in normal cell growth, differentiation,
programmed death, and tissue repair [1,2]. A particular polyamine of interest in this
manuscript,

the

spermine

(SPM),

was

shown

to

be

synthesized

by

the

aminopropyltransferase enzyme-spermine synthase (SMS) through conversion of
spermidine (SPD) to SPM [3]. Computational modeling in previous chapters has revealed
that the missense mutations (G56S, V132G, I150T and Y328C) affect SMS stability,
flexibility, interactions, and formation of the dimer structures [4-7].
Similarly to SMS, the spermidine synthase (SRM) is widespread from E. coli,
mammals, and plants to yeast. It is an aminopropyltransferase with a very high degree of
specificity for putrescine as the amine acceptor and synthases SPD [8]. It was shown that
the SRM of Thermotoga maritima, which is the only bacterium known to grow at a high
temperature as well as 90°C [9], is remarkably stable to thermal denaturation particularly
in the presence of the amine acceptor substrate putrescine with a half-life larger than 25 h
at 90°C. In contrast, the human SRM (HsSRM) and SMS (HsSMS) are less stable under
the same temperature [10,11]. The goal of this study is to probe the effect of transferring
sequence information from Thermotoga maritima SRM (TmSRM) and SMS (TmSMS) to
HsSMS and to reveal the effect of the amino acid substitutions on its stability and
function. Previous in silico studies have indicated that mutations of the wild type amino
acids may not be degrading the native properties (monomer stability, dimer affinity,
hydrogen bond network and ionized states) of HsSMS even if they are introduced at sites
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known to harbor disease-causing mutations [5]. Here the mutation sites are chosen not to
coincide with disease-causing mutation sites and the amino acid substitutions are aimed
at enhancing wild type activity of HsSMS. Notice that, two species (human and
thermotoga maritima) are mentioned in this chapter, in order to keep from confusing the
reader, we use HsSMS to refer human spermine synthase; while TmSRM to refer the
Thermotoga maritime spermidine synthase.

Materials and Methods
In silico Modeling
(a) Protein structure
The pdb file of WT structure (PDB ID: 3C6K) was downloaded from the pdb bank
and rebuilt by profix as the method reported in Chapter 2. Comparing the protein
sequence of HsSMS and TmSRM, four mutations were made in HsSMS: p. S165D p.
L175E, p. T178H, and p. C206R (they are p. S180D, p.L190E, p.T193H and p.C221R in
the amino acid sequence, respectively). The selection was based on several
considerations: a) mutations sites should be on the surface of the HsSMS so that their
substitution would not to cause any significant structural perturbations. Thus, S165D,
L175E and C206R were selected since they are located at the surface of HsSMS; b) any
residue predicted should be correlated with the above three to address the cooperativity.
Thus, the T178H was selected since it is predicted to be correlated with L175E; c) Since
the goal is to alter the properties of HsSMS, only substitutions resulting in a change of
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the biophysical properties such as the polarity or the hydrophobicity between the WT
residue and the mutant residue were considered; d) In order to avoid abolishing the
function of HsSMS, only sites that were not conserved in multiple sequence alignments
were analyzed. However, preference was given to non-conserved sites neighboring other
well-conserved sites since it was expected that such a substitution would have a larger
effect on HsSMS than a substitution at an isolated non-conserved site; (e) Preference was
given to amino acid substitutions that occurred with the highest frequency in the multiple
sequence alignment. Taking in all these considerations, the four amino acid substitutions
mentioned above are subject of the investigations described in this work, with the goal of
enhancing the WT properties of HsSMS.
The mutant structures were built in silico by side chain replacement with the method
introduced in Chapter 2. Several mutant structures were generated in both C chain and D
chain: a) the mutant with a single mutation S165D, which is named “SDmut”; b) the
mutant with a single mutation C206R, which is named “CRmut”; c) the double mutant
with two mutations L175E and T178H together. Making such “PAIR” mutations was
prompted by the analysis of multiple sequence alignment (MSA), which will be
introduced in a latter section. This mutant is named “Pmut”; d) the mutant with all of the
above four mutations S165D, C206R, L175E and T178H. This mutant was named
“Fmut”. The mutation sites are shown in Figure 6.1.
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Figure 6.1 3D structure of HsSMS dimer in ribbon presentation. Four mutation sites are
shown with ball representation: Yellow: S165D; Magenta: C206R; Cyan: L175E; and
Orange: T178H.

(b) Multiple sequence alignment
To investigate the evolutionary relationship of the above four mutations among
different species and homologous proteins, the multiple sequence alignment (MSA) was
performed by Constraint-based Multiple Alignment Tool (COBALT) [12], which is
currently provided by National Center for Biotechnology Information (NCBI) [13]. Three
datasets were selected to do such an investigation: a) MSA only between HsSMS and
TmSRM; b) MSA among SMS from different species; c) MSA among all the
homologous to HsSMS proteins.
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Protein sequences between HsSMS and TmSRM were aligned by COBALT since
these four mutations were suggested by TmSRM. Additionally this comparison is
intended to give a global view of sequence differences between these two species.
The pioneering work on HsSMS [10] analyzed MSA of representative members of
SMS family among different species: human (Homo sapiens; NP_004586), chicken
(Gallus gallus; NP_001025974), zebrafish (Danio rerio; NP_571831), fruit fly
(Drosophila melanogaster; NP_729798), mosquito (Anopheles gambiae; XP_315341),
bee (Apis mellifera; XP_393567), sea urchin (S. purpuratus; XP_789223), sea anemone
(N. vectensis; XP_001636780), M. brevicollis (Joint Genome Institute protein ID 30201),
A. thaliana (NP_568785), and Saccharomyces cerevisiae (AAC19368). In the present
work, we use the same species mentioned above. The FASTA sequences were
downloaded from NCBI and uploaded to COBALT for the MSA analysis.
MSA among the homologous proteins were also investigated with the same tools.
Protein-BLAST (Basic Local Alignment Search Tool) [14] was used to search the
homologous proteins. The max target sequences were set as 500 to include the sequences
of all of the above SMS from difference species along with the sequence of other
homologues proteins.
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(c) pKa calculations
Since all of the above four mutations involve titratable group, pKa calculations were
carried out to investigate the ionized states of each titratable group in both WT and
mutants.

(d) Energy calculations
The effects of the mutations were modeled on two energies, folding energy and
binding energy following the protocols introduced in Chapter 2. In addition, Eris [15-17],
a webserver based on the Medusa force field [15], was also used to predict the folding
energy change due to these mutations. With the experience of our previous work [4,18],
we applied a “fixed backbone” prediction method without a “backbone pre-relaxation”
for Eris.

e) Potential map generation and analysis
Since HsSMS reaction involves highly charged substrates, it can be expected that
electrostatics and potential distribution play significant roles in the HsSMS functions. To
assess the effects of the mutations on the electrostatic properties of SMS, the wild type
and mutant HsSMS proteins were subjected to continuum electrostatic potential
calculations using DelPhi [19]. The following parameters were used: scale – 1 grid/Å;
percent of protein filling of the cube – 70 %; a dielectric constant of 2 for the protein and
80 for the solvent; the ionic strength 0.15 M; the water probe radius 1.4 Å; and the Stern
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ion exclusion layer 2.0 Å. The results were outputted into a file in CUBE format
(http://compbio.clemson.edu/delphi.php) that represents the electrostatic potential at each
grid point within the grid. To determine the changes in electrostatic potential due to the
mutation, the electrostatic potential map for wild type protein was subtracted from one of
mutant type. The results were then visualized with VMD software [20]. The red color
represents area with negative potential difference, and blue color represents that with
positive one. Since both substrates are positively charged, the enhancement of the
negative potential is expected to facilitate their approach to active site of SMS.

(f) Normal mode analysis
The synthesis of SPM requires the substrate SPD to come inside the enzyme and after
the catalytic reaction, the product SPM will be released. Bearing in mind that domain
formation is shown to be critical for HsSMS function, it is natural to assume that cleft
formed between HsSMS units in the dimer is the pathway of substrates. Because of that,
the frequency of the cleft “opening” and “closing” is expected to be related to the
efficiency of the catalytic reaction. This mechanism, described as “conformational
gating”, was investigated by Zhou et al. in the case of acetylcholinesterase [21]. It was
shown that the frequency of the gate opening and closing affects the substrate entering to
the active site.
The theory and methodology of normal mode (NM) is well developed and described
elsewhere [22,23]. In the NM model, the protein is presented as an elastic network [24]
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and each residue of protein is modeled as a node in the network and the connections
between nodes are described as elastic potentials. In particular, the anisotropic network
model (ANM) [24,25] considers the molecule as a collection of N sites (one site for each
residue, resulting in ensemble of 3N-6 independent modes). An important parameter in
the ANM analysis is the force constant γ, describing the strength of intramolecular
potentials. The optimal value of γ has been obtained by comparing the theoretically
predicted mean-square fluctuations of alpha-carbons with those indicated by the X-ray
crystallographic B-factor and it was found that the best value is 1.0±0.5 kcal/(mol·Å2)
[24]. In our analysis we used 1.0 kcal/(mol·Å2) as the optimal value.
The cutoff distance rc is another parameter in the ANM model which requires
optimization. It specifies the threshold distance within which the residues/atoms are
considered to interact with each other. In this work, rc and distance weight for interaction
between Cα atoms are set as the default parameters shown on the website (rc =15Å and
the distance weight is 0). All of the TINKER minimized structures were submitted to the
ANM webserver (http://ignmtest.ccbb.pitt.edu/cgi-bin/anm/anm1.cgi) [25]. Analysis of
the predicted vibrational modes with respect to the plausible substrate pathways
(pathways A and B in Figure 6.3) made us select mode 1, mode 2, and mode 3 for further
investigations. The predicted motions (the directions of the vibrational vectors) and their
plausible implications for the SPD/SPM pathways can be seen in the supplementary
material (Figure 6.1S). The corresponding frequencies were calculated as:

ωi = (γαi)1/2 and fi = (ωi/2π)
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(6.1)

where γ is the force constant;  i is the ith eigenvalue, for 1≤i≤ 3N-6 (for 3D or N-1 for
1D) and f i is the frequency.

In vitro Experiments
All of the following in vitro experiments were done by our colleague Dr. Yoshihiko
Ikeguchi.

(a) Expression and purification of HsSMS
A DNA fragment encoding HsSMS was amplified by PCR and subcloned into the
pQE-30 vector downstream of the polyhistidine coding region [26]. The resulting
plasmids were used to transform XL1-Blue cells. Recombinant human SS was purified
by immobilized metal affinity chromatography using TALON affinity resin (Clontech
Laboratories, Palo Alto, CA, U.S.A.), in accordance with manufacturer's instruction.

(b) Assay of HsSMS activity
Activity was measured by following the production of [35S]MTA from
[35S]dcAdoMet in 100 mM sodium phosphate buffer (pH 7.5), in the presence of SPD
[27]. The reaction was stopped by acidification and [35S]MTA separated from
[35S]dcAdoMet using phosphocellulose columns. All assays were conducted with an
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amount of protein and for a period of time in which product formation was linear with
time. Reactions were run with an amount of enzyme that gave a linear rate of MTA
production over the assay time period. Assays were conducted for 1 h at 37°C. All assays
were carried out in triplicate, and results agreed within ±5%.

(c) Production of HsSMS mutants
The four amino acid mutated HsSMS was generated by PCR and subcloned into the
pQE30 vector. The following oligodeoxynucleotides (with mismaches underlined) were
used to generate the mutant indicated:
5'-ATCACTCTCTGCCAAATTAACATCCCCATCAAGGATGAGAAT-3' (antisense)
for S165D
5'-TTGGCAGAGAGTGATGAGGCATATCACCGGGCCATCATG-3' (sense) for
L175E and T178H
5'-GGAGGCATATTGCGTGAAATAGTCAAA-3' (sense) for C206R
5'-TTTGACTATTTCACGCAATATGCCTCC-3' (antisense) for C206R
The entire coding sequence of each of the SMS mutants was verified by DNA
sequencing to ensure that no other mutations were introduced during PCR. The entire
coding region of both plasmids was verified by DNA sequencing carried out by the
Macromolecular Core Facility, Hershey Medical Center. The SMS mutant proteins were
purified as described above before assays.
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Results
Computational Results
(a) Results of MSA
The sequences of HsSMS and TmSRM were aligned at the starting point of the
investigation. The alignment is shown in Figure 6.2(A), where conserved residues are
marked by star “*” and the bold italic letters indicate the four mutation sites. The query
coverage is 50% and E value is 5e-13 given by Protein-BLAST [14]. As seen below, the
sequences of HsSMS and TmSRM share many similarities but are also significantly
different at many sites. The alignment (Figure 6.2(A)) was mapped onto HsSMS 3D
structure and all sites being either invariant (with respect to amino acid substitution) or
buried were removed from the candidate list. The remaining candidates, which are
surface exposed residues in HsSMS (Table 6.1S), were subjected to additional
considerations, as described in supplementary material, reducing the candidate sites to
twenty five. The next step was to utilize multiple sequence alignment (MSA) from
different species and from homologous sequences to further reduce the list of candidates.
The MSA among different species is shown in Figure 6.2(B). The whole comparison is
quite long (Supplementary materials Table 6.2S), thus we only list the “four mutations”
section in the figure. MSA of all homologous to HsSMS protein is shown in
supplementary materials Table 6.3S. The frequency of residue appearance for each of the
four mutations sites is shown in Table 6.1.
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Table 6.1 Frequency and percentage of residue appearance at the mutation sites among
500 homologous proteins.
Mutation
Site
S165D
L175E
T178H
C206R

Residues and Appearance
Residues

Asp

Ser

Asn

Tyr

Gaps

Freq. (%)

428 (85.6%)

57 (11.4%)

10 (2.0%)

1 (0.2%)

4 (0.8%)

Residues

Glu

Leu

Thr

Ile

Gaps

Freq. (%)

380 (76.0%)

103 (20.6%)

4 (0.8%)

4 (0.8%)

2 (0.4%)

Residues

Gln

His

Thr

Asp

Gaps

Freq. (%)

203 (40.6%)

167 (33.4%)

114 (22.8%)

10 (2.0%)

2 (0.4%)

Residues

Arg

Cys

Tyr

Trp

Gaps

Freq. (%)

386 (77.2%)

45 (9.0%)

38 (7.6%)

11 (2.2%)

1 (0.2%)
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Figure 6.2 Multiple sequence alignment (MSA). (A) MSA between HsSMS and TmSRM.
Conserved residues are indicated by star “*”, and the four mutations are represented in
bold italic letters; (B) MSA among different SMS species. The star “*” indicates the
conserved residue among different species, and the residues corresponding to the
mutation sites are marked in bold italic letters.

Further refinement of the candidate list was based on the MSA (Figure 6.2(B) and
Table 6.2S). Sites located next to the conserved site were given preference with respect to
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isolated non-conserved sites (Table 6.2S). This resulted in eight residues: N149, N160,
S165, L175, C206, Q223, M224, and C347.
Additionally N149 is just next to a disease-causing mutation site I150 [4,5] and quite
close to the active site. Because of that, it is considered that its mutation could abolish the
function of HsSMS and this candidate was removed from the list.
Frequency and percentage of residue appearance at the mutation sites among 500
homologous proteins suggested the final selection: if the TmSRMHsSMS substitution
is found to appear less than 50% in the MSA, the candidate was deleted. Thus, N160,
M224 and C347 were deleted because N160V, M224L and C347F substitutions
were found in less than 50% of cases. The site Q223 is gap (Table 6.3S) and was deleted
as well.
As result, only three sites were kept in the candidate list, namely S165D, L175E
and C206R to be mutated to the corresponding residues in TmSRM. In addition, the
site T178 was included in the list because it is correlated with L175. The corresponding
mutation is T178H. Finally four mutations were selected (S165D, L175E, T178H and
C206R) and for the purpose of this investigation, several tags are introduced, i.e. SDmut
for S165D; CRmut for C206R; Pmut for the double mutant “L175E and T178H”; and
Fmut for the 4a.a. mutant “S165D, L175E, T178H and C206R”.
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(b) Effect on ionized states due to the four mutations
pKa calculations indicated only few titratable groups are affected by the mutations
(Table 6.2). Particularly, the active site Asp201 is predicted to experience a large pKa
shift due to the “pair” mutations (L175E and T178H). This shift was predicted for both
Pmut (L175E and T178H) and Fmut (S165D, L175E, T178H and C206R) structures. No
effect was calculated upon S165D and C206R substitutions and because of that only
results obtained Pmut are shown.

Table 6.2 pKa value of Glu175, His178 and Asp201 in C monomer of Pmut.
Residue

WT

Pmut (L175E & T178H)

Glu175

N/A

2.926

His178

N/A

3.573

Asp201

0
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The mutation at position 175 results in fully ionized Glu residue, simply because
E175 side chain is fully solvent accessible. In contrast, the side chain of H178 is fully
buried inside the protein, thus it is predicted to be deprotonated. Asp201 is fully ionized
in the WT structure which is exactly the same as suggested in our previous work [4], but
it is fully protonated in the mutant structure. Detailed analysis addressing structural
reasons for these pKa shifts will be presented in the Discussion.
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(c) Effect on monomer stability due to the four mutations
In the following three sections we reported the computational results with respect to
effect of mutations on monomer stability, dimer affinity, change of the electrostatic
potential distribution.
Table 6.3 shows the calculated results for folding energy changes due to the
mutations. The negative folding energy change indicates that the mutation results in a less
stable monomer, while positive change indicates that the mutant is more stable than the
WT.
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Table 6.3 The results of structure – based (3C6K) folding energy calculation on monomer
stability changes under three force fields.

Mutants ID

Monomer ID

AMBER98
(kcal/mol)

CHARMM27

OPLSaa

(kcal/mol)

(kcal/mol)

Ave three
force fields
(kcal/mol)

Ave C & D
(kcal/mol)

Adjustment
according to
sMMGB
[18]*
(kcal/mol)

SDmut
(S165D)

CRmut
(C206R)

Pmut
(L175E/

C

51.07

109.92

90.89

83.96

D

42.60

107.56

97.66

82.60

C

194.73

276.20

56.20

175.71

D

203.56

276.14

81.06

186.92

C

3.48

106.25

139.76

83.16

D

9.07

114.50

167.26

96.94

83.28

6.66

181.32

15.77

90.05

7.29

354.65

31.89

355.42

31.97

T178H)

Sum

C

249.28

492.37

286.85

342.83

D

255.23

498.20

345.98

366.46

C

249.59

508.35

292.48

350.14

D

274.07

493.99

314.02

360.69

Fmut
(S165D/
L175E/
T178/
C206R)

* Two parameters were used to adjust the prediction according to the experimental data.
For details of sMMGB refer to [18].

The energy calculations predict that all mutants are much more stable than WT,
especially the Fmut which is estimated to stabilize monomer structure by more than 30
kcal/mol. The last number is clearly an overestimation and should not be assumed to be
confirmed experimentally, but rather should be considered as a tendency. In addition, all
three force fields gave the same trend of change, i.e. increasing the monomer stability

147

upon the mutations. It should be pointed out that the calculations with C monomer and D
monomer always gave quite close results, demonstrating the robustness of the
computational protocol.
Table 6.3 provides a row termed “Sum”, which shows the sum of predicted energy
changes taken from individual mutants (note that that the pair 175-178 is taken together).
The motivation of carrying calculations for “sum” is to test the additivity. Thus, one can
see from Table 6.3 that the sum of individual energy change is almost the same as the
combined effect of four mutations (last row in Table 6.3). Thus the effect of these
mutations in current research is additive indicating that sites 165, 206 and 175 plus 178
do not interact with each other.
Furthermore the webserver Eris was also used for the prediction of folding energy
change. Since Eris has a difficulty in modeling the disulfide bond, thus Cys related
mutations are not supported. Therefore only SDmut and Pmut were submitted. The
results are shown in Table 6.4. With the protocol of Eris, this result implied that SDmut
and Pmut have more stable structure, which agreed with the prediction by sMMGB
method.
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Table 6.4 The prediction of folding free energy change due to the mutations by Eris.
Monomer

ΔΔG

Ave. C & D

Mutants ID

ID

(kcal/mol)

(kcal/mol)

SDmut (S165D)

C

1.44

1.15

D

0.85

C

0.51

D

1.16

Pmut
(L175E/T178H)

0.84

(d) Effect on dimer affinity due to the four mutations
Dimer formation was shown to be crucial for the function of HsSMS. Therefore we
carried analysis of the effects of mutations on dimer affinity. Results are shown in Table
6.5. Positive values indicate that the mutation increases the dimer affinity while the
negative values indicate that the mutant has a less stable dimer formation.
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Table 6.5 The results of structure – based (3C6K) binding energy calculation on dimer
affinity changes under three force fields.

Mutants ID

AMBER98

CHARMM27

OPLSaa

(kcal/mol)

(kcal/mol)

(kcal/mol)

Ave three force
fields
(kcal/mol)

SDmut (S165D)

-1.71

-1.61

-0.22

-1.18

CRmut (C206R)

3.79

0.78

1.41

1.99

Pmut (L175E/T178H)

0.50

-1.47

-1.20

-0.73

Sum

2.58

-2.3

-0.01

0.08

0.36

-2.11

-0.07

-0.61

Fmut (S165D/
L175E/T178H/C206R)

It can be seen that all of the predicted binding energy changes listed in the table are
very small. According to our previous work [5], such small binding energy change is
considered not to have effect on dimer affinity. Such a conclusion is expected from
structural perspective, since all four mutation sites are located within the C-domain and
quite far away from the dimer interface. Note that the original experimental work has
shown that the N-terminal domain is the cause of dimerization [10].

(e) Effect on potential distribution due to the four mutations
One plausible reason why HsSMS functions as a dimer could be that the dimerization
is necessary to provide guidance and steer the positively charged SPD/SPM in and out the
active site. It can be speculated that there are two paths shown in Figure 6.3(A) as path
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“A” and “B”. The electrostatic field lines form a kind of funnel leading to the vicinity of
the active sites. The path “A” is in the cleft between HsSMS domains and is a single path.
In contrast, the path “B” is perpendicular to the dimer axis and is symmetrical (doubled)
with an angle of symmetry 1800 (Figure 6.3(A)). Neither of these paths, “A” or “B”, exist
if one uses in the modeling the HsSMS monomer only, i.e. they are product of the
dimerization. The mutations further increase the magnitude of the electrostatic potential
along the both paths as it is illustrated in Figure 6.3(B), where the change of the potential
due to the mutations is shown. The potential difference is mapped onto molecular surface
of the dimer. Red color patch indicates that the potential is more negative in the dimer as
compared with the WT, and blue color the opposite. It can be seen that patches
corresponding to both paths, “A” and “B”, are more negative in the mutant than in the
WT, providing support of the hypothesis that the mutant enhanced activity is caused by
better steering of the substrates to the active site.

Figure 6.3 Potential distribution. (A) Electrostatic field lines for the WT HsSMS;
Drawing method: FieldLines; GardientMag: 1.45; Min Length: 35.31; Max Length:
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50.90; Coloring Scale Data Range: -1; 1; (B) Potential difference (mutant – WT) mapped
onto HsSMS surface; Coloring method: Volume; 1. Drawing method: Surf; Coloring
Scale Data Range: -1; 1 (blue – positive, red – negative)

(f) Results of normal mode analysis
The ANM webserver calculates 36 smallest eigenvalues and each of them
corresponded to a vibration mode. Out of them, the first 20 non-zero eigenvalues
correspond to the 20 vibrational modes and are visualized in Jmol at the ANM site.
Considering the two plausible pathways of SPD/SPM and inspecting the corresponding
motions, it was found that the first three modes correspond to relevant domain motions
(See supplementary material Figure 6.1S). The results for these normal modes calculated
with different force field minimized structures are shown in Table 6.6. From the table,
one can see that Fmut has a slightly higher frequency of domain motion than the WT.
The change of the domain vibrational frequency is expected to affect the reaction by
modulating the approach time of the substrates as they travel along either of the
electrostatic funnels.
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Table 6.6 The results of normal mode analysis.
Ave three force
fields

AMBER98

CHARMM27

OPLSaa

(GHz)

(GHz)

(GHz)

Modes

Mode1/2/3

Mode1/2/3

Mode1/2/3

Mode1/2/3

WT

29.21/34.77/39.55

24.93/27.26/32.77

28.98/34.05/37.96

27.71/32.02/36.76

30.00/35.56/40.76

24.38/27.34/32.71

29.26/33.66/37.59

27.88/32.19/37.02

Structures

(GHz)

Fmut (S165D/
L175E/T178H/C
206R)

Experimental Results
The HsSMS is highly specific for SPD as an amine acceptor. Kinetic analysis of the
HsSMS reaction indicated that the Km values for SPD and dcAdoMet are 0.8 mM and
0.45 μM, respectively, and that the activity is 3776 ± 494 nmol / h / mg (Table 6.7). On
the other hand, the activity of four mutants HsSMS (Fmut) is over ten times higher than
that of WT, whereas Km for both substrate of dcAdoMet and SPD are much less affected
by the mutations. Still the decrease of the Km for SPD indicates that the mutant affinity
toward SPD increases in HsSMS (Fmut), while the affinity toward dcAdoMet decreases.
The dramatic increase of the activity, therefore, cannot be attributed to the change of the
affinity of mutant HsSMS to the reactants. Rather it should be associated with a change
of the maximum rate (Vm), which in turn may indicate better ability of reactants to find
their way to the active site and to bind there.
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Table 6.7 Comparison of SMS activity between WT and Fmut.
Protein

Activity ( nmol / h / mg )

Km for dcAdoMet ( μM )

Km for SPD ( mM )

WT

3776 ± 494

0.5

0.8

40418 ± 3247

0.9

0.6

Fmut (S165D/
L175E/T178H/C206R)

Discussion
The experimental data shows that the designed HsSMS mutant is more active than the
WT HsSMS and computational investigations indicate that biophysical characteristics of
the mutant are altered as compared with the WT characteristics. What are the structural
origins for the predicted changes? The MSA among homologous proteins implied that the
sites 175 and 178 are correlated. In the WT HsSMS, L175 and T178 are quite close, and
the polar hydrogen of T178 makes a hydrogen bond (hydrogen bond length 1.81Å) with
OD2 of Asp 201 (Figure 6.4(A)), and thus providing support for the ionized form of Asp
201. The substitution with a charged residue Glu at site 175 introduces extra negative
charge, but the side chain of E175 is almost fully exposed to the water phase and thus is
solvated. However, the substitution causes slight backbone reengagement and at the same
time, the negative potential of E175 suppresses the ionized form of D201 and makes
D201 protonated. There is no hydrogen acceptor in the vicinity of D201 and Thr at
position 178 is replaced with hydrogen donor/acceptor with a longer side chain, His, to
make a hydrogen bond with the polar hydrogen of D201 (Figure 6.4(B)). The negative
charge of E175 also supports the tautameric orientation of the side chain of His at
position 178 by orienting the polar proton of H178 toward the negatively charged OE
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atoms of E175 (Figure 6.4(B)). It can be speculated that by favoring the protonated form
of D201, the mutations weaken the interactions between the product, the spermine, and
the protein moiety and thus facilitates the release of the product (note that the product, the
spermine, has one extra positive charge as compared with the reactant, the spermidine).
In addition, the protonation of D201 lowers a bit the pKa value of D276 (from
pKa(WT)=9.7 to pKa(Fmut)=9.4) and thus reduces the work need to be done to protonate
D276 upon substrate binding. It can be speculated that it will enhance the turnover of the
reaction and will increase the reaction rate.

Figure 6.4 Interaction networks among product SPM, active sites: D201 & D276, and
pair mutation sites. (A) WT; (B) Pmut. Pair mutation sites were shown with sticks:
magenta represented L175 in WT and E175 in mutant; blue represents T178 in WT and
H178 in mutant. The active sites (D201 and D276) and SPM are shown in ball and sticks:
yellow represents SPM; orange represents D276 and cyan represents D201. The short red
lines indicate hydrogen bonds.
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The energy calculations indicated that all mutations stabilize the monomeric structure
of HsSMS. The couple, E175 and H178, increases stability by lowering the desolvation
penalty for D201, which is protonated in the mutant, and by providing stabilizing
hydrogen bonds. The other two mutations, S165D and C206R, also stabilize the
monomer, especially C206R is predicted to increase the monomer stability by 15.77
kcal/mol. In the WT structure, C206 forms a hydrogen bond with D239 (Figure 6.5(A));
while in the CRmut structure, R206 forms hydrogen bonds with the backbone oxygens of
both D239 and G238 (Figure 6.5(B)). The extra hydrogen bond is the main reason for
increased stability of CRmut. The S165D stabilizes the monomer as well, because the
WT residue, Ser 165 is not involved in any specific interactions, while in the mutant, the
Asp 165 interacts with N149 while being exposed (Figure 6.6), does not pay any
desolvation penalty.

Figure 6.5 Effects on hydrogen networks surrounding the mutation site C206. (A) WT;
(B) Mutant C206R. The residues are presented in sticks: green sticks represent C206 in
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WT and R206 in the mutant; yellow sticks represent G238; and cyan sticks represent
D239. The red dash indicates the hydrogen bonds.

Figure 6.6 Effects on hydrogen bond networks surrounding the mutation site S165D. The
WT (green) and mutant S165D (orange) structures are superimposed. The S165
(magenta) in WT structure, D165 (blue) in mutant structure and their neighbor N149
(pink) are shown with stick.

At the same time, the analysis showed that neither of the mutations nor the Fmut
affects the HsSMS dimer affinity. Structurally they are far away from the dimer interface
and are situated in the C-terminal domain. Because of that, from structural perspective
they are not expected to alter the dimer affinity. The fact that computation protocol
predicted no effect is reassuring and indicates that numerical protocol is robust.
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How the increased stability may be related to enhanced activity is not an obvious
question. Typically a decrease of the stability (or folding free energy) caused by mutation
is considered to be bad for the function of proteins and frequently associated with
diseases [28-33]. However, the opposite effect of increasing stability was also shown to
cause disease [34,35]. Perhaps the key factor of estimating the relations between stability
and function is the understanding the mechanism of the corresponding reaction. The
HsSMS needs to bind two reactants and to release two products, while being a dimer. The
less conformational changes are involved in the reaction, the faster the reaction will be. It
can be speculated that such predicted overall rigidification will enhance the reaction rate,
while allowing the necessary local and small conformational changes still to be allowed
to carry the conversion SPD SPM. Similar effect, an increase of the reaction rate upon
mutations to be associated with structural stabilization was reported before [36,37].
One of the most important finding is that the four mutations, Fmut, result in a structure
which carries more negative charge than the WT. The distribution of the extra negative
charge is not uniform and results in stronger (negative) potential within the dimer cleft
(path “A”) and within a patch at the bottom of the C-terminal domain (path “B”) (Figure
6.3(A), Figure 6.3(B)). There is no experimental data to provide insights why the
dimerization is necessary for the HsSMS function, except the original work which
showed that if N-domain is removed the HsSMS does not form dimer and does not
function [10]. However, each of the HsSMS monomers carries an active site and in
principle should be capable to function as a monomer. Perhaps the dimerization is
needed not for the reaction itself, but to promote the delivery of the reactants and the
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release of the products of the reaction. Electrostatic calculations support such a notion.
Indeed in both the WT and the mutant, we identified two plausible electrostatic funnels,
marked as path “A” and “B” in Figure 6.3(A), however the potential is more negative in
the mutant. It can be speculated that this extra negative potential provides better steering
of the SPD to enter the dimer cleft and to increase the concentration of SPD in the
proximity of the active sites. Indeed, the experimental data suggests that the affinity of
HsSMS to SPD is higher in the mutant (Table 6.7). In addition, the dramatic increase of
the reaction rate could be attributed to the increase of the maximal rate (Vm) in the
mutant, which in turn can be effect of the increased effective concentration of SPD at the
entrance of the active site.
From the normal mode analysis, we can see the Fmut has a slightly higher frequency
of domain motion than the WT, the difference being 170~260MHz. Such difference most
probably will affect the rate and efficiency of the reaction by affecting the substrate
approach to and release from the active site. Following the original work of Zhou and
coworkers [21], it can be speculated that HsSMS dimer forms a conformation gate.
During the reaction, the substrate, the SPD, follows the electrostatic funnels and makes
repeated attempts to go inside the active pocket. As pointed by Zhou and co-workers [21],
the higher the frequency of the gate is, the better is the chance that the substrate will
successfully pass the gate, since the gate will be more frequently open when the SPD
happens to be at the entrance. The same speculation can be made for the release of the
products, i.e. the increased frequency of gate switching should increase the efficiency of
product releasing [21].
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Taking all these effects together, seems to us that increased activity in the mutant is
due to a combinations of factors, ranging from enhanced access of the substrates to the
active site via better electrostatic guiding and gate switching, structural stabilization and
better protonation environment for the reaction. This indicates the complexity of the
reaction process taking place in SMS and shows the complex interplay between structural
and thermodynamic factors.
At the same time, it should be noticed that the amino acid sequence of HsSMS
currently does not have known variants. A search in various databases (as for example
dbSNP at NCBI, NIH [38-40]) resulted in no hits. The only mutations found in human
population are the missense mutations causing Snyder-Robinson syndrome [4,41-43].
Our recent computations analysis [5] indicated that HsSMS should be able to tolerate
mutations even at the disease-causing sites; however, such variants are not seen in the
human population yet. Combining these observations with the result of this manuscript, it
can be speculated that the function of HsSMS is precisely tuned toward its wild type
value to satisfy some currently unknown constraints in vivo. Perhaps, any deviation from
the wild type sequence is unwanted and disease-causing. However, caution should be
used in the interpretation of the in silico results, since the threshold indicating a deviation
is perhaps specific for each protein and reaction involved.
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CHAPTER SEVEN
SNYDER-ROBINSON SYNDROME: RESCUING THE DISEASE-CAUSING
EFFECT BY SMALL MOLECULE BINDING
Abstract
Previous chapters demonstrated that disease-causing missense mutations affect the
spermine synthase (SMS) function by either destabilizing SMS monomer or SMS dimer;
the dimerization being shown experimentally to be critical for SMS function. In this
study we explore the possibility of rescuing the dimer affinity of the SMS mutant (G56S)
by small molecule binding to suitable pockets at the N-terminal domain of SMS. The
binding of selected small molecules is predicted to compensate for the missense mutation
effect causing SRS (in terms of dimer stabilization) and the structural origins of the
compensation are revealed along with energy analysis. The experimental validation of in
silico predicted effects is ongoing. Preliminary results show 3 molecules slightly increase
the mutant activity.
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Background
In this chapter, we focus on the effect of missense mutations on the protein-protein
interactions (PPIs). The PPIs are essential component of any biological system and
particularly in humans: approximately 650,000 interactions are predicted in human
interactome [1]. It can be expected that substituting the WT side chain with another at the
dimer/oligomer interface will affect the geometry of the epitope and will alter the binding
free energy [2-9]. Indeed, recent studies comparing disease-causing and harmless
mutations have confirmed this expectation, although it was pointed that because of the
plasticity of the protein-protein interfaces, the effects are typically reduced due to
structural rearrangements [3,10,11]. However, even a relatively small perturbation of WT
binding characteristics can have an enormous effect on cellular function, especially for
proteins involved in complex networks of PPIs [3]. Because of the importance of PPIs for
the normal cellular function, significant efforts were invested to develop approaches to
alter the effects of missense mutations on the WT PPIs.
One current promising approach is to modulate PPIs with small molecules binding,
which in turn can be divided into two approaches: Inhibition of PPIs (PPIs inhibitors)
[12-20] and stabilization of PPIs (PPIs stabilizers) [21-25]. In a simplistic manner, one
wants to inhibit PPI, if the mutation makes the interaction stronger than in the WT
[26,27]. Conversely, if the mutation destabilizes PPI, then one wants to stabilize it to
make it similar to the WT PPI [24,28]. In a more complex case scenario, one should map
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the altered PPI into the interactome and consider alternative approaches to restore the WT
interactome, rather than just a particular PPI.
In this work we consider a particular mutation (G56S) occurring in human spermine
synthase (SMS) (OMIM 309583) and causing the Snyder Robinson Syndrome (SRS) [2932]. Since dimerization of SMS was shown to be crucial for its function [33], the disease
effect of G56S was attributed to an absence of dimers in sick individuals. In the present
thesis, we report an investigation of the possibility of restoring the dimer formation of the
G56S mutant by small molecule binding.
Identification of the best set of small molecule candidates which bind to the target
molecule was done via virtual screening (VS) of large databases of small molecule
compounds [12,34-38]. The VS is capable of handling large sets of compounds and is
shown to improve the “hit-rate” of drug discovery programs [39-41]. The VS methods
can be divided into two categories: ligand-based (LBVS) and structure-based (SBVS)
[42]. The structure-based method is widely used if the 3D structure of targets is obtained
either by experiments (X-ray crystallography or NMR) [38,43] or computer-modeled
structures [44-48]. The basic procedure of SBVS is to dock all of the molecules presented
in the libraries to the selected binding pocket of the target protein. However, protein
structure is a dynamical entity constantly sampling different conformations over the time.
Thus the flexibility of the target protein should be taken into account in order to generate
the energetically acceptable poses of a ligand. Both of the local and global
conformational changes can affect the shape and volume of the binding pocket as well as
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the groups which potentially interact with the ligands. Additionally for the binding sites
located at the protein-protein interface, the relative motion of the two domains should be
also investigated. Molecular dynamic (MD) simulation is an efficient method to model
the flexibility of the protein structure along the simulation time. Identification of putative
binding pockets requires a detailed analysis of the MD trajectories, particularly how did
the geometrical properties of these binding pocket change during the simulation time
[12,49-52].
In this work, two docking programs: Surflex [53,54] and Autodock Vina [55] were
used to perform SBVS based on the dimer crystal structure and several representative
snapshots were taken from molecular dynamics simulations of the SMS G56S mutant.
The potential molecules were selected from the common compounds (consensus list)
ranked by both approaches, and energy calculations were carried out to evaluate the
effect of ligand binding on the dimer stability. It was suggested that the top ranked small
molecule candidates indeed increase the dimer affinity of the G56S mutant making it
similar to the WT affinity. Selected small molecule candidates are being experimentally
tested for increased mutant activity.
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Materials and Methods
3D Structure of Human SMS
The WT 3D structure was taken from the pdb bank and shown in Figure 7.1. The
disease-causing mutation site G56 is indicated in a blue ball representation. Note that in
this thesis we kept the original residue number of the mutation site (G56) reported in the
literatures [31].

Figure 7.1 The 3D structure of human SMS (PDB ID: 3C6K). C chain is represented in
green and D chain is represented in magenta. The disease-causing mutation G56S is
shown in blue balls; the substrates SPD (sky blue) and MTA (orange) were shown in
stick representation circled by black triangles, which are also the active region.

169

Molecular Dynamics (MD) Simulations
The protein dynamics may result in different conformations of the binding site
providing alternative sites for in silico screening. To assess these alternative
conformations and find putative druggable pockets on the dimer surface, molecular
dynamics simulations were performed by CHARMM (Chemistry at HARvard
Macromolecular Mechanics, version c35b1) [56]. The detailed description of running
MD simulation has been shown in Chapter 2.

Identification of the Putative Binding Sites
Since the goal is to identify small molecules capable to bind to the G56S mutant, the
identification of the putative binding sites was only performed in the mutant structure. In
order to choose binding cavities, we first performed interactive structural analysis of the
cavities around the mutation obtained on the minimized and the averaged MD trajectory
dimer structure. Residues at the center of the cavities in the minimized structure are: Y91
in C chain, I78 in D chain; residues at the center of the cavities in the average MD
structure are: I78 and Y79, both of which are in D chain; next, we employed with a
probe-mapping algorithm with the Surﬂex-Protomol [53] (CH4, C = O, and N-H groups
were used to search for areas capable of interacting favorably with an incoming ligand).
Finally we selected one cavity for further consideration located at the dimer interface and
the list of the selected residues are shown in the supplementary materials Table 7.1S.
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We extracted one structure each picosecond from the last 1500ps of the MD
trajectory of the mutant structure of the human SMS. Root Mean Square Deviation
(RMSD) was calculated over all atoms from the suggested binding site of the different
1500 structures. We then clustered the different conformations of the binding sites using
Hierarchical Ascendant Classification with the aggregative method ward implemented in
R software (http://cran.r-project.org/), and applied it on the RMSD matrix previously
calculated. Each cluster has a RMSD distance of at least 1.3Å. We took the centroid
structure of each cluster in order to define a representative set of protein conformations
for virtual screening experiments and obtained 8 clusters. We analyzed the druggability
of the centroid conformations using the web-server DoGSiteScorer [57].

Using a

difference of Gaussian filter, DoGSite detects pockets and calculates several descriptors.
A subset of the most contributing descriptors is used in a support vector machine and
returns a score of druggability between 0 and 1. The higher the score is, the more
druggable the pocket is estimated to be. We finally selected 3 structures for the VS:
Charmm_mini: the minimized structure; Charmm_ave: the averaged structure over all the
trajectories and then minimized; Charmm_458ps: the snap shot at 458ps.

Preparation of the Chemical Library
To provide valuable starting points for the virtual and in vitro screens, we prepared a
diverse compound collection. Four commercial libraries were assembled: Asinex Merged
Libraries (436,012 compounds), ChemBridge Express Pick (324,909 compounds),
ChemDiv Full Discovery Chemistry (1,183,665 compounds) and LifeChemicals Stocks

171

(344,693 compounds). After merging and removing the redundant molecules, we
employed drug-like filtering using the FAF-Drugs2 web-service [58] previously
developed in our lab in order to remove molecules with undesired physico-chemical
properties and reactive groups. It has been recently observed that the physico-chemical
properties of small molecules acting as protein-protein interaction (PPI) modulators
[19,20,25,59-61] differ from those defined by Lipinski’s rule of 5 [62]. Such molecules
are generally larger and more lipophilic. In order to increase the chance to find potent PPI
stabilizers molecules while remaining drug-like, we decided to filter our compounds in
the ranges: 100< Molecular Weight< 700; 0< tPSA (topological polar surface area)< 160;
-4< logP< 6; 0< number of HBD (hydrogen bond donors) < 5; 0< number of HBA
(hydrogen bond acceptors) < 10; 0< Rotatable Bonds< 15; Further, we removed
compounds embedding reactive or toxic groups.
Compound Clustering
The filtered library contained 1,960,000 molecules that were clustered using the
Cluster Molecule Protocol (Accelrys Pipeline Pilot v8.5) by applying the FCFP-4
fingerprint using a maximum distance of 0.3 in the clusters.

3D Generation
Each compound from the final 273,226 molecules was processed by the Corina
Component embed in the Accelrys Pipeline Pilot v8.5, in order to obtain their 3D
structures. The procedure was launched without generating multiple ring conformations,
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but by keeping a maximum of 2 stereocenters and a maximum of 4 stereoisomers per
compound.

Virtual Screening
The docking of compounds from Asinex, ChemBridge, ChemDiv and LifeChemicals
into the selected 3 structures was performed with both Surflex [53,54] and AutoDock
Vina [55].

(a) Surflex
Surflex creates a protomol which is a list of small chemical probes to which potential
ligands will be aligned based on the molecular similarity. In this work, Surflex generated
the protomol based on the selected residues in the pockets and the residue lists are
provided in the supplementary material Table 7.1S. In addition, the parameter
“proto_thresh” was set to control the degree of burying for the primary volume (Table
7.2S); and the other parameter “proto_bloat” was set to indicate how far the protomol
should be expanded beyond the primary volume (Table 7.2S). In the docking process, the
docking accuracy parameter (-pgeom) was used to start each docking from multiple
initial poses to ensure good search coverage.
We performed several post-processing runs to optimize the scoring parameters.
Two terms in the scoring function were modified: the “polar” term (polar score) was
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increased to 1.5; while the “penetration” term (crash score), was set to “-3.0” (default
values). This term “-3.0” allows some protein-ligand atom overlaps, thereby permitting
slight “induced fit”.

(b) AutoDock Vina
AutoDock Vina needs a grid box to define the search space including the box center
coordinates and the dimensions of x, y and z. And the grid points were separated by 1Å.
This procedure were done with a graphical user interface namely AutoDockTools (ADT)
[63]. The parameters set for running AutoDock Vina are provided in Table 7.3S. The grid
enveloped the whole binding pocket surface of the target protein, so the docking was
performed to the target protein only in the grid. Different from Surflex, Vina uses a
united-atom model to perform docking, thus all of the poses were collected in a PDBQT
file. For the visual selection, these PDBQT file were converted into a mol2 file, and the
compounds were protonated with Chimera [64].

Energy Calculations of Dimer Affinity in Presence of Small Molecules
To probe the stabilizing effect of the ligands, which were selected by the consensus
docking list form Surflex and Autodock Vina, we carried out binding energy calculations.
It was done by calculating the difference of the energy of the complex (protein dimer and
a small molecule) and energies of the dimer protein (without the small molecule) and of
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the small molecule itself. The ability of selected ligands to alter dimer stability was
investigated in two aspects: a) what is the binding affinity between the dimer protein and
the small molecules; b) what is the stabilization of the dimer due to the small molecule
binding.
The energy calculation was performed by CHARMM and the topology/parameter files
for small molecules were created by the webserver Swissparam (http://swissparam.ch)
[65]. For each complex, SMS dimer, and small molecule, we ran MD simulation for 2000
ps then took the average of the energy for the last 20ps. The formulas of energy
calculation are shown in Equ. 7.1 and 7.2 (binding affinity between the dimer protein and
a small molecule) with rigid and relaxed protocol, respectively:

ΔG(binding) = G(complex) - G(protein dimer) - G(ligand)

(7.1)

where ΔG(binding) is the binding energy between the dimer protein and the ligand;
G(complex) is the potential energy of the complex; G(protein dimer) is the potential
energy of the dimer protein extracted from the complex; and G(ligand) is the potential
energy of the ligand extracted from the complex. This is the rigid approach. The relaxed
approach is shown below:

ΔG(binding-relaxed) = G(complex) – G’(protein dimer) – G’(ligand)
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(7.2)

where ΔG(binding-relaxed) is the free binding affinity between the dimer and the small
molecule calculated by the relaxed approach; G(complex) is the potential energy of the
complex; G’(protein dimer) is the potential energy of the dimer protein calculated from
MD performed only on the dimer; and G’(ligand) is the potential energy of ligand
calculated from MD performed only on the small molecule. The difference between Equ.
(7.1) and Equ (7.2) is that the energies are calculated from independent MD simulations
of the complex, protein dimer, and ligand. The Equ (7.1) and Equ (7.2) are used to
estimate the effect of small molecule binding on the stability of the dimer. A more
detailed analysis will be presented in future work.
In the above formulas the following energy components were included: bond energy,
angle energy, Urey-Bradley energy term, dihedral energy, improper dihedral energy, van
der Waal energy, electrostatic energy, and solvation energy. The entropy is only taken by
the allowed movement during the dynamics (for Equ. 7.2) but not explicitly.

Results
MD Simulation
In this work we performed two nano-seconds molecular dynamic simulations on both
the dimer WT and the dimer mutant G56S. In order to ensure the reliability of the MD
trajectories of the simulated WT/mutant structures, we calculated the root-mean-square
deviations (RMSD) corresponding to the average structure for backbone atoms in the
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entire protein. In this procedure, the snapshots were taken each picosecond from the 2ns
dynamic production run, and the average structure of these extracted 2000 snapshots was
then minimized by CHARMM using the same protocol as the initial minimization. The
RMSD of both WT and the mutant are shown in Figure 7.2. As expected, less stable than
the WT, the mutant G56S shows larger fluctuation compared to the WT. This was also
found in our previous studies showing destabilization due to the mutation [5,6], i.e. the
mutant showed large conformational changes during the trajectory. We took a large
conformational ensemble of 1500 snapshots, from 500 to 2000 ps, for further
consideration.

Figure 7.2 RMSD for backbone atoms between each trajectory and the minimized
average structure (Red: WT; Black: Mutant G56S). The dynamics itself was set to 2000
steps and each time step is 1ps.
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The root-mean-square fluctuation (RMSF) for the Cα atoms is shown in Figure 7.3.
The B-factors of Cα atoms of the SMS WT X-ray crystal structure are also presented in
the same figure. The RMSF of the simulated WT structure is in a good agreement with
the B-factors obtained from the X-Ray diffraction experiments, i.e. the zones with the
large flexibility in the simulated WT structure have a similar trend to that in the X-Ray
crystal structure. However some differences are noted, i.e. the B factor of the residue (e.g.
residues around Lys250) in the X-ray crystal structure is higher than the fluctuation of the
corresponding residue in the simulated structure. Such difference can be due to the
missing residues in the X-Ray crystal structure. At the same time, we found the RMSF of
the mutant G56S is relatively higher than that of the WT with a broad overview as well as
the region around the mutation site. Therefore RMSF also confirmed the conclusion that
the mutant G56S has a larger flexibility comparing to the WT.
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Figure 7.3 RMSF of simulated WT structure (red) and mutant G56S structure (black);
and B factors (Cα atoms) of the WT X-Ray crystal structure (green). Note that for the
convenience of making the plot, the residue numbers in D chain, which includes 381
amino acids as well as C chain, were counted from No. 382 to No. 762. The mutation site
G56S in both C chain and D chain has been pointed out by the blue arrow.
Based on the above analysis of the MD simulation trajectories, we concluded that the
MD simulation is reliable for the following procedures, i.e. identifying binding pockets
and selecting MD conformations to perform virtual screening.

Selection of MD Structures for Virtual Screening
Following the clustering procedure (see Methods for details), we found 8 structures
with diverse binding site conformation. Additional structural analysis (as explained in
Methods) was performed on the 8 obtained centroids and we finally selected three
structures to perform virtual screening. They are: Charmm_mini (the Charmm minimized
mutant structure, which is also the input file just before the heating procedure in
simulation process); Charmm_ave (the average structure of the MD trajectory); and
Charmm_458ps (a snapshots from the MD simulation).
Based on the analysis of the 3D structure, we found that the long NTR tail of 17
amino acids (added to complete the missing residues) covers the binding pocket in the
structure Charmm_458ps and seriously affect the docking. Taking into account the large
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flexibility of the tail, several residues were deleted from Charmm_458ps (M1, G2, S3, S4,
H5).

Putative binding sites found on the DDI (domain-domain interaction) zone
SMS forms a homo-dimer with two identical subunits (C chain and D chain) and each
subunit has two domains: N-terminal domain (NTR) and C-terminal domain (CTR)
(Figure 7.1). Two NTRs from each subunit contain two large pseudo-symmetric beta
sheets forming a dimer interface and harbor the disease-causing missense mutation G56S.
To find putative transient pockets, we focused on the NTR containing the mutation site.
To prioritize a binding zone around the mutation to be targeted by in silico screening, we
analyzed the above selected 3 target structures and a prediction of druggable pockets
around the mutation site was carried out using Surflex protomols.
We took the NTR of the subunit C chain for Charmm_mini as the front view, and the
structural analysis showed 3 cavity candidates (A, B, and C; Figure 7.4(A)) close to the
mutation place on this structure. Subpocket A is fully formed by the residues from C
chain and it is the largest and most hydrophobic one among these three cavities, thus it
has a huge potential to harbor large lipophilic compounds, especially the ones having
aromatic rings; subpocket B is fully located at D chain and relatively small, but it also
consists hydrophobic/aromatic residues, i.e. the side chains of A32, I78 and V84
contribute five methyl groups which can have very strong hydrophobic effects with
lipophilic groups of the incoming compounds. At the same time the backbone NHCO
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group of the residue A32 can be involved as hydrogen bond donor or acceptor; the side
chain of Y62 can form a strong stacking with the aromatic rings of the compounds;
additionally at the boundary of the cavity, D33 and E35 have negatively charged side
chains which can be involved either in a hydrogen bond or in a salt bridge with the
compounds. Different from the above analyzed two cavities, subpocket C goes across the
dimer interface and has channels to both subpocket A and B, with a potential to
accommodate a ligand stabilizing the mutant dimer.
Charmm_ave is the average MD structure containing two subpockets (A and B;
Figure 7.4(B)). Subpocket B includes the same essential residues for incoming
compounds as subpocket B in the Charmm_mini. But subpocket A shows a different
geometry in Charmm_ave compared with that in Charmm_mini. The crevice of
subpocket A in Charmm_ave goes along with the dimer interface towards to the subunit
C. The mutation site G56S is located in the deep cavity of this pocket. Additionally the
polar residues R17 (C chain), S19 (C chain), S56 (C chain, mutation site), D92 (C chain),
H60 (D chain) and R77 (D chain) in subpocket A forms a strong polar environment
which can interact with the incoming compounds through electrostatic interactions,
hydrogen bonds or salt bridge. Meanwhile Y91 provides aromatic environment for those
incoming compounds including aromatic rings.
Similar to Charmm_ave, Charmm_458ps has two subpockets (A and B; Figure
7.4(C)), and the properties (geometry, residues etc.) of subpocket A are exactly the same
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as that in Charmm_ave. But subpocket B provides a more polar environment contributed
by the backbone oxygen atoms in L28, G29 and H81 (subunit D).
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(A) Charmm_mini

(B) Charmm_ave
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(C) Charmm_458ps

Figure 7.4 Structural Analysis of Putative Binding Pockets in Targeted Protein Structures.
(A)-(C) showed three targeted structures of NTR: (A) Charmm_mini; (B) Charmm_ave;
(C) Charmm_458ps. In the cartoon representations, the orange surface represented
hydrophobic/aromatic residues; the red surface represented oxygen atoms or negative
charged groups; the blue surface represented nitrogen atoms or positive charged groups;
and the magenta surface represented the disease-causing missense mutation. The black
solid lines were used to point out the position of the dimer interface; the black dash
circles indicated the subpockets. Yellow residue numbers and arrows pointed to the
essential residues mentioned in the text. A probe mapping algorithm [53] was used to
analyze the interface area: green balls highlighted the region where the carbon atoms can
bind with reasonable affinity; blue balls represented nitrogen atoms and highlighted the
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region where the nitrogen atoms/positive charged groups can bind; while the red balls
represented carbonyl groups and highlighted the region where the oxygen atoms/negative
charged groups can bind.

Virtual Screening Protocol
After the procedure of compound clustering for preparation of chemical library,
finally 273,226 centroids with their generated 3D structure were kept for the virtual
screening experiments. We maintained the 3 targeted structures rigid during the docking
computations.
Surflex generated top 20 docking poses for each compound based on the predicted
binding affinity. In Surflex, the binding affinity was approximated by an empirical
scoring function and the binding affinity score was placed in a “log” file as well as the
crash score. A larger binding affinity score indicates a more stable protein-ligand
complex and a higher binding affinity between the ligand and the receptor protein.
Compounds were ranked according to their binding affinity with a threshold of polar
score and crash score (see the details in the method), and the top 3500 compounds for
each receptor structure were kept from this procedure for a further selection.
Similarly to Surflex, AutoDock Vina also generated 20 best poses for each compound
based on the predicted binding affinity. The binding affinity in Vina was calculated in
kcal/mol. The top 8000 compounds in the rank list were selected.
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A consensus list of common compounds (~200) selected by the above two docking
programs was created. After the generation of the consensus list, we used a visual tool,
the PyMOL, to manually select the best 90 compounds which have good poses in the
pockets. Finally we kept three best, but with diverse poses for each compound to carry
the energy calculation.

Results for Energy Calculation of Binding Affinity
MD simulations were applied to create the trajectories for the energy calculations.
Table 7.1 shows the top 30 small molecules, which were predicted to best stabilize the
mutant dimer are shown in the table as well. These molecules were purchased and are
being experimentally tested by our collaborator (Dr. Ikeguchi (Josai Univ, Japan). The
goal of the ongoing experiments is to identify small molecules among the in silico
suggested candidates which are capable to increase the SMS G56S activity via the dimer
stabilization. Preliminary results show that 3 molecules slightly increase the mutant
activity, but additional work is ongoing.
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Table 7.1 Top 30 small molecules best binding to the mutant dimer.

Molecule ID- NO real NAMES
HERE
Molecule 1
Molecule 2
Molecule 3
Molecule 4
Molecule 5
Molecule 6
Molecule 7
Molecule 8
Molecule 9
Molecule 10
Molecule 11
Molecule 12
Molecule 13
Molecule 14
Molecule 15
Molecule 16
Molecule 17
Molecule 18
Molecule 19
Molecule 20
Molecule 21
Molecule 22
Molecule 23
Molecule 24
Molecule 25
Molecule 26
Molecule 27
Molecule 28
Molecule 29
Molecule 30

Binding Affinity
Relaxed approach
(kcal/mol)
-103.08
-91.72
-91.52
-86.43
-79.39
-79.10
-76.92
-76.24
-75.58
-69.96
-66.43
-65.60
-64.56
-63.16
-62.59
-62.49
-55.82
-54.48
-53.68
-51.81
-47.40
-46.36
-44.71
-43.78
-42.12
-40.83
-37.49
-34.60
-33.57
-103.08
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Binding Affinity
Rigid approach
(kcal/mol)
-41.95
-31.76
-45.85
-36.40
-34.69
-29.21
-39.38
-34.41
-28.71
-26.32
-39.91
-26.92
-26.33
-37.97
-40.86
-34.93
-38.00
-30.49
-28.35
-32.03
-39.93
-47.11
-14.22
-32.59
-31.34
-35.94
-42.65
-28.63
-41.36
-41.95

Discussion
This work focused on a particular disease, the Snyder-Robinson Syndrome and a
particular missense mutation (G56S) causing the malfunctioning of Spermine Synthase.
The choice was motivated by our previous studies [5,6] and the observation, both
computational and experimental, that G56S mutation destabilizes the SMS dimer without
affecting the active site of the enzyme. This provides an opportunity to restore the WT
function of SMS and to open the door for the development of an innovative therapeutic
treatment for patients suffering Snyder-Robinson Syndrome by altering the G56S mutant
dimer affinity. The possibility of rescuing disease-causing effects of missense mutation
was investigated by other researchers as well. For example, the familial amyotrophic
lateral sclerosis (FALS) is a fatal motor neuron disease which affects more than 7000
Americans and many more individuals in the world. It is mainly caused by point
mutations in the gene–encoding superoxide dismutase 1 (SOD1) [66,67]. One of the
mutations A4V was identified to cause the FALS by decreasing the dimer affinity and
causing SOD1 aggregation. Ray et al. combined in silico and in vitro screening and
assessed 15 compounds out of 1.5 million molecules, and found 100 hits which were
shown to stabilize the dimer of the mutant SOD1 and significantly slowed the mutant
A4V aggregation [21]. Another example was reported using small molecules to stabilize
the transthyretin (TTR) tetramer, which is a transporter for thyroxine (T4) and retinol.
Several mutations are known to destabilize the tetramer conformation and facilitate the
formation of amyloid fibril to cause amyloid disease. Miroy and coworkers identified an
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efficient stabilizer, the ligand 2,4,6-triiodophenol, which binding to the T4 binding site
stabilizes the TTR tetramer and inhibits fibril formation in vitro [23].
Drug-like small molecules can also play the role of PPI stabilizers indirectly. The p53
is a tumor suppressor protein in the cell’s defense against cancer. It prevents cancer by
arresting the cell cycle of a potentially cancerous cell and inducing apoptosis [68,69]. It
interacts with other molecules, such as DNA and proteins, in the cell [70-74]. A mutant
p53 may lose its natural function if a missense mutation destabilizes its structure and in
turn can be degraded by proteasome at an early stage. Binding drug-like small molecules
can rescue the destabilized mutant p53 [38,75], and in turn can stabilize the PPI between
p53 and the other protein partners. Thus the small molecules stabilizing the mutant p53
structure play a critical role for PPIs indirectly.
Despite of the similar goals of the above mentioned studies, the investigation
presented in this work show several specifics: the work was preceded by series of in
silico and in vitro experiments to identify the molecular origin of the SRS; the G56S
mutation was purposely selected since it does not affect the active site of the SMS; the
VS analysis was preceded by conformational analysis via MD simulations to identify
putative binding pockets; the effect of the small molecules binding on dimer affinity was
computationally investigated and the experimental validation for restoring the activity of
SMS is ongoing. Below we summarize the importance of these steps for the success of
the present study.
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Previous work on modeling the effect of missense mutations associate with SRS [5]
revealed that the molecular mechanism of mutation G56S causing SRS by destabilizing
the dimer conformation, which is playing a crucial role on SMS function. Based on this
investigation, the goal of mitigating the effect of G56S become clear, which is to rescue
the dimer affinity. The site G56 is solvent accessible and far away from the active site,
thus binding a small molecule around the mutation site has low risk to affect the
properties of active site, therefore the VS can be performed. In terms of small molecule
binding, the binding requires an existence of a druggable binding cavity. In this study,
MD simulations were performed to identify putative pockets on the target protein by
considering the protein flexibility. These pockets are suggested to be capable of
accommodating drug candidates. The power of VS is demonstrated by filtering the drug
candidate from ~300,000 to 30, which made the in vitro experiments feasible. The
experimental tests are in progress and we hope that we will identify small molecules
capable to increase sufficiently the mutant activity.
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Appendix B
Supplementary Materials: Figures

Figure 2.1S ΔΔGexp vs. sΔΔGcal for the training data set. The calculation was performed
with 3, 5, 7, 9, 11, and 13 residue segments, respectively.
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Figure 2.2S ROC (Receiver Operating Characteristic) curve. If both sΔΔGcal and ΔΔGexp
are positive, then the case will be defined as truly positive (TP); if both sΔΔGcal and
ΔΔGexp are negative, then the case will be defined as truly negative (TN); If sΔΔGcal is
positive but ΔΔGexp is negative, then the case will be defined as false positive (FP); while
if sΔΔGcal is negative but ΔΔGexp is positive, then the case will be defined as false
negative (FN). We defined three rating categories: “1”: Definitely negative; “2”:
Probably positive or negative; “3”: Definitely positive. As the paper (Khan and Vihinen)
suggested, the experimental value could have the error ±0.48kcal/mol; thus we set the
“0.5 kcal/mol” as the threshold for the experimental value; considering the standard
deviation (SD) of our predication, we will set our standard deviation as the threshold for
our predictions. For the case of FP, if | ΔΔGexp |≤0.5 & | sΔΔGcal |≤SD, then we will set
the category “2”, otherwise it will be set as “1”; for the case of FN, if | ΔΔGexp |≤0.5 & |
sΔΔGcal |≤SD, then we will set the category “2”, otherwise it will be set as “3”. Setting up
such threshold is to consider both calculated value and experimental value have the
possibility to change the sign from positive/negative to negative/positive in the range of
their error.
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Figure 2.3S Comparison of three force field parameters. The solid square represents
Amber98; the circle represents Charmm27; and triangle represents Oplsaa. (A) Training
database; (B) Blind test; (C) Entire dataset

Figure 6.1S The first three vibrational modes calculated with the ANM server. The
plausible pathways of substrates SPD/SPM are indicated with the black arrows. The letter
code of pathways “A” (the cleft between C-terminal domains) and “B” (the cleft between
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adjacent C- and N-terminal domains) corresponds to Figure 2 in the main body of the
manuscript. The directions of vibrational vectors of the three vibrational modes are
shown with orange arrows.
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Appendix C
Supplementary Materials: Tables
Table 2.1S Summary of the results obtained by reshuffling the dataset. The reshuffling
was done by mixing the Table 2.2S (Training dataset) and Table 2.3S (Blind test) then
split them randomly by half (554 mutants and 555 mutants).
(a) Using the current parameter (a = 0.093 and b = -1.088) to scale the new datasets
(Table 2.1(a))
The purpose of doing this is to see if these two parameters are sensitive to the choice of
the dataset.

Table 2.1S(a):
Subsets

Slope

R value

RMSD

Mean of
ΔΔGcal

Standard
Deviation

Dataset
with 554
mutants

0.9

0.3

1.9

-1.2

0.5

Dataset
with 555
mutants

1.1

0.4

1.7

-1.2

0.6

II Using the first subset (with 554 mutants) as the training database to optimize the
parameters, then using the other subset of 555 mutants for a blind test (Table 2.1S(b))
The optimized parameters “a = 0.093 and b= -0.923” were obtained and results of
benchmarking shown below:
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Table 2.1S(b):
Subsets

Slope

R value

RMSD

Mean of
ΔΔGcal

Standard
Deviation

Training
set (554
mutants)

0.9

0.3

1.9

-1.0

0.5

Blind test
(555
mutants)

1.1

0.4

1.7

-1.0

0.6

Table 2.2S: Summary statistics of ROC analysis
Training Dataset
Blind Test
Entire Dataset

Accuracy
80.8%
84.1%
82.1%

Sensitivity
88.9%
50.0%
73.3%

Specificity
80.6%
85.1%
82.4%

Table 2.3S: Comparison of all methods using a test set of mutations not included in IMutant training set.
Methods

Slope

R value

RMSD

Mean of
ΔΔGcal

Standard
Deviation

sMMGB

1.1

0.3

1.8

-1.2

0.5

Eris

0.8

0.4

3.9

-1.3

1.9

FoldX

0.5

0.2

4.7

-1.3

1.9

I-Mutant
2.0

0.6

0.4

1.8

-1.1

1.2
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Table 2.4S: Additional test on 57 new mutations recently added in ProTherm database (as
of Oct, 2011)
Methods

Slope

R value

RMSD

Mean of
ΔΔGcal

Standard
Deviation

sMMGB

0.9

0.3

1.8

-1.2

0.6

Eris

0.9

0.4

4.0

-1.5

2.0

FoldX

0.8

0.4

4.0

-1.3

1.9

I-Mutant
2.0

0.8

0.5

1.7

-1.1

1.2

I-Mutant
3.0

1.2

0.5

1.7

-0.94

0.8

Table 4.1S Binding free energy change due to the mutations. Three force fields
parameters were used then results averaged. The clinically missense mutation is highlighted. The mean of the binding free energy change due to the mutations over all 19
substitutions is 0.07 kcal/mol and the average of HSTD over 19 substitutions is 1.33
kcal/mol (HSTD = 1.33 kcal/mol).
Mutations

Charmm27
(kcal/mol)

Amber98
(kcal/mol)

Oplsaa
(kcal/mol)

WT
328A
328C
328D
328E
328F
328G
328H
328I
328K
328L
328M
328N
328P

0.000
-1.123
-0.024
-1.579
-1.546
-0.500
-0.912
-2.625
0.164
-3.020
-0.106
0.231
-0.924
-3.900

0.000
2.781
2.791
-0.868
-1.777
0.452
0.733
2.262
1.761
2.040
0.819
-1.444
0.956
0.894

0.000
2.127
0.979
0.664
1.660
1.308
1.915
5.327
2.736
5.656
2.454
3.388
2.587
2.091
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Ave of the
three force
fields
(kcal/mol)
0.000
0.126
0.125
-0.059
-0.055
0.042
0.058
0.165
0.155
0.156
0.106
0.072
0.087
-0.031

Standard
Deviation
(kcal/mol)
0.000
0.209
0.143
0.115
0.192
0.090
0.142
0.401
0.130
0.436
0.130
0.245
0.176
0.317

328Q
328R
328S
328T
328V
328W

-2.973
1.529
-1.163
-7.196
-3.712
-0.599

0.727
1.950
0.859
0.868
0.200
0.586

3.468
-9.885
2.331
-14.405
2.541
0.254

0.041
-0.214
0.068
-0.691
-0.032
0.008

0.323
0.671
0.175
0.764
0.316
0.061

Table 4.2S Folding free energy change due to the mutations. Three force fields
parameters were used then results averaged. And the calculation was performed for both
C chain and D chain, then the results averaged. The clinically missense mutation is highlighted. The mean of the folding free energy change due to the mutations over all 19
substitutions is -3.39 kcal/mol and the average of HSTD over 19 substitutions is 1.6
kcal/mol (HSTD = 1.6 kcal/mol).
Mutations

Charmm27
(kcal/mol)

Amber98
(kcal/mol)

Oplsaa
(kcal/mol)

WT
328A
328C
328D
328E
328F
328G
328H
328I
328K
328L
328M
328N
328P
328Q
328R
328S
328T
328V
328W

0.000
-5.932
0.131
-18.152
-16.041
3.443
-10.986
12.964
-3.686
1.730
2.389
-1.182
-1.346
-1.947
-3.428
3.567
-6.228
-5.253
-4.133
-8.188

0.000
-6.272
-4.435
-14.519
-8.996
3.999
-6.473
8.238
1.881
1.486
2.067
5.260
-1.928
-2.010
2.116
5.251
-4.069
-4.837
-2.143
1.509

0.000
-1.842
-5.881
-19.671
-30.004
2.662
-7.330
-0.469
-4.609
-2.195
0.084
1.372
-4.883
-0.515
-3.819
-1.662
-9.195
-2.630
-4.668
-11.757

208

Ave.of the three
force fields
(kcal/mol)
0.000
-0.468
-0.340
-1.745
-1.835
0.337
-0.826
0.691
-0.214
0.034
0.151
0.182
-0.272
-0.149
-0.171
0.239
-0.650
-0.424
-0.365
-0.615

Standard
Deviation
(kcal/mol)
0.000
0.247
0.314
0.265
1.069
0.067
0.240
0.681
0.351
0.220
0.125
0.324
0.190
0.085
0.331
0.360
0.257
0.141
0.133
0.687

Table 5.1S Results of folding free energy change calculations: (a) For site 56. Mean of
the standard deviation over 19 mutations: 3.8 Kcal/mol; So Half Standard (HSTD)=1.9
Kcal/mol; (b) For site 132. Mean of the standard deviation over 19 mutations: 6.2
Kcal/mol; So Half Standard (HSTD)=3.1Kcal/mol; (c) For site 150. Mean of the standard
deviation over 19 mutations: 5.2Kcal/mol; So Half Standard (HSTD)=2.6Kcal/mol;
(a)
Mutation

Charmm27/19

Amber98

Oplsaa

Mean

A
C
D
E
F
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y

-0.9
0.4
2.1
-0.4
2.9
5.4
-2.7
10.4
0.2
3.3
3.2
0.6
-0.2
12.0
0.4/-7.9
-1.0
0.9
-4.5
6.7

1.0
-2.4
-2.4
1.5
-0.0
-0.1
3.4
3.1
0.0
2.5
3.1
4.3
-1.7
6.6
-0.5
-2.6
3.2
6.2
8.9

6.6
8.1
1.8
8.2
0.4
3.5
-0.4
17.1
0.9
9.4
-3.1
-4.7
8.1
1.2
-3.1
2.9
-8.0
-4.1
11.6

2.2
2.0
0.5
3.1
1.1
3.9
0.1
10.2
0.4
5.1
1.1
0.1
2.1
6.6
-2.8
-0.2
-1.3
-0.8
9.1

Mutation

Charmm27/19

Amber98

Oplsaa

Mean

A
C
D
E
F
G
H
I
K
L

2.9
5.3
-6.8
-8.2
-3.1
1.9/-11.6
14.0
-3.8
3.0
-1.8

-3.4
-0.8
-18.1
-11.4
-10.0
1.6
-4.5
-7.7
0.6
-14.6

2.1
3.6
3.3
2.2
7.2
4.8
12.0
-0.5
12.2
6.7

0.5
2.7
-7.2
-5.8
-2.0
-1.1
7.2
-4.0
5.2
-3.2

Standard
deviation
3.9
5.4
2.5
4.5
1.6
2.8
3.1
7.0
0.5
3.8
3.6
4.6
5.3
5.4
1.8
2.8
5.9
6.1
2.5

(b)
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Standard
deviation
3.4
3.2
10.7
7.1
8.7
2.4
10.2
3.6
6.1
10.7

M
N
P
Q
R
S
T
W
Y

-2.1
2.0
5.6
-2.4
-4.4
2.0
0.9
-2.5
-3.2

-2.7
-5.0
3.3
-3.2
-5.0
5.5
-0.4
-14.5
-11.1

10.5
4.3
4.8
3.6
7.4
-4.6
4.3
6.2
8.8

1.9
0.4
4.6
-0.7
-0.7
1.0
1.6
-3.6
-1.8

7.4
4.8
1.2
3.7
7.0
5.1
2.4
10.4
10.0

Mutation

Charmm19/27

Amber98

Oplsaa

Mean

A
C
D
E
F
G
H
K
L
M
N
P
Q
R
S
T
V
W
Y

5.9
2.7
-24.3
-17.8
-6.6
-2.9
7.7
-1.0
0.4
1.3
-1.1
1.2
4.4
12.7
-2.6
-3.5/2.1
-0.8
3.0
-9.6

-10.6
-6.0
-17.9
-9.0
-5.4
-13.4
13.1
-1.7
-5.0
-4.6
-14.9
-2.8
-7.5
0.2
-10.7
-12.3
-8.9
-16.1
-7.2

-1.7
-1.2
-20.2
-17.3
-4.3
-4.9
4.5
-14.5
-6.5
0.8
-1.2
0.6
3.4
-1.1
-1.5
-0.5
0.8
4.9
-12.9

-2.1
-1.5
-20.8
-14.7
-5.4
-7.1
8.4
-5.7
-3.7
-0.9
-5.7
-0.3
0.1
3.9
-4.9
-3.5
-3.0
-2.7
-9.9

Standard
deviation
8.2
4.3
3.3
5.0
1.1
5.6
4.4
7.6
3.6
3.3
7.9
2.2
6.6
7.6
5.1
2.4
5.2
11.6
2.8

(c)
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Table 5.2S Results of the change of the binding free energy change calculations. (a) For
site 56. Mean of the standard deviation over 19 mutations: 7.2 Kcal/mol; So Half
Standard (HSTD)=3.6Kcal/mol; (b) For site 132. Mean of the standard deviation over 19
mutations: 4.9 Kcal/mol; So Half Standard (HSTD)=2.5Kcal/mol; (c) For site 150. Mean
of the standard deviation over 19 mutations: 1.6Kcal/mol; So Half Standard
(HSTD)=0.8Kcal/mol.
(a)
Mutation

Charmm27/19

Amber98

Oplsaa

Mean

A
C
D
E
F
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y

-5.2
-0.3
-17.4
-19.9
-3.3
-1.0
-8.1
-12.7
-12.4
-5.8
-8.7
-25.0
0.7
-8.2
-17.0/-12.4
-8.8
-10.9
1.2
-7.2

-3.4
-3.3
-25.3
-4.2
-14.8
11.5
-28.7
-4.4
-25.9
6.1
-7.5
-0.9
-2.8
2.5
-18.9
-7.8
-11.6
-1.0
-16.4

-11.1
1.8
-15.7
17.9
0.4
15.0
3.7
5.1
-11.1
3.6
8.1
-16.4
9.5
0.8
-7.1
-6.3
-1.4
-0.5
-3.7

-6.5
-0.6
-19.5
-2.1
-5.9
8.5
-11.0
-4.0
-16.5
1.3
-2.7
-14.1
2.4
-1.6
-13.9
-7.6
-8.0
-0.1
-9.1

Mutation

Charmm27/19

Amber98

Oplsaa

Mean

A
C
D
E
F
G
H
I
K

2.1
4.3
-14.9
-10.7
-5.8
4.3/-5.6
-1.5
-5.2
2.2

0.4
1.0
-16.6
-21.1
8.0
-0.5
23.2
1.7
16.5

1.7
3.5
-17.4
-23.6
3.2
-7.1
22.3
-0.5
14.2

1.4
2.9
-16.3
-18.5
1.8
-0.4
14.7
-1.4
11.0

Standard
deviation
4.1
2.6
5.1
19.0
8.0
8.4
16.4
8.9
8.2
6.3
9.4
12.2
6.3
5.8
2.6
1.2
5.7
1.2
6.6

(b)
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Standard
deviation
0.9
1.7
1.3
6.9
7.0
2
14.0
3.6
7.7

L
M
N
P
Q
R
S
T
W
Y

-0.3
1.1
-1.4
-2.0
-1.2
9.9
3.5
3.4
22.3
-2.3

-6.6
2.2
5.1
5.0
1.2
36.0
0.2
3.4
10.0
-7.0

0.2
2.8
2.8
2.5
3.9
31.0
4.0
5.0
25.5
9.2

-2.2
2.1
2.2
1.8
1.3
25.7
2.6
3.9
19.3
-0.0

3.8
0.9
3.3
3.5
2.5
13.9
2.0
0.9
8.2
8.4

Mutation

Charmm27/19

Amber98

Oplsaa

Mean

A
C
D
E
F
G
H
K
L
M
N
P
Q
R
S
T
V
W
Y

0.4
0.5
-1.7
-1.6
-0.1
-0.0
1.6
0.0
0.5
-0.2
-0.2
-0.2
-0.1
0.4
0.2
0.3/-0.8
0.4
-2.1
-0.5

-0.8
0.0
-2.7
-1.5
-0.3
0.8
1.6
0.5
0.0
-1.7
4.4
0.9
-0.3
1.6
0.2
-0.2
1.4
-0.0
0.1

1.1
1.3
-0.5
0.6
0.3
-15.3
3.6
4.2
3.5
0.4
2.0
1.4
1.7
1.2
1.0
1.4
1.7
0.5
3.2

0.2
0.6
-1.6
-0.9
-0.0
-4.8
2.3
1.6
1.3
-0.5
2.1
0.7
0.4
1.0
0.4
0.2
1.1
-0.5
0.9

Standard
deviation
1.0
0.6
1.1
1.2
0.3
9.0
1.2
2.3
1.9
1.1
2.3
0.8
1.1
0.6
0.5
0.5
0.7
1.4
2.0

(c)

Table 5.3S Site-directed mutation primers
G56D FOR

5'-CCTACACAAACAAGAACGACAGCTTTGCCAATTTGAG-3'

G56D REV

5'-CTCAAATTGGCAAAGCTGTCGTTCTTGTTTGTGTAGG-3'

G56L FOR

5'-ATTTAGCAACCTACACAAACAAGAACCTAAGCTTTGCCAATTTGAGAATTTACCC-3'

G56L REV

5'-GGGTAAATTCTCAAATTGGCAAAGCTTAGGTTCTTGTTTGTGTAGGTTGCTAAAT-3'

G56W FOR

5'-GCAACCTACACAAACAAGAACTGGAGCTTTGCCAATTTGAGAATT-3'
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G56W REV

5'-AATTCTCAAATTGGCAAAGCTCCAGTTCTTGTTTGTGTAGGTTGC-3'

G56H FOR

5'-GCAACCTACACAAACAAGAACCACAGCTTTGCCAATTTGAGAAT-3'

G56H REV

5'-ATTCTCAAATTGGCAAAGCTGTGGTTCTTGTTTGTGTAGGTTGC-3'

G56Y FOR

5'-TATTTAGCAACCTACACAAACAAGAACTATAGCTTTGCCAATTTGAGAATTTACCCA-3'

G56Y REV

5'-TGGGTAAATTCTCAAATTGGCAAAGCTATAGTTCTTGTTTGTGTAGGTTGCTAAATA-3'

V132D FOR

5'-CCGACGGGCGCCTGGATGAATATGACATAGAT-3'

V132D REV

5'-ATCTATGTCATATTCATCCAGGCGCCCGTCGG-3'

V132E FOR

5'-GCCGACGGGCGCCTGGAGGAATATGACATAGATGA-3'

V132E REV

5'-TCATCTATGTCATATTCCTCCAGGCGCCCGTCGGC-3'

V132Q FOR

5'-CCGCCGACGGGCGCCTGCAGGAATATGACATAGATGAA-3'

V132Q REV

5'-TTCATCTATGTCATATTCCTGCAGGCGCCCGTCGGCGG-3'

V132R FOR

5'-CGCCGACGGGCGCCTGCGTGAATATGACATAGATG-3'

V132R REV

5'-CATCTATGTCATATTCACGCAGGCGCCCGTCGGCG-3'

V132W FOR

5'-ACCGCCGACGGGCGCCTGTGGGAATATGACATAGATGAAG-3'

V132W REV

5'-CTTCATCTATGTCATATTCCCACAGGCGCCCGTCGGCGGT-3'

I150D FOR

5'-GTATATGACGAAGATTCACCTTATCAAAATGATAAAATTCTACACTCGAAGCAGTTTGGAAAT-3'

I150D REV

5'-ATTTCCAAACTGCTTCGAGTGTAGAATTTTATCATTTTGATAAGGTGAATCTTCGTCATATAC-3'

I150E FOR

5'-GTATATGACGAAGATTCACCTTATCAAAATGAGAAAATTCTACACTCGAAGCAGTTTGGAAAT-3'

I150E REV

5'-ATTTCCAAACTGCTTCGAGTGTAGAATTTTCTCATTTTGATAAGGTGAATCTTCGTCATATAC-3'

I150Q FOR

5'-GTATATGACGAAGATTCACCTTATCAAAATCAGAAAATTCTACACTCGAAGCAGTTTGGAAAT-3'

I150Q REV

5'-ATTTCCAAACTGCTTCGAGTGTAGAATTTTCTGATTTTGATAAGGTGAATCTTCGTCATATAC-3'

I150H FOR

5'-GTATATGACGAAGATTCACCTTATCAAAATCATAAAATTCTACACTCGAAGCAGTTTGGAAAT-3'

I150H REV

5'-ATTTCCAAACTGCTTCGAGTGTAGAATTTTATGATTTTGATAAGGTGAATCTTCGTCATATAC-3'

I150R FOR

5'-CGAAGATTCACCTTATCAAAATAGAAAAATTCTACACTCGAAGCAGT-3'

I150R REV

5'-ACTGCTTCGAGTGTAGAATTTTTCTATTTTGATAAGGTGAATCTTCG-3'
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Table 7.1S: Residue list for generating the protomol for docking with surflex:
Charmm_mini

Charmm_ave

Charmm_458ps

C chain

D chain

C chain

D chain

C chain

D chain

S11
S12
V15
P16
R17
N70
S71
Y91
D92
A95
Q96

M27
L28
G29
A30
A32
D33
G34
E35
I37
D59
H60
G61
Y62
I78
Y79
P80
H81
G82

H5
S11
S12
L14
P16
R17
G18
S19
S71
Y91
D92
G93
A95

A32
D33
G34
E35
I37
Q58
D59
H60
G61
Y62
R77
I78
Y79
P80
H81
G82

L14
P16
R17
G18
S19
S71
Y91
D92
G93

M27
L28
G29
A30
K31
A32
D33
G34
E35
I37
Q58
D59
H60
G61
Y62
R77
I78
Y79
P80
H81
G82

Note: Charmm_mini: Minimized structure; Charmm_ave: Average structure extracted from all the trajectories; Charmm_458ps: The
snap shot at 458ps.

Table 7.2S: Additional parameter of protomol set to control the buriedness (proto_thresh)
and extention (proto_bloat):
proto_thresh
proto_bloat

Charmm_mini Charmm_ave Charmm_458ps
0.6
0.5
0.6
5
5
4

Note: Charmm_mini: Minimized structure; Charmm_ave: Average structure extracted from all the trajectories; Charmm_458ps: The
snap shot at 458ps.
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Table 7.3S: The coordinates of the grid box center and the dimension of the grid box used
for docking with vina:
Structures
Center
(Coordinates)
Dimension

x
y
z
x
y
z

mini
9.546
29.052
-90.227
26
30
29
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ave
19.242
39.173
-94.053
14
28
20

458ps
17.738
37.35
-95.176
12
25
20

